DDI-DrugBank.d263.s18	Amphotericin NNP B-noun.person	, , 0	Foscarnet NNP B-noun.person	, , 0	and CC 0	Aminoglycosides NNP B-noun.person	, , 0	Drugs NNS B-noun.person	such JJ 0	as IN 0	amphotericin NN B-noun.person	, , 0	foscarnet NN B-noun.person	, , 0	and CC 0	aminoglycosides NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	developing VBG B-verb.communication	peripheral JJ B-adj.pert	neuropathy JJ B-noun.state	or CC 0	other JJ 0	HIVID NNP B-noun.group	- : 0	associated JJ B-verb.cognition	adverse JJ B-adj.all	events NNS B-noun.person	by IN 0	interfering VBG B-verb.social	with IN 0	the DT 0	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	zalcitabine NN B-noun.phenomenon	( ( 0	thereby RB B-adv.all	raising VBG B-verb.creation	systemic JJ B-adj.all	exposure NN B-noun.cognition	) ) 0	. . 0	. . 0
DDI-DrugBank.d309.s0	Additive JJ 0	CNS NNP 0	depression NN 0	may MD 0	occur VB B-verb.cognition	when WRB 0	antihistamines NNS B-noun.animal	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	including VBG B-verb.social	barbiturates NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d548.s4	Paroxetine NNP B-noun.person	( ( 0	20 CD 0	mg DT 0	QD NNP 0	) ) 0	increased VBD B-verb.change	the DT 0	concentration NN B-noun.event	of IN 0	duloxetine NN B-noun.location	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	) ) 0	by IN 0	about RB 0	60 CD B-adj.all	% NN 0	, , 0	and CC 0	greater JJR B-adj.all	degrees NNS B-noun.communication	of IN 0	inhibition NN B-noun.process	are VBP 0	expected VBN B-verb.cognition	with IN 0	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	paroxetine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d140.s3	Blood NNP B-noun.person	sampling VBG B-verb.motion	for IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	everolimus NN 0	and CC 0	cyclosporine NN B-noun.person	was VBD 0	performed VBN B-verb.social	on IN 0	day NN 0	1 CD 0	, , 0	on IN 0	weeks NNS B-noun.time	1 CD 0	, , 0	2 CD B-adj.all	, , 0	3 CD B-adj.all	, , 0	and CC 0	4 CD B-adj.all	, , 0	and CC 0	on IN 0	months NNS B-noun.communication	2 CD B-adj.all	, , 0	3 CD B-adj.all	, , 0	6 CD B-adj.all	, , 0	9 CD B-adj.all	, , 0	and CC 0	12 CD B-adj.all	. . 0	. . 0
DDI-DrugBank.d386.s11	The DT 0	extent NN B-noun.attribute	to TO 0	which WDT 0	SSRI NNP B-noun.group	- : 0	TCA NNP B-noun.group	interactions NNS B-noun.possession	may MD 0	pose VB B-verb.possession	clinical JJ B-adj.all	problems NNS B-noun.communication	will MD 0	depend VB B-verb.cognition	on IN 0	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	and CC 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	SSRI NNP B-noun.group	involved VBD B-verb.stative	. . 0	. . 0
DDI-DrugBank.d362.s3	In IN 0	a DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	study NN B-noun.artifact	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	orally RB B-adv.all	inhaled JJ B-adj.all	ciclesonide NN B-noun.location	and CC 0	oral JJ B-noun.body	erythromycin NN I-noun.body	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	, , 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	des NNS B-noun.person	- : 0	ciclesonide NN B-noun.act	or CC 0	erythromycin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d47.s5	Iron NNP B-noun.person	salts NNS B-noun.substance	may MD 0	reduce VB B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	carbidopa NN B-noun.food	and CC 0	levodopa NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d82.s6	However RB 0	, , 0	when WRB 0	any DT 0	additional JJ B-adj.all	drug NN B-noun.person	, , 0	including VBG B-verb.change	INDOCIN NNP B-noun.group	, , 0	is VBZ 0	added VBN B-verb.change	to TO 0	the DT 0	treatment NN B-noun.communication	of IN 0	patients NNS B-noun.person	on IN 0	anticoagulant JJ B-adj.all	therapy NN B-noun.person	, , 0	the DT 0	patients NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	for IN 0	alterations NNS B-noun.act	of IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d3.s1	Warfarin NNP B-noun.person	, , 0	Digoxin NNP B-noun.person	, , 0	Salicylate NNP B-noun.person	, , 0	and CC 0	Heparin NNP B-noun.person	The NNP I-noun.person	in FW 0	vitro FW 0	binding NN 0	of IN 0	warfarin NN 0	to TO 0	plasma VB B-verb.social	proteins NNS B-noun.person	is VBZ B-verb.stative	only RB B-adv.all	slightly RB B-adv.all	reduced VBN B-verb.change	by IN 0	ketorolac_tromethamine NN B-noun.person	( ( 0	99.5 CD 0	% NN 0	control NN B-noun.act	vs IN 0	99.3 CD 0	% NN 0	) ) 0	when WRB 0	ketorolac NN B-noun.person	plasma NN B-noun.person	concentrations NNS I-noun.person	reach VBP B-verb.stative	5 CD B-adj.all	to10 NNP 0	m FW 0	g FW 0	/ FW 0	mL. FW 0	. . 0
DDI-MedLine.d109.s0	Effect NN 0	of IN 0	rofecoxib NN B-noun.animal	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.food	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d512.s3	Amitriptyline NNP B-noun.person	, , 0	Concurrent NNP B-noun.person	administration NN I-noun.person	of IN 0	25 CD B-adj.all	mg NN B-noun.quantity	or CC 0	100 CD 0	mg NN B-noun.quantity	cinacalcet NN 0	with IN 0	50 CD 0	mg IN 0	amitriptyline NN B-noun.person	increased VBD B-verb.change	amitriptyline JJ B-adj.all	exposure NN B-noun.person	and CC 0	nortriptyline NN B-noun.person	( ( 0	active JJ B-adj.all	metabolite NN B-noun.attribute	) ) 0	exposure NN B-noun.quantity	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	in IN 0	CYP2D6 CD 0	extensive JJ B-adj.all	metabolizers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d289.s24	No DT 0	dose NN 0	adjustment NN 0	of IN 0	bosentan NN B-noun.animal	is VBZ B-verb.stative	necessary JJ B-adj.all	, , 0	but CC 0	increased VBD B-verb.change	effects NNS B-noun.phenomenon	of IN 0	bosentan NN B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d522.s0	Terfenadine NN B-noun.person	, , 0	In IN 0	a DT 0	prospective JJ B-adj.all	study NN B-noun.artifact	involving VBG B-verb.competition	six CD I-verb.competition	- : 0	healthy JJ B-adj.all	- : 0	male NN B-noun.person	volunteers NNS B-noun.person	, , 0	dirithromycin NN B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	terfenadine NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d568.s13	Pimozide NNP B-noun.person	and CC 0	Celexa NNP B-noun.person	; : 0	In IN 0	a DT 0	controlled JJ B-adj.all	study NN B-noun.artifact	, , 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	pimozide NN B-noun.communication	2 CD B-adj.all	mg NN B-noun.quantity	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	racemic JJ B-adj.all	citalopram NN B-noun.communication	40 CD B-adj.all	mg NN B-noun.quantity	given VBN B-verb.possession	once RB B-adv.all	daily RB B-adv.all	for IN 0	11 CD B-adj.all	days NNS B-noun.person	was VBD 0	associated VBN B-verb.cognition	with IN 0	a DT 0	mean JJ B-adj.all	increase NN B-noun.event	in IN 0	QTc NNP 0	values NNS B-noun.attribute	of IN 0	approximately RB B-adv.all	10 CD B-adj.all	msec NNS B-noun.communication	compared VBN B-verb.communication	to TO 0	pimozide VB 0	given VBN B-verb.possession	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d198.s9	Since IN 0	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	ketoconazole NN B-noun.cognition	( ( 0	400 CD 0	mg PRP$ 0	daily JJ B-noun.event	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	higher JJR B-adj.all	increases NNS B-noun.person	in IN 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	, , 0	a DT 0	single JJ B-adj.all	2.5 CD 0	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	Vardenafil NNP B-noun.location	should MD 0	not RB 0	be VB 0	exceeded VBN B-verb.stative	in IN 0	a DT 0	24-hour JJ 0	period NN B-noun.time	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	ketoconazole NN B-noun.communication	400 CD 0	mg NN B-noun.quantity	daily RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d263.s9	Concomitant JJ B-adj.all	use NN 0	of IN 0	zalcitabine NN B-noun.person	and CC 0	lamivudine NN B-noun.act	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d132.s3	No DT 0	data NNS B-noun.cognition	from IN 0	prospective JJ B-adj.all	clinical JJ B-adj.all	trials NNS B-noun.person	currently RB B-adv.all	exist VBP 0	comparing VBG B-verb.cognition	the DT 0	3 CD 0	approved VBN B-verb.communication	agents NNS B-noun.person	( ( 0	efavirenz NN B-noun.person	, , 0	nevirapine JJ B-adj.all	or CC 0	delavirdine NN B-noun.act	) ) 0	. . 0	. . 0
DDI-DrugBank.d142.s1	Antacids NNP B-noun.person	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	LEVSIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d353.s6	Microdosed VBN B-verb.consumption	minipill NN 0	progestin NN B-noun.person	preparations NNS I-noun.person	are VBP B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	for IN 0	use NN 0	with IN 0	Soriatane NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s42	Methadone NN 0	levels NNS B-noun.state	may MD 0	be VB 0	decreased VBN B-verb.change	, , 0	increased VBD B-verb.change	dosages NNS B-noun.artifact	may MD 0	be VB 0	required VBN B-verb.stative	to TO 0	prevent VB B-verb.creation	symptoms NNS B-noun.communication	of IN 0	opiate JJ B-adj.all	withdrawal NN B-noun.person	. . 0	Methadone NNP B-noun.person	maintained VBD B-verb.stative	patients NNS B-noun.person	beginning VBG B-verb.change	nevirapine JJ B-adj.all	therapy NN B-noun.artifact	should MD 0	be VB 0	monitored VBN B-verb.possession	forevidence NN B-noun.attribute	of IN 0	withdrawal NN B-noun.person	and CC 0	methadone NN 0	dose NN 0	should MD 0	be VB 0	adjusted VBN B-verb.change	accordingly RB B-adv.all	. . 0	. . 0
DDI-MedLine.d14.s0	[ IN 0	A DT 0	pharmacological JJ B-noun.body	analysis NN I-noun.body	of IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	angiotensin NN B-noun.person	on IN 0	stimulated VBN B-verb.creation	gastric JJ B-adj.all	secretion NN B-noun.act	] : 0	_ CC 0	Chronic NNP B-adj.pert	experiments NNS B-noun.cognition	on IN 0	dogs NNS B-noun.artifact	with IN 0	gastric JJ B-adj.pert	fistulas NNS B-noun.person	were VBD 0	carried VBN B-verb.stative	out IN 0	to TO 0	study VB B-verb.cognition	the DT 0	influence NN B-noun.cognition	of IN 0	angiotensin_1 NNP B-noun.person	and CC 0	angiotensin_2 NN B-noun.person	on IN 0	pentagastrin- NNS B-noun.artifact	and CC 0	histamine NN B-noun.person	- : 0	induced VBN B-verb.creation	gastric JJ B-adj.all	acid NN B-noun.act	secretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d94.s8	Agents NNS B-noun.person	that WDT 0	are VBP B-verb.stative	CYP NNP 0	inducers NNS 0	that WDT 0	have VBP 0	been VBN 0	found VBN B-verb.possession	, , 0	or CC 0	are VBP 0	expected VBN B-verb.cognition	, , 0	to TO 0	decrease VB B-verb.change	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	EQUETROTM NNP B-noun.group	are VBP B-verb.stative	the DT 0	following NN 0	, , 0	Cisplatin NNP B-noun.person	, , 0	doxorubicin_HCL NNP B-noun.person	, , 0	felbamate NN B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	Phenytoin(2 NN 0	) ) 0	, , 0	primidone NN B-noun.person	, , 0	methsuximide NN B-noun.attribute	, , 0	and CC 0	theophylline PRP 0	Thus RB 0	, , 0	if IN 0	a DT 0	patient NN B-noun.person	has VBZ 0	been VBN 0	titrated VBN B-verb.communication	to TO 0	a DT 0	stable JJ B-adj.all	dosage NN B-noun.attribute	on IN 0	EQUETROTM NNP B-noun.group	, , 0	and CC 0	then RB B-adv.all	begins VBZ B-verb.stative	a DT 0	course NN B-noun.object	of IN 0	treatment NN B-noun.plant	with IN 0	one CD 0	of IN 0	these DT 0	CYP3A4 NNP B-noun.person	inducers NNS I-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	reasonable JJ B-adj.all	to TO 0	expect VB B-verb.cognition	that IN 0	a DT 0	dose NN B-noun.act	increase NN B-noun.act	for IN 0	EQUETROTM NNP B-noun.group	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d150.s3	Tricyclic_antidepressants NNS B-noun.act	may MD 0	enhance VB B-verb.change	the DT 0	seizure NN B-noun.act	risk NN 0	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	tramadol NN I-verb.social	. . 0
DDI-DrugBank.d278.s0	Enoxaparin NNP B-noun.person	dosed VBD B-verb.competition	as IN 0	a DT 0	1.0 CD 0	mg PRP 0	/ ( 0	kg DT 0	subcutaneous JJ B-adj.all	injection NN B-noun.event	q12h NN 0	for IN 0	four CD B-adj.all	doses NNS B-noun.artifact	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	eptifibatide NN B-noun.cognition	or CC 0	the DT 0	level NN B-noun.state	of IN 0	platelet NN B-noun.phenomenon	aggregation NN I-noun.phenomenon	in IN 0	healthy JJ B-adj.all	adults NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d415.s11	During IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	ibuprofen NNS B-noun.person	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	signs NNS B-noun.communication	of IN 0	renal JJ B-adj.all	failure NN B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	to TO 0	assure VB B-verb.change	diuretic JJ B-adj.all	efficacy NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d522.s20	Digoxin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	erythromycin NN B-noun.food	and CC 0	digoxin NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	result VB B-verb.stative	in IN 0	elevated JJ B-adj.all	digoxin NN B-noun.person	serum NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d246.s3	However RB 0	, , 0	in IN 0	another DT 0	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	butorphanol NN 0	were VBD B-verb.stative	significantly RB B-adv.all	altered VBN B-verb.change	( ( 0	29 CD B-noun.quantity	% NN 0	decrease NN B-noun.act	in IN 0	AUC NNP 0	and CC 0	38 CD 0	% NN 0	decrease NN B-noun.act	in IN 0	Cmax NNP B-noun.location	) ) 0	when WRB 0	a DT 0	1-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	STADOL_NS NNS B-noun.location	was VBD 0	administered VBN B-verb.possession	1 CD B-adj.all	minute NN B-noun.quantity	after IN 0	a DT 0	20-mg JJ 0	dose NN B-noun.quantity	of IN 0	sumatriptan NN B-noun.phenomenon	nasal NN I-noun.phenomenon	spray NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d346.s4	Patients NNS B-noun.person	taking VBG B-verb.social	REVIA NNP B-noun.group	may MD 0	not RB 0	benefit VB B-verb.stative	from IN 0	opioid JJ B-adj.all	containing VBG B-verb.stative	medicines NNS B-noun.substance	, , 0	such JJ 0	as IN 0	cough NN B-noun.person	and CC 0	cold JJ B-noun.person	preparations NNS I-noun.person	, , 0	antidiarrheal JJ B-adj.all	preparations NNS B-noun.person	, , 0	and CC 0	opioid_analgesics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d522.s5	in IN 0	one CD 0	man NN 0	, , 0	the DT 0	C NNP 0	max NN 0	of IN 0	terfenadine NN B-noun.person	was VBD B-verb.stative	8.1 CD 0	ng PRP 0	/ : 0	mL CC 0	with IN 0	terfenadine NN 0	alone RB 0	and CC 0	7.2 CD 0	ng PRP 0	/ : 0	mL CC 0	with IN 0	terfenadine NN B-noun.person	plus CC 0	dirithromycin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d522.s8	Also RB B-adv.all	, , 0	in IN 0	vitro NN B-noun.location	experiments NNS B-noun.person	demonstrated VBD B-verb.perception	a DT 0	lack NN B-noun.person	of IN 0	interaction NN B-noun.act	between IN 0	dirithromycin NN B-noun.person	and CC 0	terfenadine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d236.s28	Veratrum_alkaloids NNS B-noun.artifact	, , 0	Amphetamines NNS B-noun.person	inhibit VBP B-verb.possession	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	veratrum_alkaloids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d466.s5	The DT 0	findings NNS B-noun.act	of IN 0	these DT 0	studies NNS B-noun.artifact	are VBP 0	summarized VBN B-verb.communication	in IN 0	the DT 0	following VBG 0	table NN B-noun.artifact	, , 0	Effects NNS B-noun.person	on IN 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	fexofenadine NN B-noun.person	pharmacokinetics NNS B-noun.person	after IN 0	7 CD B-adj.all	days NNS B-noun.act	of IN 0	co SYM 0	- : 0	administration NN B-noun.time	with IN 0	fexofenadine_hydrochloride JJ 0	120 CD 0	mg IN 0	every DT 0	12 CD B-adj.all	hours NNS B-noun.person	( ( 0	two CD 0	times NNS 0	the DT 0	recommended VBN B-verb.communication	twice RB I-verb.communication	daily JJ B-adj.pert	dose NN B-noun.event	) ) 0	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	n=24 NNP 0	) ) 0	. . 0
DDI-DrugBank.d328.s42	Coadministration NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	with IN 0	doses NNS B-noun.food	higher JJR B-adj.all	than IN 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	omeprazole NN 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d48.s6	The DT 0	effects NNS B-noun.phenomenon	of IN 0	diethyl_pyrocarbonate NN B-noun.other	could MD 0	be VB 0	reversed VBN B-verb.change	by IN 0	hydroxylamine NN 0	treatment NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d41.s9	NSAIDs NNS B-noun.person	, , 0	In IN 0	in IN 0	vitro NN B-noun.artifact	studies NNS B-noun.artifact	, , 0	M1 PRP 0	was VBD 0	shown VBN B-verb.perception	to TO 0	cause VB B-verb.communication	increases NNS B-noun.event	ranging VBG B-verb.stative	from IN 0	13 CD B-adj.all	; : 0	50 CD B-adj.all	% NN 0	in IN 0	the DT 0	free JJ B-adj.all	fraction NN B-noun.act	of IN 0	diclofenac NN B-noun.person	and CC 0	ibuprofen NNS B-noun.person	at IN 0	concentrations NNS B-noun.food	in IN 0	the DT 0	clinical JJ B-adj.all	range NN B-noun.location	. . 0	. . 0
DDI-MedLine.d125.s6	Prior JJ B-adj.all	administration NN B-noun.time	of IN 0	4-methylpyrazole JJ 0	( ( 0	90 CD 0	mg IN 0	kg(-1 NNP 0	) ) 0	body NN 0	weight NN B-noun.attribute	) ) 0	was VBD 0	shown VBN B-verb.perception	to TO 0	prevent VB B-verb.creation	the DT 0	conversion NN B-noun.cognition	of IN 0	1,3-difluoro-2-propanol NN 0	( ( 0	100 CD 0	mg IN 0	kg(-1 NNP 0	) ) 0	body NN 0	weight NN B-noun.attribute	) ) 0	to TO 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate NN B-noun.person	in IN 0	vivo NN B-noun.animal	and CC 0	to TO 0	eliminate VB B-verb.change	the DT 0	fluoride NN B-noun.plant	and CC 0	citrate JJ B-adj.all	elevations NNS B-noun.artifact	seen VBN B-verb.perception	in IN 0	1,3-difluoro-2-propanol CD 0	- : 0	intoxicated JJ B-adj.all	animals NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d454.s4	- : 0	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.group	may MD 0	reduce VB B-verb.change	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	lofexidine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d114.s1	The DT 0	effects NNS B-noun.phenomenon	of IN 0	ruthenium_red JJ 0	( ( 0	RR NNP 0	) ) 0	on IN 0	inositol_1,4,5-trisphosphate JJ 0	( ( 0	InsP(3))-induced JJ 0	responses NNS B-noun.person	were VBD 0	studied VBN B-verb.cognition	in IN 0	rat NN 0	bone NN 0	marrow NN 0	megakaryocytes NNS B-noun.person	with IN 0	the DT 0	patch NN B-noun.artifact	- : 0	clamp NN B-noun.group	whole JJ B-noun.artifact	- : 0	cell NN 0	recording NN B-verb.possession	technique NN B-noun.cognition	in IN 0	combination NN 0	with IN 0	fura-2 JJ B-noun.body	microfluorometry NN I-noun.body	. . 0	. . 0
DDI-DrugBank.d399.s0	Preliminary JJ B-adj.all	data NNS B-noun.cognition	which WDT 0	suggest VBP B-verb.communication	that IN 0	dapsone NN 0	may MD 0	inhibit VB B-verb.change	the DT 0	anti NNS B-noun.person	- : 0	inflammatory JJ B-adj.all	activity NN B-noun.process	of IN 0	Lamprene NNP B-noun.person	have VBP 0	not RB 0	been VBN 0	confirmed VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d273.s1	However RB 0	, , 0	interactions NNS B-noun.possession	may MD 0	be VB 0	expected VBN B-verb.cognition	, , 0	and CC 0	UROXATRAL NNP B-noun.group	should MD 0	NOT RB 0	be VB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	alpha NN B-noun.person	- : 0	blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d489.s6	Hypotension NN 0	, , 0	AV NNP 0	conduction NN 0	disturbances NNS B-noun.artifact	, , 0	and CC 0	left VBD B-verb.motion	ventricular JJ B-adj.all	failure NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	some DT 0	patients NNS B-noun.person	receiving VBG B-verb.communication	beta NN B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.group	when WRB 0	an DT 0	oral JJ B-adj.all	calcium_antagonist NN B-noun.person	was VBD 0	added VBN B-verb.change	to TO 0	the DT 0	treatment NN B-noun.plant	regimen NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d283.s17	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	fenofibric_acid NNP B-noun.location	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	affected VBN B-verb.change	by IN 0	atorvastatin NN B-noun.communication	. . 0
DDI-DrugBank.d341.s1	However RB 0	, , 0	it PRP 0	was VBD 0	observed VBN B-verb.perception	that IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	ENBREL NNP B-noun.group	_ , 0	was VBD B-verb.stative	unaltered JJ B-adj.all	by IN 0	concomitant JJ B-adj.all	methotrexate NN B-noun.attribute	in IN 0	rheumatoid JJ B-adj.all	arthritis NN B-noun.group	patients NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d63.s2	The DT 0	blockade NN B-noun.attribute	of IN 0	the DT 0	spinal JJ B-adj.all	endorphinergic JJ B-noun.cognition	system NN I-noun.cognition	by IN 0	intrathecal JJ B-adj.all	naloxone NN B-noun.person	on IN 0	the DT 0	production NN B-noun.artifact	of IN 0	tail NN B-noun.time	- : 0	flick NN 0	inhibition NN 0	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	beta NN B-noun.food	- : 0	endorphin NN B-noun.person	and CC 0	morphine NN B-noun.person	was VBD 0	then RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d314.s31	Corticosteroids NNS B-noun.person	may MD 0	also RB B-adv.all	potentiate VBP B-verb.communication	the DT 0	replication NN B-noun.act	of IN 0	some DT 0	organisms NNS B-noun.cognition	contained VBN B-verb.stative	in IN 0	live_attenuated_vaccines NNS 0	. . 0	. . 0
DDI-DrugBank.d499.s15	Warfarin NNP B-noun.person	, , 0	In IN 0	a DT 0	short JJ B-noun.body	- : 0	term NN B-noun.person	controlled VBD B-verb.social	study NN B-noun.artifact	in IN 0	14 CD B-adj.all	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	ketoprofen NN B-noun.person	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	on IN 0	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d53.s1	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	nelfinavir NN B-noun.person	at IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	with IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	azithromycin NN B-noun.substance	( ( 0	2 CD 0	x IN 0	600 CD 0	mg NN B-noun.quantity	tablets NNS B-noun.artifact	) ) 0	results NNS B-noun.communication	in IN 0	increased VBN B-verb.change	azithromycin NN B-adj.all	serum NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d281.s0	Probenecid NNP B-noun.person	may MD 0	decrease VB B-verb.change	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	cephalosporins NNS B-noun.animal	when WRB 0	used VBN B-verb.consumption	concurrently RB B-adv.all	, , 0	resulting VBG B-verb.stative	in IN 0	increased VBN B-verb.change	and CC 0	more RBR B-adv.all	prolonged JJ B-adj.all	cephalosporin NN 0	blood NN B-noun.body	levels NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d63.s7	The DT 0	results NNS B-noun.communication	indicate VBP B-verb.communication	that IN 0	a DT 0	spinal JJ B-adj.all	naloxone NN B-noun.person	- : 0	sensitive JJ B-adj.all	endorphinergic JJ B-noun.cognition	system NN I-noun.cognition	is VBZ 0	involved VBN B-verb.stative	in IN 0	the DT 0	production NN B-noun.artifact	of IN 0	beta JJ B-adj.pert	- : 0	endorphin NN B-noun.person	but CC 0	not RB B-adv.all	morphine JJR B-adv.all	- : 0	induced VBN B-verb.creation	tail NN B-noun.body	- : 0	flick NN B-noun.substance	inhibition NN I-noun.substance	, , 0	and CC 0	suggest VBP B-verb.communication	that IN 0	intraventricular JJ B-adj.all	beta NN B-noun.food	- : 0	endorphin NN B-noun.person	and CC 0	morphine NN B-noun.person	elicit VB B-verb.emotion	their PRP$ 0	pharmacological JJ B-noun.body	actions NNS I-noun.body	via IN 0	the DT 0	activation NN B-noun.act	of IN 0	different JJ B-noun.substance	descending VBG B-verb.contact	pain NN B-noun.person	inhibitory JJ B-adj.all	systems NNS B-noun.body	, , 0	. . 0
DDI-MedLine.d90.s0	Interaction NN B-noun.act	of IN 0	gentamycin NN B-noun.food	and CC 0	atracurium NN B-noun.person	in IN 0	anaesthetised JJ B-adj.all	horses NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d423.s0	In IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	nonselective JJ B-adj.all	monoamine_oxidase_inhibitors NNS B-noun.person	( ( 0	MAOIs NNP 0	) ) 0	( ( 0	e.g. UH 0	, , 0	selegiline_hydrochloride VBP 0	) ) 0	in IN 0	combination NN 0	with IN 0	serotoninergic_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	venlafaxine NN B-noun.location	) ) 0	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	serious JJ B-adj.all	, , 0	sometimes RB B-adv.all	fatal JJ B-adj.all	, , 0	reactions NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s37	Lopinavir NNP B-noun.person	/ NNP I-noun.person	Ritonavir NNP I-noun.person	. . 0
DDI-DrugBank.d448.s4	Beta SYM 0	- : 0	adrenergic_blocking_agents NNS B-noun.group	may MD 0	also RB 0	interact VB B-verb.contact	with IN 0	sympathomimetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d498.s1	These DT 0	antibiotics NNS B-noun.attribute	should MD 0	be VB 0	used VBN B-verb.consumption	in IN 0	the DT 0	myasthenic JJ B-adj.all	patient NN B-noun.person	only RB B-adv.all	where WRB 0	definitely RB B-adv.all	indicated VBN B-verb.communication	, , 0	and CC 0	then RB B-adv.all	careful JJ B-adj.all	adjustment NN B-noun.act	should MD 0	be VB 0	made VBN B-verb.social	of IN 0	adjunctive JJ B-adj.all	anticholinesterase NN B-noun.attribute	dosage NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d462.s3	In IN 0	one CD 0	controlled VBN B-verb.social	clinical JJ B-adj.all	study NN B-noun.artifact	, , 0	the DT 0	ureidopenicillins NNS B-noun.artifact	, , 0	including VBG B-verb.change	piperacillin NN B-noun.food	, , 0	were VBD 0	reported VBN B-verb.communication	to TO 0	prolong VB B-verb.stative	the DT 0	action NN B-noun.process	of IN 0	vecuronium NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d438.s13	Phenobarbital JJ B-adj.all	, , 0	Estimates NNPS B-noun.person	of IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.person	for IN 0	phenobarbital JJ B-adj.all	or CC 0	gabapentin NN B-noun.substance	( ( 0	300 CD 0	mg IN 0	TID NNP 0	, , 0	. . 0
DDI-DrugBank.d350.s10	A DT 0	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	with IN 0	rifampin NN B-noun.food	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	has VBZ 0	shown VBN B-verb.perception	a DT 0	30 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	caspofungin NN 0	trough NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d115.s9	Particular JJ B-adj.all	caution NN B-noun.communication	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	administering VBG B-verb.communication	Gleevec NNP B-noun.person	with IN 0	CYP3A4 JJ B-adj.all	substrates NNS B-noun.time	that WDT 0	have VBP B-verb.stative	a DT 0	narrow JJ B-adj.all	therapeutic JJ B-adj.all	window NN B-noun.substance	( ( 0	e.g. UH 0	, , 0	cyclosporine NN B-noun.person	or CC 0	pimozide NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d68.s3	Possible JJ B-adj.all	extrarenal JJ B-adj.all	mechanisms NNS B-noun.person	of IN 0	action NN B-noun.process	of IN 0	cimetidine NN B-noun.person	on IN 0	verografine NN B-noun.artifact	and CC 0	iodamide VB B-verb.social	transport NN B-noun.act	were VBD B-verb.stative	also RB B-adv.all	examined VBD B-verb.communication	. . 0	. . 0
DDI-DrugBank.d411.s10	Cytokines NNS 0	( ( 0	interferon NN B-noun.person	, , 0	interleukin NN 0	) ) 0	, , 0	Cytokines NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	induce VB B-verb.cognition	both DT 0	hyperthyroidism NN B-noun.artifact	and CC 0	hypothyroidism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d148.s1	However RB 0	, , 0	if IN 0	Argatroban NNP B-noun.person	is VBZ B-verb.stative	to TO 0	be VB 0	initiated VBN B-verb.creation	after IN 0	cessation NN B-noun.time	of IN 0	heparin NN B-noun.person	therapy NN B-noun.person	, , 0	allow VBP B-verb.possession	sufficient JJ B-adj.all	time NN B-noun.time	for IN 0	heparins NNS B-noun.possession	effect NN 0	on IN 0	the DT 0	aPTT NNP B-noun.person	to TO 0	decrease VB B-verb.communication	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	Argatroban JJ B-noun.phenomenon	therapy NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d568.s22	Carbamazepine NNP B-noun.person	; : 0	Combined VBN B-verb.cognition	administration NN B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	14 CD B-adj.all	days NNS B-noun.act	) ) 0	and CC 0	carbamazepine NN 0	( ( 0	titrated VBN 0	to TO 0	400 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	35 CD 0	days NNS B-noun.act	) ) 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	carbamazepine NN B-noun.communication	, , 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN B-noun.person	. . 0	. . 0
DDI-MedLine.d83.s5	In IN 0	the DT 0	first JJ B-adj.all	double JJ B-noun.communication	- : 0	blind JJ B-adj.all	comparative JJ B-adj.all	study NN B-noun.artifact	( ( 0	28-week JJ 0	) ) 0	of IN 0	olanzapine JJ B-adj.all	and CC 0	risperidone NN 0	, , 0	olanzapine JJ B-noun.communication	10 CD B-adj.all	to TO 0	20 CD B-adj.all	mg RB B-noun.quantity	/ JJ 0	day NN 0	proved VBD B-verb.stative	to TO 0	be VB B-verb.stative	significantly RB B-adv.all	more RBR B-adv.all	effective JJ B-adj.all	than IN 0	risperidone NN 0	4 CD 0	to TO 0	12 CD 0	mg RB 0	/ JJ 0	day NN 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	negative JJ B-adj.all	and CC 0	depressive JJ B-adj.all	symptoms NNS B-noun.person	but CC 0	not RB B-adv.all	on IN 0	overall JJ B-adj.all	psychopathology NN B-noun.animal	symptoms NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d341.s4	Patients NNS B-noun.person	in IN 0	a DT 0	clinical JJ B-adj.all	study NN B-noun.artifact	who WP 0	were VBD B-verb.stative	on IN 0	established VBN B-verb.creation	therapy NN 0	with IN 0	sulfasalazine NN B-noun.person	, , 0	to TO 0	which WDT 0	ENBREL NNP B-noun.group	was VBD 0	added VBN B-verb.change	, , 0	were VBD 0	noted VBN B-verb.perception	to TO 0	develop VB B-verb.change	a DT 0	mild JJ B-adj.all	decrease NN B-noun.act	in IN 0	mean JJ B-adj.all	neutrophil NN B-noun.artifact	counts NNS B-noun.act	in IN 0	comparison NN 0	to TO 0	groups NNS B-noun.group	treated VBN B-verb.social	with IN 0	either DT 0	ENBREL NNP B-noun.group	CI NNP 0	or CC 0	sulfasalazine VB B-verb.social	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d314.s3	Antibiotics NNS B-noun.person	, , 0	Macrolide_antibiotics NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	cause VB B-verb.creation	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	corticosteroid JJ B-adj.all	clearance NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s18	Although IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	Clozapine NNP B-noun.other	and CC 0	carbamazepine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	, , 0	it PRP 0	should MD 0	be VB 0	noted VBN B-verb.communication	that IN 0	discontinuation NN B-noun.act	of IN 0	concomitant JJ B-adj.all	carbamazepine NN 0	administration NN 0	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	Clozapine NNP B-noun.other	plasma NN B-noun.substance	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d51.s0	ATROVENT NNP B-noun.group	Inhalation NNP I-noun.group	Aerosol NNP I-noun.group	has VBZ 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.stative	sympathomimetic_bronchodilators NNS I-verb.stative	, , 0	methylxanthines NNS B-noun.object	, , 0	and CC 0	steroids NNS B-noun.artifact	, , 0	commonly RB B-adv.all	used VBN B-verb.consumption	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	chronic JJ B-adj.all	obstructive JJ B-adj.all	pulmonary NN B-noun.artifact	disease NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d66.s5	Methotrexate NNP B-noun.person	; : 0	There EX 0	is VBZ B-verb.stative	one CD 0	report NN B-noun.communication	that WDT 0	methotrexate VBP B-verb.cognition	may MD 0	decrease VB B-verb.cognition	the DT 0	possible JJ B-adj.all	effectiveness NN B-noun.cognition	of IN 0	supplemental JJ B-adj.all	L NNP B-noun.group	- : 0	glutamine NN B-noun.person	for IN 0	chemotherapy NN B-noun.act	- : 0	induced VBN B-verb.creation	mucositis NN 0	. . 0	. . 0
DDI-DrugBank.d283.s13	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	fenofibrate NN B-noun.animal	( ( 0	equivalent JJ B-adv.all	to TO 0	145 CD 0	mg IN 0	TRICOR NNP B-noun.group	) ) 0	with IN 0	pravastatin NN B-noun.substance	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	) ) 0	once RB B-adv.all	daily RB B-adv.all	for IN 0	10 CD B-adj.all	days NNS B-noun.time	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	the DT 0	mean JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	values NNS B-noun.attribute	for IN 0	pravastatin NN B-noun.act	by IN 0	36 CD 0	% NN 0	( ( 0	range NN B-noun.person	from IN 0	69 CD B-adj.all	% NN 0	decrease NN B-noun.act	to TO 0	321 CD 0	% NN 0	increase NN B-noun.event	) ) 0	and CC 0	28 CD B-adj.all	% NN 0	( ( 0	range NN B-noun.person	from IN 0	54 CD B-adj.all	% NN 0	decrease NN B-noun.act	to TO 0	128 CD 0	% NN 0	increase NN B-noun.event	) ) 0	, , 0	respectively RB B-adv.all	, , 0	and CC 0	for IN 0	3 CD B-adj.all	-hydroxy JJ B-noun.group	- : 0	iso SYM 0	- : 0	pravastatin NN B-noun.person	by IN 0	55 CD 0	% NN 0	( ( 0	range NN B-noun.person	from IN 0	32 CD 0	% NN 0	decrease NN B-noun.act	to TO 0	314 CD 0	% NN 0	increase NN B-noun.event	) ) 0	and CC 0	39 CD 0	% NN 0	( ( 0	range NN B-noun.person	from IN 0	24 CD B-adj.all	% NN 0	decrease NN B-noun.act	to TO 0	261 CD 0	% NN 0	increase NN B-noun.event	) ) 0	, , 0	respectively RB B-adv.all	in IN 0	23 CD B-adj.all	healthy JJ B-adj.all	adults NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d368.s10	Acetazolamide NNP B-noun.person	reduces VBZ B-verb.change	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	quinidine NN B-noun.location	and CC 0	may MD 0	enhance VB B-verb.change	its PRP$ 0	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d7.s1	The DT 0	physician NN B-noun.communication	should MD 0	be VB B-verb.stative	alert JJ B-adj.all	for IN 0	possible JJ B-adj.all	combined VBN B-verb.possession	drug NN B-noun.person	actions NNS B-noun.person	, , 0	desirable JJ B-adj.all	or CC 0	undesirable JJ B-adj.all	, , 0	involving VBG B-verb.stative	cyclophosphamide NN 0	even RB 0	though IN 0	cyclophosphamide NN 0	has VBZ 0	been VBN 0	used VBN B-verb.consumption	successfully RB B-adv.all	concurrently RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.change	other JJ 0	cytotoxic JJ B-adj.all	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d217.s4	Therefore RB 0	, , 0	cyclosporine JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	and CC 0	appropriate JJ B-adj.all	cyclosporine JJ B-adj.all	dosage NN B-noun.artifact	adjustments NNS B-noun.person	made VBN B-verb.social	when WRB 0	these DT 0	drugs NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d328.s6	In IN 0	a DT 0	parallel JJ B-adj.all	group NN B-noun.artifact	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	comparing VBG B-verb.cognition	the DT 0	intravenous JJ B-adj.all	prodrug NN B-noun.communication	form NN B-noun.attribute	of IN 0	valdecoxib NN B-noun.attribute	at IN 0	40 CD 0	mg IN 0	BID NNP 0	( ( 0	n=10 NNP 0	) ) 0	vs IN 0	placebo NN 0	( ( 0	n=9 NNP 0	) ) 0	, , 0	valdecoxib NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	in IN 0	vitro NN 0	aspirin NN 0	- : 0	mediated JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	arachidonate- JJ B-noun.shape	or CC 0	collagen NN B-noun.person	- : 0	stimulated JJ B-adj.all	platelet NN B-noun.body	aggregation NN I-noun.body	. . 0	. . 0
DDI-MedLine.d87.s5	Postoperatively RB B-adj.all	, , 0	45 CD 0	patients NNS B-noun.person	were VBD B-verb.stative	randomly RB B-adv.all	assigned VBN B-verb.possession	in IN 0	a DT 0	double JJ B-adj.all	- : 0	blind JJ B-adj.all	fashion NN B-noun.cognition	to TO 0	receive VB B-verb.communication	ADL_8 NNS B-noun.person	- : 0	2698 CD 0	( ( 0	4 CD B-adj.all	mg NN B-noun.quantity	) ) 0	or CC 0	placebo NN B-noun.substance	and CC 0	intravenous JJ B-adj.all	morphine NN B-noun.person	( ( 0	0.15 CD 0	mg PRP B-noun.quantity	/ : 0	kg LS 0	) ) 0	or CC 0	to TO 0	receive VB B-verb.possession	oral JJ B-adj.all	and CC 0	intravenous JJ B-adj.all	placebo NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d79.s1	Oral JJ B-adj.all	contraceptives NNS B-noun.possession	may MD 0	be VB B-verb.stative	less RBR B-adv.all	effective JJ B-adj.all	while IN 0	you PRP 0	are VBP 0	taking VBG B-verb.social	lymecycline NN I-verb.social	. . 0	. . 0
DDI-DrugBank.d179.s38	- : 0	Methotrexate NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Mexate NNP B-noun.location	) ) 0	Use NNP 0	of IN 0	methotrexate NN B-noun.food	with IN 0	sulfapyridine NN 0	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	liver NN B-noun.possession	and/or CC 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	methotrexate NN B-noun.food	. . 0
DDI-DrugBank.d198.s27	In IN 0	these DT 0	patients NNS B-noun.person	whose WP$ 0	hypertension NN B-noun.person	was VBD 0	controlled VBN B-verb.social	with IN 0	nifedipine NN B-noun.person	, , 0	Vardenafil NNP B-noun.communication	20 CD 0	mg DT 0	produced VBN B-verb.creation	mean JJ B-adj.all	additional JJ B-adj.all	supine NN 0	systolic JJ 0	/ CC 0	diastolic JJ B-adj.all	blood NN B-noun.act	pressure NN B-noun.act	reductions NNS B-noun.act	of IN 0	6/5 CD 0	mm IN 0	Hg NNP 0	compared VBN 0	to TO 0	placebo VB B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d314.s11	Cyclosporine NNP B-noun.person	, , 0	Increased JJ B-adj.all	activity NN B-noun.process	of IN 0	both DT 0	cyclosporine NN B-noun.person	and CC 0	corticosteroids NNS B-noun.object	may MD 0	occur VB B-verb.cognition	when WRB 0	the DT 0	two CD 0	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d258.s7	TABLE NN B-noun.group	1 CD 0	Effects NNS 0	on IN 0	Plasma NNP B-noun.group	Concentrations NNPS I-noun.group	( ( 0	AUC NNP B-noun.group	0 CD B-noun.quantity	- : 0	24 CD B-adj.all	hrs NNS B-noun.artifact	) ) 0	of IN 0	Loratadine NNP B-noun.location	and CC 0	Descarboethoxyloratadine NNP B-noun.location	After IN 0	10 CD B-adj.all	Days NNS B-noun.time	of IN 0	Coadministration NNP B-noun.person	( ( 0	Loratadine NNP 0	10 CD B-adj.all	mg NN B-noun.quantity	) ) 0	in IN 0	Normal NNP B-noun.group	Volunteers NNPS I-noun.group	. . 0
DDI-DrugBank.d231.s3	Patients NNS B-noun.person	receiving VBG B-verb.perception	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	salicylates NNS B-noun.location	concomitantly RB B-adv.all	with IN 0	furosemide NN B-noun.artifact	, , 0	as IN 0	in IN 0	rheumatic JJ B-adj.all	disease NN B-noun.state	, , 0	may MD 0	experience VB B-verb.cognition	salicylate JJ 0	toxicity NN 0	at IN 0	lower JJR B-adj.all	doses NNS B-noun.act	because IN 0	of IN 0	competitive JJ B-adj.all	renal JJ B-noun.body	excretory NN I-noun.body	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d514.s4	Cocaine NN 0	sometimes RB B-adv.all	proves VBZ B-verb.cognition	to TO 0	be VB B-verb.stative	fatal JJ B-adj.all	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	heroin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d48.s4	Modification NN B-noun.person	of IN 0	toxin_A NN 0	with IN 0	diethyl_pyrocarbonate NNP B-noun.person	abolished VBD B-verb.contact	both DT 0	its PRP$ 0	cytotoxic JJ B-adj.all	activity NN B-noun.state	and CC 0	the DT 0	ability NN B-noun.cognition	of IN 0	the DT 0	toxin NN 0	to TO 0	bind VB B-verb.social	Zn SYM 0	- : 0	Sepharose JJ 0	gel NN 0	. . 0	. . 0
DDI-DrugBank.d158.s10	Antihistamines NNS 0	, , 0	Amphetamines NNPS B-noun.person	may MD 0	counteract VB B-verb.change	the DT 0	sedative JJ B-adj.all	effect NN B-noun.cognition	of IN 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d283.s8	Drug NN B-noun.person	- : 0	drug NN B-noun.act	interactions NNS I-noun.act	In IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	using VBG B-verb.consumption	human JJ B-adj.all	liver NN B-noun.person	microsomes NNS B-noun.person	indicate VBP B-verb.communication	that IN 0	fenofibrate NN B-noun.person	and CC 0	fenofibric_acid NNP B-noun.person	are VBP B-verb.stative	not RB I-verb.stative	inhibitors NNS B-noun.person	of IN 0	cytochrome NN 0	( ( 0	CYP NNP 0	) ) 0	P450 NN 0	isoforms NNS B-verb.change	CYP3A4 NNP I-verb.change	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP2E1 NNP B-noun.person	, , 0	or CC 0	CYP1A2 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d287.s0	Cevimeline NN 0	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	beta_adrenergic_antagonists NNS B-noun.person	, , 0	because IN 0	of IN 0	the DT 0	possibility NN B-noun.state	of IN 0	conduction NN B-noun.act	disturbances NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d231.s15	Literature NN B-noun.person	reports NNS I-noun.person	indicate VBP B-verb.cognition	that DT 0	coadministration NN B-noun.person	of IN 0	indomethacin NN B-noun.animal	may MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	furosemide NN B-noun.attribute	in IN 0	some DT 0	patients NNS B-noun.person	by IN 0	inhibiting VBG B-verb.possession	prostaglandin NN B-noun.possession	synthesis NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d41.s3	In IN 0	a DT 0	small JJ B-noun.person	( ( 0	n=30 NN 0	) ) 0	combination NN B-noun.communication	study NN B-noun.artifact	of IN 0	ARAVA NNP B-noun.group	with IN 0	methotrexate NN B-noun.food	, , 0	a DT 0	2- PRP 0	to TO 0	3-fold JJ B-adj.all	elevation NN B-noun.act	in IN 0	liver NN B-noun.animal	enzymes NNS B-noun.location	was VBD 0	seen VBN B-verb.perception	in IN 0	5 CD 0	of IN 0	30 CD B-adj.all	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s8	Antiarrhythmics NNS B-noun.person	, , 0	amiodarone NN 0	. . 0
DDI-DrugBank.d202.s4	The DT 0	therapeutic JJ B-adj.all	efficacy NN B-noun.phenomenon	of IN 0	tricyclic_antidepressants NNS B-noun.group	may MD 0	be VB 0	compromised VBN B-verb.communication	in IN 0	these DT 0	patients NNS B-noun.person	when WRB 0	cimetidine NN B-noun.person	is VBZ 0	discontinued VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d202.s2	In IN 0	addition NN 0	, , 0	higher JJR B-adj.all	- : 0	than IN 0	expected VBN B-verb.cognition	steady JJ I-noun.cognition	- : 0	state NN B-adj.all	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	tricyclic_antidepressants NNS B-noun.plant	have VBP 0	been VBN 0	observed VBN B-verb.perception	when WRB 0	therapy NN 0	is VBZ 0	initiated VBN B-verb.creation	in IN 0	patients NNS B-noun.location	already RB B-adv.all	taking VBG B-verb.competition	cimetidine NN I-verb.competition	. . 0	. . 0
DDI-DrugBank.d569.s5	Among IN 0	494 CD 0	subjects NNS B-noun.person	who WP 0	received VBD B-verb.possession	Angiomax NNP B-noun.person	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	and CC 0	were VBD 0	tested VBN B-verb.social	for IN 0	antibodies NNS B-noun.attribute	, , 0	2 CD B-adj.all	subjects NNS B-noun.person	had VBD 0	treatment NN B-noun.communication	- : 0	emergent NN B-noun.person	positive JJ B-adj.all	bivalirudin NN B-noun.act	antibody NN I-noun.act	tests NNS B-noun.cognition	. . 0	. . 0
DDI-MedLine.d3.s5	Serial JJ B-adj.all	plasma NN B-noun.attribute	and CC 0	urine NN B-noun.act	samples NNS B-noun.cognition	for IN 0	measurement NN B-noun.attribute	of IN 0	amprenavir NN B-noun.person	, , 0	rifabutin NN B-noun.person	, , 0	and CC 0	rifampin NN B-noun.person	and CC 0	their PRP$ 0	25-O JJ 0	- : 0	desacetyl_metabolites NNS B-noun.time	, , 0	were VBD 0	measured VBN B-verb.cognition	by IN 0	high JJ B-adj.all	- : 0	performance NN B-noun.person	liquid JJ B-adj.all	chromatography NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d485.s18	Clofibric_acid JJ B-adj.all	, , 0	Combination NNP B-noun.group	hormonal_contraceptives NNPS I-noun.group	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	clofibric_acid JJ B-noun.other	. . 0	. . 0
DDI-DrugBank.d325.s2	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	low JJ B-adj.all	- : 0	dose NN B-noun.person	dopamine_HCl NN I-noun.person	and CC 0	diuretic_agents NNS B-noun.person	may MD 0	produce VB B-verb.cognition	an DT 0	additive JJ B-adj.all	or CC 0	potentiating VBG B-verb.possession	effect NN B-noun.cognition	on IN 0	urine NN B-noun.artifact	flow NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d124.s2	Observations NNS B-noun.person	from IN 0	drug NN B-noun.animal	interaction NN I-noun.animal	studies NNS B-noun.artifact	with IN 0	FORTOVASE NNP B-noun.group	may MD 0	not RB 0	be VB B-verb.stative	predictive JJ B-adj.all	for IN 0	INVIRASE NNP B-noun.act	. . 0	. . 0
DDI-DrugBank.d132.s12	Acetaminophen NNP B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	diflunisal NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d489.s4	Should MD 0	it PRP 0	be VB 0	decided VBN B-verb.cognition	to TO 0	discontinue VB B-verb.social	therapy NN B-noun.act	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	beta NN B-noun.person	- : 0	blockers NNS B-noun.person	and CC 0	clonidine NN B-noun.person	concurrently RB B-adv.all	, , 0	the DT 0	beta NN B-noun.body	- : 0	blocker NN B-noun.person	should MD 0	be VB 0	discontinued VBN B-verb.cognition	slowly RB B-adv.all	over IN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	before IN 0	the DT 0	gradual JJ B-adj.all	withdrawal NN B-noun.act	of IN 0	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d116.s1	The DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	warfarin NN B-noun.location	and CC 0	rifampin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	well RB 0	known VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d310.s0	It PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	the DT 0	cardiovascular JJ B-adj.all	action NN B-noun.process	of IN 0	other JJ B-adj.all	calcium_channel_blockers NNS B-noun.person	could MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	the DT 0	addition NN B-noun.act	of IN 0	Nimotop NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d231.s10	Tablets NNS B-noun.artifact	Simultaneous JJ B-adj.all	administration NN B-noun.act	of IN 0	sucralfate JJ B-adj.all	and CC 0	furosemide JJ B-adj.all	tablets NNS B-noun.group	may MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d45.s5	Twelve CD B-adj.all	strains NNS B-noun.communication	of IN 0	Staphylococcus NNP B-noun.person	aureus NN I-noun.person	( ( 0	a DT 0	frequent JJ B-adj.all	cause NN B-noun.act	of IN 0	infection NN B-noun.cognition	in IN 0	heroin NN 0	, , 0	but CC 0	not RB B-adv.all	in IN 0	pentazocine NN 0	and CC 0	tripelennamine NN B-noun.act	, , 0	addicts NNS B-noun.location	) ) 0	were VBD B-verb.stative	completely RB B-adv.all	inhibited VBN B-verb.change	by IN 0	the DT 0	drug NN 0	combination NN 0	. . 0	. . 0
DDI-DrugBank.d277.s6	Carbamazepine NNP B-noun.person	, , 0	Tiagabine NNP B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	carbamazepine NN B-noun.communication	or CC 0	its PRP$ 0	epoxide NN 0	metabolite NN B-noun.attribute	in IN 0	patients NNS B-noun.person	with IN 0	epilepsy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d236.s23	Phenobarbital JJ B-adj.all	, , 0	Amphetamines NNPS B-noun.person	may MD 0	delay VB B-verb.stative	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	phenobarbital NN B-noun.artifact	, , 0	. . 0
DDI-MedLine.d110.s9	Ibogaine NNP B-noun.person	attenuates VBZ B-verb.communication	, , 0	but CC 0	18-MC JJ 0	potentiates NNS B-noun.person	, , 0	the DT 0	acute JJ B-adj.all	locomotor NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	morphine NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d492.s0	MAO_inhibitors NNS B-noun.person	prolong VBP B-verb.stative	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d40.s19	- : 0	Drugs NNS B-noun.person	whose WP$ 0	efficacy NN B-noun.phenomenon	is VBZ 0	impaired VBN B-verb.change	by IN 0	phenytoin NN B-noun.person	include VBP B-verb.change	, , 0	anticoagulants NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	coumarin NN B-noun.person	, , 0	digitoxin NN B-noun.person	, , 0	doxycycline NN B-noun.person	, , 0	estrogens VBZ B-verb.cognition	, , 0	furosemide RB 0	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	theophylline PRP 0	, , 0	vitamin_D. NNP B-noun.person	. . 0
DDI-DrugBank.d187.s12	Since IN 0	the DT 0	therapeutic JJ B-adj.pert	range NN B-noun.state	of IN 0	theophylline PRP 0	is VBZ B-verb.stative	narrow JJ B-adj.all	theophylline NN B-noun.body	serum NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	, , 0	and CC 0	appropriate JJ B-adj.all	dosage NN B-noun.possession	adjustments NNS B-noun.act	of IN 0	theophylline PRP 0	should MD 0	be VB 0	made VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d58.s7	These DT 0	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	ginsenosides NNS B-noun.person	are VBP B-verb.stative	negatively RB B-adv.all	coupled VBN B-verb.social	to TO 0	three CD 0	types NNS B-noun.person	of IN 0	calcium NN B-noun.artifact	channels NNS B-noun.artifact	in IN 0	bovine NN 0	chromaffin NN B-adj.all	cell NN B-noun.body	, , 0	including VBG B-verb.stative	an DT 0	omega NN B-noun.person	- : 0	conotoxin_GVIA SYM 0	- : 0	sensitive JJ B-noun.time	( ( 0	N SYM 0	- : 0	type NN B-noun.person	) ) 0	channel NN 0	, , 0	an DT 0	omega NN B-noun.person	- : 0	agatoxin_IVA SYM 0	- : 0	sensitive JJ B-noun.time	( ( 0	P SYM 0	- : 0	type NN B-noun.person	) ) 0	channel NN 0	and CC 0	nimodipine NN B-noun.communication	/ : 0	omega JJ B-adj.all	- : 0	conotoxin_GVIA NNS B-noun.time	/ CC 0	omega JJ B-adj.pert	- : 0	agatoxin_VIA SYM 0	- : 0	resistant NN B-noun.person	( ( 0	presumptive JJ B-adj.all	Q NNP 0	- : 0	type NN B-noun.person	) ) 0	channel NN 0	. . 0	. . 0
DDI-DrugBank.d20.s11	The DT 0	administration NN B-noun.time	of IN 0	other JJ B-adj.all	potassium NN B-noun.person	- : 0	sparing_antihypertensives VBZ B-verb.stative	with IN 0	NSAIDs NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	reduce VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	in IN 0	some DT 0	patients NNS B-noun.person	and CC 0	result NN B-noun.act	in IN 0	severe JJ B-adj.all	hyperkalemia NN B-noun.state	in IN 0	patients NNS B-noun.person	with IN 0	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d272.s0	The DT 0	risk NN 0	of IN 0	using VBG B-verb.consumption	bromocriptine_mesylate NNP B-noun.person	in IN 0	combination NN 0	with IN 0	other JJ 0	drugs NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	systematically RB B-adv.all	evaluated VBN B-verb.communication	, , 0	but CC 0	alcohol NN B-noun.person	may MD 0	potentiate VB B-verb.communication	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	bromocriptine_mesylate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d141.s5	However RB 0	, , 0	in IN 0	the DT 0	second JJ B-adj.all	study NN B-noun.artifact	, , 0	administration NN B-noun.person	of IN 0	12 CD B-adj.all	g IN 0	cholestyramine NN B-noun.communication	1 CD B-adj.all	hour NN 0	before IN 0	the DT 0	evening NN 0	meal NN B-noun.attribute	and CC 0	0.3 CD 0	mg DT 0	cerivastatin_sodium NN 0	approximately RB B-verb.stative	4 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	the DT 0	same JJ B-adj.all	evening NN 0	meal NN B-noun.person	resulted VBD B-verb.communication	in IN 0	a DT 0	decrease NN B-noun.event	in IN 0	the DT 0	cerivastatin NN 0	AUC NNP 0	of IN 0	less JJR B-noun.quantity	than IN 0	8 CD B-adj.all	% NN 0	, , 0	and CC 0	a DT 0	decrease NN B-noun.event	in IN 0	Cmax NNP B-noun.location	of IN 0	about IN 0	30 CD B-adj.all	% NN 0	when WRB 0	compared VBN B-verb.cognition	to TO 0	dosing VBG B-verb.social	cerivastatin_sodium NN 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d558.s2	Cimetidine NNP B-noun.person	at IN 0	400 CD 0	mg IN 0	BID NNP 0	( ( 0	the DT 0	usual JJ B-adj.all	prescription NN B-noun.act	dose NN B-noun.event	) ) 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	TIKOSYN NNP B-noun.group	( ( 0	500 CD 0	mcg NN 0	BID NNP 0	) ) 0	for IN 0	7 CD B-adj.all	days NNS B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	dofetilide JJ 0	plasma NN B-noun.substance	levels NNS B-noun.state	by IN 0	58 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d263.s23	The DT 0	clinical JJ B-adj.all	significance NN B-noun.communication	of IN 0	this DT 0	reduction NN B-noun.act	is VBZ B-verb.stative	not RB B-adj.all	known VBN I-adj.all	, , 0	hence RB 0	zalcitabine NN 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	to TO 0	be VB 0	ingested VBN B-verb.consumption	simultaneously RB B-adv.all	with IN 0	magnesium NN 0	/ : 0	aluminum NN B-noun.person	- : 0	containing VBG B-verb.stative	antacids NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d289.s31	Clinical JJ B-adj.all	experience NN B-noun.event	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	bosentan NN B-noun.food	and CC 0	warfarin NN B-noun.act	in IN 0	patients NNS B-noun.person	with IN 0	pulmonary JJ B-adj.all	arterial JJ B-adj.all	hypertension NN B-noun.person	did VBD 0	not RB B-adv.all	show VB B-verb.communication	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	INR NNP 0	or CC 0	warfarin NN B-noun.substance	dose NN B-noun.substance	( ( 0	baseline NN 0	vs. NN 0	end NN 0	of IN 0	the DT 0	clinical JJ B-adj.all	studies NNS B-noun.group	) ) 0	, , 0	and CC 0	the DT 0	need NN 0	to TO 0	change VB B-verb.change	the DT 0	warfarin NN B-noun.location	dose NN 0	during IN 0	the DT 0	trials NNS B-noun.cognition	due JJ 0	to TO 0	changes NNS B-noun.act	in IN 0	INR NNP 0	or CC 0	due JJ 0	to TO 0	adverse JJ B-adj.all	events NNS B-noun.person	was VBD B-verb.stative	similar JJ B-adj.all	among IN 0	bosentan- NNP B-noun.person	and CC 0	placebo NN B-noun.person	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s22	However RB 0	, , 0	other JJ 0	published VBN B-verb.creation	reports NNS B-noun.artifact	describe VBP B-verb.stative	modest JJ B-adj.all	elevations NNS B-noun.person	( ( 0	less JJR B-noun.quantity	than IN 0	two CD 0	- : 0	fold NN B-noun.attribute	) ) 0	of IN 0	clozapine NN B-noun.act	and CC 0	metabolite JJ B-adj.all	concentrations NNS B-noun.possession	when WRB 0	clozapine NN B-noun.person	was VBD 0	taken VBN 0	with IN 0	paroxetine NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	and CC 0	sertraline NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d521.s9	- : 0	phenytoin NN B-noun.substance	( ( 0	Dilantin NNP B-noun.person	) ) 0	, , 0	. . 0
DDI-DrugBank.d466.s18	This DT 0	observed JJ B-adj.all	increase NN B-noun.act	in IN 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	fexofenadine NN B-noun.location	may MD 0	be VB B-verb.stative	due JJ 0	to TO 0	transport VB B-verb.motion	- : 0	related JJ B-adj.all	effects NNS B-noun.phenomenon	, , 0	such JJ 0	as IN 0	p SYM 0	- : 0	glycoprotein NN B-noun.person	. . 0	in IN 0	vivo JJ B-adj.all	animal NN B-noun.animal	studies NNS I-noun.animal	also RB B-adv.all	suggest VBP B-verb.communication	that IN 0	in IN 0	addition NN 0	to TO 0	enhancing VBG B-verb.change	absorption NN B-noun.artifact	, , 0	ketoconazole NN B-noun.person	decreases VBZ B-verb.change	fexofenadine JJ B-adj.all	gastrointestinal JJ B-adj.all	secretion NN B-noun.act	, , 0	while IN 0	erythromycin NN B-noun.person	may MD 0	also RB 0	decrease VB B-verb.change	biliary JJ B-adj.all	excretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d209.s8	Further RB B-adv.all	, , 0	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	with IN 0	PROSCAR NNP B-noun.group	( ( 0	finasteride VB 0	, , 0	5 CD B-adj.all	mg NN B-noun.quantity	) ) 0	when WRB 0	used VBN B-verb.consumption	in IN 0	older JJR B-adj.all	men NNS B-noun.person	who WP 0	have VBP B-verb.stative	benign JJ B-adj.all	prostatic JJ B-adj.all	hyperplasia NN B-noun.person	( ( 0	BPH NNP 0	) ) 0	, , 0	PSA NNP B-noun.person	levels NNS I-noun.person	are VBP 0	decreased VBN B-verb.change	by IN 0	approximately RB B-adv.all	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d140.s1	OBJECTIVE NNP B-noun.group	, , 0	Our PRP$ 0	objective NN B-noun.cognition	was VBD B-verb.stative	to TO 0	characterize VB B-verb.change	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	pharmacokinetics NNS B-noun.person	of IN 0	everolimus NN 0	and CC 0	cyclosporine NN B-noun.person	( ( 0	INN NNP 0	, , 0	ciclosporin NN B-noun.location	) ) 0	when WRB 0	coadministered VBN B-verb.communication	in IN 0	de FW 0	novo FW 0	kidney NN B-noun.act	allograft NN B-noun.artifact	recipients NNS B-noun.artifact	during IN 0	the DT 0	first JJ B-adj.all	year NN B-noun.time	after IN 0	transplantation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d328.s36	Coadministration NN B-noun.person	of IN 0	glyburide NN 0	with IN 0	doses NNS B-noun.food	higher JJR B-adj.all	than IN 0	40 CD B-adj.all	mg NN B-noun.quantity	valdecoxib NN B-noun.attribute	( ( 0	e.g. UH 0	, , 0	40 CD 0	mg IN 0	BID NNP 0	) ) 0	have VBP 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d75.s1	In IN 0	vivo JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	in IN 0	humans NNS B-noun.animal	have VBP 0	demonstrated VBN B-verb.cognition	that IN 0	digoxin NN B-noun.person	and CC 0	warfarin NN B-noun.act	do VBP 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	PK NNP 0	properties NNS B-noun.attribute	of IN 0	anagrelide NN B-noun.animal	, , 0	nor CC 0	does VBZ 0	anagrelide VB 0	affect VB B-verb.change	the DT 0	PK NNP 0	properties NNS B-noun.attribute	of IN 0	digoxin NN B-noun.substance	or CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d31.s3	Beta SYM 0	- : 0	blockers NNS B-noun.person	( ( 0	metoprolol NN B-noun.person	, , 0	propranolol NN 0	) ) 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	and CC 0	pharmacologic JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d489.s7	Hypotension NN B-noun.person	was VBD B-verb.stative	more RBR B-adv.all	likely JJ B-adj.all	to TO 0	occur VB B-verb.cognition	if IN 0	the DT 0	calcium_antagonist JJ 0	were VBD B-verb.stative	a DT 0	dihydropyridine_derivative JJ B-noun.other	, , 0	e.g. NNP B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	while IN 0	left JJ B-adj.all	ventricular JJ B-adj.all	failure NN B-noun.person	and CC 0	AV NNP 0	conduction NN 0	disturbances NNS B-noun.artifact	, , 0	including VBG B-verb.stative	complete JJ B-adj.all	heart NN B-noun.person	block NN B-noun.person	, , 0	were VBD B-verb.stative	more RBR B-adv.all	likely JJ B-adj.all	to TO 0	occur VB B-verb.stative	with IN 0	either DT 0	verapamil NN B-noun.location	or CC 0	diltiazem NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d509.s20	When WRB 0	carbamazepine NN 0	is VBZ 0	added VBN B-verb.change	to TO 0	aripiprazole VB B-verb.change	therapy NN I-verb.change	, , 0	aripiprazole NN B-noun.cognition	dose NN I-noun.cognition	should MD 0	be VB 0	doubled VBN B-verb.contact	. . 0	. . 0
DDI-MedLine.d124.s0	Lack NN B-noun.person	of IN 0	interaction NN B-noun.act	between IN 0	levofloxacin NN B-noun.state	and CC 0	oxycodone NN B-noun.person	, , 0	pharmacokinetics NNS B-noun.person	and CC 0	drug NN B-noun.person	disposition NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d521.s3	- : 0	a DT 0	sulfa NN B-noun.person	- : 0	based VBN B-verb.cognition	drug NN 0	such JJ 0	as IN 0	sulfamethoxazole NN B-noun.person	- : 0	trimethoprim NN B-noun.person	( ( 0	Bactrim NNP B-noun.other	, , 0	Septra NNP B-noun.location	) ) 0	, , 0	sulfisoxazole NN B-noun.person	( ( 0	Gantrisin NNP B-noun.person	) ) 0	, , 0	or CC 0	sulfasalazine NN B-noun.substance	( ( 0	Azulfidine NNP B-noun.location	) ) 0	, , 0	. . 0
DDI-MedLine.d90.s8	Recovery NN B-noun.person	from IN 0	50 CD B-adj.all	% NN 0	twitch NN B-noun.act	to TO 0	75 CD 0	% NN 0	fade NN B-noun.attribute	recovery NN B-noun.process	took VBD B-verb.motion	13.8 CD 0	+ : 0	/- $ 0	0.8 CD 0	min NN B-noun.quantity	for IN 0	atracurium NN 0	alone RB 0	and CC 0	13.7 CD 0	+ : 0	/- # 0	1.2 CD 0	min NN B-noun.quantity	for IN 0	atracurium NN B-noun.person	plus CC 0	gentamycin NN B-noun.state	. . 0	. . 0
DDI-MedLine.d111.s14	Coingestion NN B-noun.person	of IN 0	acetaminophen NN B-noun.person	with IN 0	theophylline PRP 0	, , 0	phenobarbital JJ B-adj.all	with IN 0	acetaminophen NN B-noun.person	, , 0	and CC 0	valproic_acid NNP B-noun.person	with IN 0	phenobarbital NN B-noun.artifact	at IN 0	high JJ B-adj.all	to TO 0	toxic JJ B-adj.all	concentrations NNS B-noun.attribute	decreases VBZ B-verb.change	the DT 0	binding NN B-noun.act	of IN 0	the DT 0	target NN B-noun.artifact	drug NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d516.s17	Omeprazole NNP B-noun.person	, , 0	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	changes NNS B-noun.relation	in IN 0	lomefloxacin NN B-adj.all	pharmacokinetics NNS B-noun.person	( ( 0	AUC NNP 0	, , 0	C NNP 0	max NN 0	, , 0	or CC 0	T NNP 0	max NN 0	) ) 0	were VBD 0	observed VBN B-verb.perception	when WRB 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	lomefloxacin NN B-noun.communication	400 CD 0	mg NN B-noun.quantity	was VBD 0	given VBN B-verb.possession	after IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	omeprazole NN B-noun.attribute	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	qd NN 0	) ) 0	in IN 0	13 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d547.s0	No DT 0	significant JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	studies NNS B-noun.act	of IN 0	candesartan_cilexetil NN 0	given VBN B-verb.possession	with IN 0	other JJ 0	drugs NNS B-noun.object	such JJ 0	as IN 0	glyburide NN 0	, , 0	nifedipine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	hydrochlorothiazide NN 0	, , 0	and CC 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	or CC 0	given VBN B-verb.possession	with IN 0	enalapril NN B-noun.person	to TO 0	patients NNS B-noun.person	with IN 0	heart NN B-noun.body	failure NN B-noun.person	( ( 0	NYHA NNP 0	class NN 0	II NNP 0	and CC 0	III NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d176.s12	In IN 0	separate JJ B-adj.all	single JJ B-adj.all	or CC 0	multiple JJ B-adj.all	dose NN B-noun.communication	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	chlorthalidone NN 0	, , 0	nifedipine NN B-noun.person	, , 0	propanolol NN B-noun.person	, , 0	hydrochlorothiazide NN 0	, , 0	cimetidine NN B-noun.person	, , 0	metoclopramide NN B-noun.attribute	, , 0	propantheline NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	and CC 0	warfarin NN B-noun.act	, , 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	fosinoprilat NN B-noun.person	was VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	fosinopril NN 0	with IN 0	any DT 0	one CD 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d270.s25	Ethinyl_estradiol NNP B-noun.person	Norethindrone NNP I-noun.person	. . 0
DDI-DrugBank.d441.s8	If IN 0	any DT 0	signs NNS B-noun.communication	or CC 0	symptoms NNS B-noun.communication	occur VBP B-verb.stative	physicians NNS B-noun.person	should MD 0	consider VB B-verb.communication	discontinuation NN B-noun.act	of IN 0	either DT 0	one CD 0	or CC 0	both DT 0	agents NNS B-noun.person	( ( 0	ZYVOX NNP B-noun.group	or CC 0	concomitant JJ B-adj.all	serotonergic_agents NNS B-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d160.s1	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	to TO 0	avoid VB B-verb.social	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	ethambutol NN 0	with IN 0	aluminum_hydroxide RB 0	containing VBG B-verb.body	antacids NNS I-verb.body	for IN 0	at IN 0	least JJS 0	4 CD B-adj.all	hours NNS B-noun.artifact	following VBG B-verb.stative	ethambutol JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-MedLine.d63.s0	Differential JJ B-adj.all	actions NNS B-noun.act	of IN 0	intrathecal JJ B-adj.all	naloxone NN B-noun.person	on IN 0	blocking VBG B-verb.change	the DT 0	tail NN B-noun.body	- : 0	flick NN 0	inhibition NN 0	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	beta NN B-noun.food	- : 0	endorphin NN B-noun.person	and CC 0	morphine NN B-noun.person	in IN 0	rats NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d343.s0	Aspirin NNP B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	heparin NN B-noun.person	, , 0	NSAIDs NNP B-noun.person	. . 0
DDI-DrugBank.d290.s1	Standard JJ B-adj.all	therapy NN B-noun.act	includes VBZ B-verb.stative	antibiotics NNS B-noun.attribute	, , 0	such JJ 0	as IN 0	penicillin NN B-noun.person	and CC 0	gentamicin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d480.s7	similar JJ B-adj.all	events NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	other JJ B-adj.all	psychotropic_drugs NNS B-noun.plant	or CC 0	even RB 0	Clozapine NNP B-noun.person	by IN 0	itself PRP 0	. . 0	. . 0
DDI-DrugBank.d506.s7	Patients NNS B-noun.person	taking VBG B-verb.social	disopyramide_phosphate JJ B-noun.other	and CC 0	erythromycin NN B-noun.person	concomitantly RB B-adv.all	may MD 0	develop VB 0	increased VBN B-verb.change	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	disopyramide NN 0	resulting VBG B-verb.stative	in IN 0	excessive JJ B-adj.all	widening NN B-noun.process	of IN 0	the DT 0	QRS NNP B-noun.group	complex JJ B-adj.all	and/or NN 0	prolongation NN B-noun.act	of IN 0	the DT 0	Q NNP 0	- : 0	T NNP 0	interval NN 0	. . 0	. . 0
DDI-DrugBank.d47.s3	In IN 0	addition NN 0	, , 0	the DT 0	beneficial JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	levodopa NN B-noun.state	in IN 0	Parkinsons NNP B-noun.other	disease NN 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	be VB 0	reversed VBN B-verb.change	by IN 0	phenytoin NN B-noun.person	and CC 0	papaverine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d305.s2	Binding VBG B-verb.social	to TO 0	plasma VB B-verb.social	protein NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	by IN 0	diazepam NN B-noun.person	, , 0	diphenylhydantoin NN B-noun.person	, , 0	or CC 0	phenylbutazone NN B-noun.substance	. . 0	. . 0
DDI-MedLine.d82.s8	Vitamin_D3 JJ B-noun.phenomenon	administration NN I-noun.phenomenon	to TO 0	rachitic JJ B-adj.all	chicks NNS B-noun.body	was VBD B-verb.stative	effective JJ B-adj.all	in IN 0	significantly RB B-adv.all	elevating VBG B-verb.social	duodenal JJ B-adj.all	arsenate NN B-noun.person	absorption NN B-noun.person	, , 0	acting VBG B-verb.stative	primarily RB B-adv.all	to TO 0	enhance VB B-verb.social	serosal NN B-noun.act	transport NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d140.s11	These DT 0	increases NNS B-noun.attribute	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	selecting VBG B-verb.cognition	an DT 0	oral JJ B-adj.all	contraceptive NN B-noun.attribute	for IN 0	a DT 0	woman NN B-noun.person	taking VBG B-verb.social	atorvastatin NN I-verb.social	. . 0	. . 0
DDI-DrugBank.d376.s0	May MD 0	interact VB B-verb.change	with IN 0	addictive JJ B-adj.all	medications NNS B-noun.person	, , 0	especially RB B-adj.all	central_nervous_system_(CNS)_depressants NNS B-noun.location	with IN 0	habituating VBG B-verb.social	potential JJ I-verb.social	( ( 0	prolonged VBN B-verb.creation	concurrent JJ B-adj.all	use NN 0	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	habituation NN 0	) ) 0	, , 0	alcohol NN B-noun.person	or CC 0	CNS NNP 0	depression NN 0	producing VBG B-verb.stative	medications NNS B-noun.person	( ( 0	concurrent JJ B-adj.all	use NN 0	may MD 0	increase VB B-verb.change	the DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	either CC 0	these DT 0	medications NNS B-noun.artifact	or CC 0	ethinamate NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d31.s0	MAO_inhibitors NNS B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	hydralazine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d450.s9	Thyroid DT 0	administration NN B-noun.motive	to TO 0	a DT 0	digitalized VBN B-verb.creation	, , 0	hypothyroid JJ B-adj.all	patient NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	dose NN B-noun.communication	requirement NN B-noun.communication	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d60.s3	Infusion NN 0	requirements NNS B-noun.object	of IN 0	NIMBEX NNP B-noun.group	in IN 0	patients NNS B-noun.person	administered VBD B-verb.communication	succinylcholine NN B-noun.person	prior RB 0	to TO 0	infusions NNS B-noun.cognition	of IN 0	NIMBEX NNP B-noun.group	were VBD B-verb.stative	comparable JJ B-adj.all	to TO 0	or CC 0	slightly RB B-adv.all	greater JJR B-adj.all	than IN 0	when WRB 0	succinylcholine NN B-noun.person	was VBD B-verb.stative	not RB B-adv.all	administered VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d340.s25	Didanosine NNP B-noun.person	, , 0	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	didanosine NN B-noun.person	be VB 0	administered VBN B-verb.possession	on IN 0	an DT 0	empty JJ B-adj.all	stomach NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d440.s9	In IN 0	the DT 0	large JJ B-adj.all	, , 0	placebo NN B-noun.person	- : 0	controlled VBN B-verb.social	osteoporosis NN 0	Treatment NNP B-noun.other	Study NNP I-noun.other	, , 0	aspirin NN B-noun.person	and CC 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.person	were VBD 0	taken VBN B-verb.social	by IN 0	62 CD 0	% NN 0	of IN 0	the DT 0	2946 CD 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d516.s16	Interaction NN B-noun.act	between IN 0	lomefloxacin NN B-noun.person	and CC 0	cyclosporine NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d179.s24	- : 0	Acetohydroxamic_acid NN B-noun.quantity	( ( 0	e.g. UH 0	, , 0	Lithostat NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d500.s5	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	tetracycline NN B-noun.attribute	and CC 0	Penthrane NNP B-noun.person	( ( 0	methoxyflurane NN B-noun.attribute	) ) 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	result VB B-verb.stative	in IN 0	fatal JJ B-adj.all	renal JJ B-noun.body	toxicity NN I-noun.body	. . 0	. . 0
DDI-MedLine.d135.s6	These DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	acute JJ B-adj.all	dosing NN B-noun.person	with IN 0	clozapine NN B-noun.person	would MD 0	not RB B-adv.all	affect VB B-verb.change	behaviors NNS 0	most RBS 0	closely RB B-adv.all	associated VBN B-verb.cognition	with IN 0	PCP NNP 0	intoxication NN 0	. . 0	. . 0
DDI-DrugBank.d324.s36	Drugs NNS B-noun.other	That IN I-noun.other	Alter NNP I-noun.other	Renal NNP I-noun.other	Excretion NNP I-noun.other	Ibuprofen NNP I-noun.other	, , 0	Ibuprofen NNP B-noun.person	is VBZ 0	known VBN B-verb.cognition	to TO 0	affect VB B-verb.change	renal JJ B-adj.all	function NN B-noun.act	and CC 0	, , 0	consequently RB B-adv.all	, , 0	alter VB B-verb.change	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	other JJ 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d94.s13	Agents NNS B-noun.person	with IN 0	Increased NNP B-noun.group	Levels NNP I-noun.group	in IN 0	the DT 0	Presence NNP B-noun.person	of IN 0	Carbamazepine NNP B-noun.location	, , 0	EQUETROTM NNP B-noun.group	increases VBZ B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	the DT 0	following VBG 0	agents NNS B-noun.person	, , 0	Clomipramine_HCl NNP B-noun.person	, , 0	Phenytoin(6 NN 0	) ) 0	, , 0	and CC 0	primidone NN 0	Thus RB 0	, , 0	if IN 0	a DT 0	patient NN B-noun.person	has VBZ 0	been VBN 0	titrated VBN B-verb.communication	to TO 0	a DT 0	stable JJ B-adj.all	dosage NN B-noun.attribute	on IN 0	one CD 0	of IN 0	the DT 0	agents NNS B-noun.person	in IN 0	this DT 0	category NN B-noun.location	, , 0	and CC 0	then RB B-adv.all	begins VBZ B-verb.stative	a DT 0	course NN B-noun.object	of IN 0	the DT 0	treatment NN B-noun.plant	with IN 0	EQUETROTM NNP B-noun.group	, , 0	it PRP 0	is VBZ B-verb.stative	reasonable JJ B-adj.all	to TO 0	expect VB B-verb.cognition	that IN 0	a DT 0	dose NN B-noun.person	decrease NN B-noun.state	for IN 0	the DT 0	concomitant JJ B-adj.all	agent NN B-noun.person	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d558.s37	The DT 0	mean JJ B-adj.all	clearances NNS B-noun.person	of IN 0	dofetilide NN 0	were VBD B-verb.stative	16 CD B-adj.all	% NN 0	and CC 0	15 CD B-adj.all	% NN 0	lower JJR B-adj.all	in IN 0	patients NNS B-noun.person	on IN 0	thiazide_diuretics NNS B-noun.artifact	and CC 0	inhibitors NNS B-noun.person	of IN 0	tubular JJ B-adj.all	organic JJ B-adj.all	cation NN B-noun.artifact	transport NN I-noun.artifact	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d136.s0	Alcohol NNP B-noun.person	( ( 0	increases VBZ B-verb.change	bioavailability NN I-verb.change	by IN 0	50 CD B-adj.all	% NN 0	) ) 0	, , 0	cimetidine NN B-noun.person	, , 0	and CC 0	valproates NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d448.s1	Concomitant JJ B-adj.all	use NN 0	of IN 0	antihistamines NNS B-noun.object	with IN 0	alcohol NN B-noun.food	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d558.s6	Verapamil NNP B-noun.person	, , 0	Concomitant JJ 0	use NN 0	of IN 0	verapamil NN B-noun.food	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d457.s0	Barbiturates NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	effectiveness NN B-noun.cognition	of IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	certain JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	theophylline PRP 0	, , 0	corticosteroids NNS B-noun.person	, , 0	anticoagulants NNS B-noun.person	, , 0	and CC 0	beta_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d153.s0	The DT 0	administration NN B-noun.time	of IN 0	local JJ B-adj.all	anesthetic_solutions NNS 0	containing VBG B-verb.stative	epinephrine NN B-noun.substance	or CC 0	norepinephrine NN B-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxidase_inhibitors NNS B-noun.person	or CC 0	tricyclic_antidepressants NNS B-noun.group	may MD 0	produce VB B-verb.cognition	severe JJ 0	, , 0	prolonged VBD B-verb.communication	hypertension NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d333.s4	Fluoxetine NN B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	clonazepam NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d415.s1	However RB 0	, , 0	because IN 0	bleeding NN B-noun.act	has VBZ 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	ibuprofen NNS B-noun.person	and CC 0	other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_agents NNS B-noun.person	have VBP 0	been VBN 0	administered VBN B-verb.perception	to TO 0	patients NNS B-noun.person	on IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	, , 0	the DT 0	physician NN B-noun.communication	should MD 0	be VB B-verb.stative	cautious JJ B-adj.all	when WRB 0	administering VBG B-verb.communication	ibuprofen NNS B-noun.person	to TO 0	patients NNS B-noun.person	on IN 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d0.s6	Patients NNS B-noun.person	taking VBG B-verb.social	Acamprosate NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	antidepressants NNS B-noun.person	more RBR B-adv.all	commonly RB B-adv.all	reported VBN B-verb.communication	both DT 0	weight NN B-noun.phenomenon	gain NN B-noun.artifact	and CC 0	weight NN B-noun.phenomenon	loss NN B-noun.process	, , 0	compared VBN B-verb.cognition	with IN 0	patients NNS B-noun.person	taking VBG B-verb.social	either DT 0	medication NN B-noun.state	alone RB 0	. . 0	. . 0
DDI-DrugBank.d345.s0	Since IN 0	colestipol_hydrochloride NN 0	is VBZ B-verb.stative	an DT 0	anion_exchange_resin NN B-noun.object	, , 0	it PRP 0	may MD 0	have VB B-verb.stative	a DT 0	strong JJ B-adj.all	affinity NN B-noun.communication	for IN 0	anions NNS B-noun.animal	other JJ 0	than IN 0	the DT 0	bile NN B-noun.group	acids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d212.s8	Valproate NNP B-noun.person	Keppra NNP I-noun.person	_ . 0	( ( 0	1500 CD 0	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	valproate NN B-noun.attribute	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d438.s19	Hydrocodone NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	Neurontin NNP B-noun.person	_ . 0	( ( 0	125 CD 0	to TO 0	500 CD 0	mg NN B-noun.quantity	, , 0	. . 0
DDI-DrugBank.d565.s14	The DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	mediated VBN B-verb.cognition	by IN 0	cimetidines NNS B-noun.person	known VBN B-verb.cognition	inhibition NN B-noun.attribute	of IN 0	hepatic JJ B-adj.all	cytochrome NN B-noun.person	P-450 NN I-noun.person	, , 0	the DT 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	responsible JJ B-adj.all	for IN 0	the DT 0	first JJ B-noun.person	- : 0	pass NN B-noun.time	metabolism NN B-noun.attribute	of IN 0	diltiazem NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d364.s3	Fluvoxamine NNP B-noun.person	increased VBD B-verb.change	mean JJ B-adj.all	alosetron JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	AUC NNP 0	) ) 0	approximately RB B-adv.all	6-fold JJ B-adj.all	and CC 0	prolonged VBD B-verb.communication	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	by IN 0	approximately RB B-adj.all	3-fold JJ I-adj.all	. . 0	. . 0
DDI-DrugBank.d237.s3	Anticholinergics NNS B-noun.person	, , 0	Concurrent NNP B-noun.person	administration NN I-noun.person	of IN 0	certain JJ B-adj.all	anticholinergic_compounds NNS B-noun.location	, , 0	such JJ 0	as IN 0	belladonna_alkaloids NNS B-noun.artifact	and CC 0	dicyclomine NN B-noun.person	, , 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	compromise VB B-verb.change	the DT 0	beneficial JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	cisapride NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d82.s33	Blunting VBG 0	of IN 0	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	beta JJ B-adj.pert	- : 0	adrenoceptor_blocking_agents NNS B-noun.person	by IN 0	non NN B-noun.person	- : 0	steroidal_antiinflammatory_drugs NNS B-noun.plant	including VBG B-verb.change	INDOCIN NNP B-noun.group	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d78.s0	Antacids NNP B-noun.person	, , 0	Sucralfate NNP B-noun.person	, , 0	Metal NNP B-noun.person	Cations NNPS I-noun.person	, , 0	Multivitamins NNP B-noun.person	Quinolones NNP I-noun.person	form NN I-noun.person	chelates VBZ B-verb.communication	with IN 0	alkaline JJ B-adj.all	earth NN B-noun.substance	and CC 0	transition NN B-noun.act	metal NN B-noun.artifact	cations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d97.s60	Anticonvulsants NNS B-noun.person	, , 0	carbamazepine NN 0	, , 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	. . 0
DDI-DrugBank.d202.s7	Fluoxetine NNP B-noun.person	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	norfluoxe RB B-adv.all	- : 0	tine NN 0	, , 0	have VBP 0	long JJ B-noun.body	half NN I-noun.body	- : 0	lives NNS B-noun.time	( ( 0	4 CD 0	to TO 0	16 CD B-adj.all	days NNS B-noun.person	for IN 0	norfluoxetine NN B-noun.location	) ) 0	, , 0	that WDT 0	may MD 0	affect VB B-verb.change	strategies NNS B-noun.artifact	during IN 0	conversion NN B-noun.cognition	from IN 0	one CD 0	drug NN 0	to TO 0	the DT 0	other JJ 0	. . 0	. . 0
DDI-DrugBank.d217.s1	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	theophylline PRP 0	- : 0	related JJ B-adj.all	side NN B-noun.location	effects NNS B-noun.phenomenon	in IN 0	patients NNS B-noun.person	on IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	norfloxacin NN B-noun.person	and CC 0	theophylline PRP 0	. . 0	. . 0
DDI-DrugBank.d165.s24	Plasma NNP B-noun.person	concentrations NNS I-noun.person	of IN 0	azole_antifungal_agents NNS B-noun.person	are VBP 0	reduced VBN B-verb.change	when WRB 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	isoniazid NN B-noun.feeling	. . 0	. . 0
DDI-DrugBank.d410.s7	SSRIs NNP 0	, , 0	Weakness NNP B-noun.person	hyperreflexia NN I-noun.person	, , 0	and CC 0	incoordination NN B-noun.act	have VBP 0	been VBN 0	reported VBN B-verb.communication	rarely RB B-adv.all	when WRB 0	5-HT1_agonists NNS B-noun.person	have VBP 0	been VBN B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	SSRIs NNP B-noun.person	( ( 0	e. FW 0	g. FW 0	. . 0
DDI-DrugBank.d321.s1	Praziquantel NNP B-noun.person	, , 0	In IN 0	the DT 0	fed VBN B-verb.consumption	state NN I-verb.consumption	, , 0	praziquantel NN 0	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	increased VBD B-verb.change	mean JJ B-adj.all	maximum JJ B-adj.all	plasma NN B-noun.substance	concentration NN B-noun.event	and CC 0	area NN B-noun.body	under IN 0	the DT 0	curve NN B-noun.communication	of IN 0	albendazole_sulfoxide JJ 0	by IN 0	about IN 0	50 CD B-adj.all	% NN 0	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	( ( 0	n=10 NNP 0	) ) 0	compared VBN B-verb.stative	with IN 0	a DT 0	separate JJ B-adj.all	group NN 0	of IN 0	subjects NNS B-noun.person	( ( 0	n=6 NNP 0	) ) 0	given VBN B-verb.possession	albendazole RP 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d526.s9	Antidiabetic_drugs NNS B-noun.animal	( ( 0	oral JJ B-adj.all	agents NNS B-noun.person	and CC 0	insulin NN B-noun.body	) ) 0	diminished VBD B-verb.change	antidiabetic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d468.s4	Digoxin NNP B-noun.person	, , 0	Some DT 0	calcium_blockers NNS B-noun.object	may MD 0	increase VB B-verb.change	the DT 0	concentration NN B-noun.event	of IN 0	digitalis_preparations NNS B-noun.food	in IN 0	the DT 0	blood NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d395.s21	Enoxacin NNP B-noun.person	interferes VBZ B-verb.contact	with IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	theophylline NN 0	resulting VBG B-verb.stative	in IN 0	a DT 0	42 CD 0	% NN 0	to TO 0	74 CD 0	% NN 0	dose NN B-noun.act	- : 0	related JJ B-adj.all	decrease NN B-noun.act	in IN 0	theophylline JJ 0	clearance NN B-noun.attribute	and CC 0	a DT 0	subsequent JJ B-adj.all	260 CD 0	% NN 0	to TO 0	350 CD 0	% NN 0	increase NN B-noun.event	in IN 0	serum NN 0	theophylline NN 0	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d20.s9	Serum NNP B-noun.person	lithium NN I-noun.person	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	frequently RB B-adv.all	if IN 0	INSPRA NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d329.s0	When WRB 0	ertapenem NN 0	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	probenecid NN B-noun.person	( ( 0	500 CD 0	mg RB 0	p.o RB 0	. . 0	every DT 0	6 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	, , 0	probenecid JJ B-adj.all	competes NNS B-noun.person	for IN 0	active JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	and CC 0	reduces VBZ B-verb.change	the DT 0	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	ertapenem NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d54.s29	Decreases NNS B-noun.person	in IN 0	TBg NNP B-noun.person	concentrations NNS I-noun.person	are VBP 0	observed VBN B-verb.perception	in IN 0	nephrosis NN B-noun.animal	, , 0	acromegaly RB B-adv.all	and CC 0	after IN 0	androgen NN B-noun.person	or CC 0	corticosteroid JJ B-adj.all	therapy NN B-noun.person	. . 0	. . 0
DDI-MedLine.d82.s7	Furthermore RB B-adv.all	, , 0	arsenate NN B-noun.person	and CC 0	phosphate NN B-noun.person	do VBP 0	not RB B-adv.all	appear VB B-verb.change	to TO 0	share VB B-verb.social	a DT 0	common JJ B-noun.person	transport NN I-noun.person	pathway NN B-noun.person	in IN 0	the DT 0	duodenum NN B-noun.artifact	and CC 0	no DT 0	evidence NN B-noun.person	was VBD 0	obtained VBN B-verb.social	for IN 0	any DT 0	interaction NN B-noun.act	between IN 0	the DT 0	two CD 0	at IN 0	this DT 0	level NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d358.s0	Since IN 0	PLETAL NNP 0	is VBZ B-verb.stative	extensively RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	cytochrome JJ B-adj.all	P-450 NN B-noun.other	isoenzymes NNS B-noun.artifact	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	PLETAL NNP 0	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	inhibitors NNS B-noun.person	of IN 0	C.P.A. NNP B-noun.group	such JJ 0	as IN 0	ketoconazole NN B-noun.person	and CC 0	erythromycin NN B-noun.person	or CC 0	inhibitors NNS B-noun.attribute	of IN 0	CYP2C19 CD 0	such JJ 0	as IN 0	omeprazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d42.s1	Blood NN B-noun.body	levels NNS B-noun.attribute	of IN 0	hydrodolasetron NN B-noun.person	increased VBD B-verb.change	24 CD B-adj.all	% NN 0	when WRB 0	dolasetron NN B-noun.person	was VBD 0	coadministered VBN B-verb.contact	with IN 0	cimetidine NN B-noun.person	( ( 0	nonselective JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	cytochrome NN 0	P-450 NN 0	) ) 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	, , 0	and CC 0	decreased VBD B-verb.change	28 CD B-adj.all	% NN 0	with IN 0	coadministration NN B-noun.person	of IN 0	rifampin NN B-noun.substance	( ( 0	potent JJ B-noun.person	inducer NN I-noun.person	of IN 0	cytochrome NN 0	P-450 NN 0	) ) 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d338.s11	Estazolam NN B-noun.person	, , 0	Interaction NNP B-noun.person	with IN 0	Other JJ 0	Drugs NNS B-noun.person	that WDT 0	are VBP 0	Metabolized VBN B-verb.cognition	by IN 0	Cytochrome NNP B-noun.person	P450 NNP I-noun.person	( ( 0	CYP NNP 0	) ) 0	, , 0	At IN 0	clinically RB B-adv.all	relevant JJ B-adj.all	concentrations NNS B-noun.person	, , 0	in IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	indicate VBP B-verb.cognition	that DT 0	estazolam NN B-noun.communication	( ( 0	0.6 CD 0	M NNP B-noun.attribute	) ) 0	was VBD B-verb.stative	not RB B-adv.all	inhibitory JJ B-adj.all	towards IN 0	the DT 0	major JJ B-adj.all	cytochrome NN B-noun.person	P450 NN I-noun.person	isoforms NNS I-noun.person	CYP1A2 NNP I-noun.person	, , 0	CYP2A6 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2C19 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	CYP2E1 NNP B-noun.person	, , 0	and CC 0	CYP3A. NNP B-noun.person	. . 0
DDI-DrugBank.d315.s1	Therefore RB 0	, , 0	if IN 0	digoxin NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	VAPRISOL NNP B-noun.group	, , 0	the DT 0	clinician NN B-noun.communication	should MD 0	be VB B-verb.stative	alert JJ B-adj.all	to TO 0	the DT 0	possibility NN B-noun.state	of IN 0	increases NNS B-noun.food	in IN 0	digoxin NN B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d107.s3	Agents NNS B-noun.person	Causing VBG I-noun.person	Renin NNP I-noun.person	Release NNP I-noun.person	, , 0	The DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	enalapril NN B-noun.person	and CC 0	enalapril VB B-verb.change	IV NNP 0	is VBZ 0	augmented VBN B-verb.change	by IN 0	antihypertensive_agents NNS B-noun.person	that WDT 0	cause VBP B-verb.emotion	renin NN I-verb.emotion	release NN B-noun.state	( ( 0	e.g. UH 0	, , 0	diuretics NNS B-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d47.s0	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	the DT 0	following VBG 0	drugs NNS B-noun.person	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	LODOSYN NNP B-noun.group	( ( 0	Carbidopa NNP 0	) ) 0	given VBN B-verb.possession	with IN 0	levodopa NN B-noun.state	or CC 0	carbidopa NN B-noun.group	- : 0	levodopa NN B-noun.person	combination NN B-noun.person	products NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d60.s6	Isoflurane NNP B-noun.person	or CC 0	enflurane NN B-noun.person	administered VBN B-verb.possession	with IN 0	nitrous_oxide JJ 0	/ DT 0	oxygen NN B-noun.quantity	to TO 0	achieve VB B-verb.social	1.25 CD 0	MAC NNP B-noun.group	[ NNP I-noun.group	Minimum NNP I-noun.group	Alveolar NNP I-noun.group	Concentration NNP I-noun.group	] ( 0	may MD 0	prolong VB B-verb.stative	the DT 0	clinically RB B-adj.all	effective JJ B-adj.all	duration NN B-noun.attribute	of IN 0	action NN B-noun.process	of IN 0	initial JJ B-adj.all	and CC 0	maintenance NN B-noun.act	doses NNS B-noun.event	of IN 0	NIMBEX NNP B-noun.group	and CC 0	decrease VB B-verb.change	the DT 0	required JJ B-adj.all	infusion NN B-noun.event	rate NN B-noun.time	of IN 0	NIMBEX NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d49.s0	Interaction NN B-noun.act	of IN 0	clindamycin NN B-noun.person	and CC 0	gentamicin NN B-noun.person	in IN 0	vitro NN B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d368.s12	Acetazolamide NNP B-noun.person	increases VBZ B-verb.cognition	lithium NN I-verb.cognition	excretion NN B-noun.act	and CC 0	the DT 0	lithium NN B-noun.location	may MD 0	be VB 0	decreased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d392.s1	Animal NN 0	toxicology NN 0	studies NNS B-noun.person	showed VBD B-verb.communication	increased VBN B-verb.change	DEET NNP B-noun.group	toxicity NN B-noun.attribute	when WRB 0	DEET NNP B-noun.person	was VBD 0	included VBN B-verb.stative	as IN 0	proof NN B-noun.person	of IN 0	the DT 0	formulation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d270.s69	Diltiazem NNP B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	verapamil RB B-adv.all	. . 0
DDI-MedLine.d61.s1	Amiodarone NNP B-noun.person	is VBZ 0	known VBN B-verb.cognition	to TO 0	raise VB B-verb.social	serum NN 0	digoxin NN 0	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d210.s27	Theophylline DT 0	VIOXX NNP B-noun.group	12.5 CD 0	, , 0	25 CD B-adj.all	, , 0	and CC 0	50 CD B-adj.all	mg NN B-noun.quantity	administered VBN B-verb.possession	once RB B-adv.all	daily RB B-adv.all	for IN 0	7 CD B-adj.all	days NNS B-noun.artifact	increased VBN B-verb.change	plasma NN 0	theophylline NN 0	concentrations NNS B-noun.attribute	( ( 0	AUC(0- VB 0	) ) 0	) ) 0	by IN 0	38 CD 0	to TO 0	60 CD B-adj.all	% NN 0	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	administered VBD B-verb.possession	a DT 0	single JJ B-adj.all	300-mg JJ 0	dose NN B-noun.quantity	of IN 0	theophylline NN 0	. . 0	. . 0
DDI-DrugBank.d367.s1	In IN 0	vitro NN B-noun.animal	data NNS B-noun.cognition	in IN 0	human JJ B-adj.all	plasma NN B-noun.person	indicate VBP B-verb.cognition	that IN 0	doxazosin_mesylate NNP B-noun.person	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	phenytoin NN B-noun.person	or CC 0	indomethacin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d29.s8	Coadministration NN B-noun.person	of IN 0	esomeprazole JJ B-noun.communication	30 CD B-adj.all	mg NN B-noun.quantity	and CC 0	diazepam NN B-noun.person	, , 0	a DT 0	CYP2C19 JJ B-adj.all	substrate NN B-noun.person	, , 0	resulted VBD B-verb.stative	in IN 0	a DT 0	45 CD 0	% NN 0	decrease NN B-noun.act	in IN 0	clearance NN B-noun.act	of IN 0	diazepam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s10	Lithium NNP B-noun.person	; : 0	Coadministration NNP B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	10 CD B-adj.all	days NNS B-noun.time	) ) 0	and CC 0	lithium NN B-noun.substance	( ( 0	30 CD B-adj.all	mmol NN B-noun.quantity	/ : 0	day NN B-noun.person	for IN 0	5 CD B-adj.all	days NNS B-noun.act	) ) 0	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	citalopram NN B-noun.location	or CC 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d196.s1	Theophylline DT 0	serum NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	and CC 0	appropriate JJ B-adj.all	dose NN B-noun.person	adjustments NNS B-noun.person	considered VBN B-verb.cognition	for IN 0	patients NNS B-noun.person	given VBN B-verb.possession	both DT 0	theophylline PRP 0	and CC 0	PEGASYS NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d107.s10	Other JJ 0	Cardiovascular NNP B-noun.group	Agents NNPS I-noun.group	, , 0	Enalapril NNP B-noun.person	and CC 0	enalapril VB B-verb.change	IV NNP 0	have VBP 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	beta_adrenergic JJ 0	- : 0	blocking_agents NNS B-noun.person	, , 0	methyldopa NN B-noun.person	, , 0	nitrates NNS B-noun.person	, , 0	calcium NN B-noun.person	- : 0	blocking_agents NNS B-noun.person	, , 0	hydralazine NN B-noun.person	, , 0	prazosin NN B-noun.person	and CC 0	digoxin NN B-noun.person	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d482.s1	Talk NN 0	to TO 0	your PRP$ 0	doctor NN B-noun.person	if IN 0	you PRP 0	are VBP 0	taking VBG B-verb.change	certain JJ B-adj.all	antibiotics NNS B-noun.attribute	such JJ 0	as IN 0	erythromycin NN B-noun.person	, , 0	clarithromycin NN B-noun.person	or CC 0	azithromycin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d530.s2	Selegiline NN B-noun.person	; : 0	L SYM 0	- : 0	phenylalanine NN B-noun.person	and CC 0	the DT 0	selective_MAO_inhibitor NN B-noun.other	selegiline NN B-noun.act	may MD 0	have VB B-verb.change	synergistic JJ B-adj.all	antidepressant JJ B-adj.all	activity NN B-noun.process	if IN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d38.s0	ZINECARD NNP B-noun.group	does VBZ 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	doxorubicin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d105.s9	Based VBN B-verb.cognition	on IN 0	the DT 0	results NNS B-noun.communication	of IN 0	these DT 0	studies NNS B-noun.artifact	, , 0	it PRP 0	is VBZ 0	concluded VBN B-verb.cognition	that IN 0	azithromycin NN B-noun.person	may MD 0	be VB 0	safely RB B-adv.all	coadministered VBN B-verb.contact	with IN 0	both DT 0	zidovudine NN B-noun.person	and CC 0	dideoxyinosine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d134.s1	An DT 0	intravenous JJ B-adj.all	dose NN B-noun.event	of IN 0	50 CD B-adj.all	mg NN B-noun.quantity	perchlorate NN B-noun.person	was VBD B-verb.stative	in IN 0	respect NN B-noun.act	of IN 0	competitive JJ B-adj.all	suppression NN B-noun.act	of IN 0	organs NNS B-noun.body	actively RB B-adv.all	concentrating VBG B-verb.communication	pertechnetate NN B-noun.person	as IN 0	effective JJ 0	as IN 0	intravenous JJ 0	1000 CD 0	mg IN 0	ClO-4- NNP B-noun.person	simultaneously RB B-adv.all	or CC 0	1000 CD 0	mg NN B-noun.quantity	orally RB B-adv.all	30 CD B-adj.all	min NN B-noun.quantity	before IN 0	the DT 0	injection NN B-noun.act	of IN 0	radiopertechnetate NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d295.s0	Since IN 0	entecavir NN B-noun.person	is VBZ B-verb.stative	primarily RB B-adv.all	eliminated VBN B-verb.emotion	by IN 0	the DT 0	kidneys NNS B-noun.person	, , 0	coadministration NN B-noun.person	of IN 0	BARACLUDE NNP 0	with IN 0	drugs NNS B-noun.artifact	that WDT 0	reduce VBP B-verb.change	renal JJ B-adj.all	function NN B-noun.act	or CC 0	compete VB B-verb.cognition	for IN 0	active JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	may MD 0	increase VB B-verb.body	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	either DT 0	entecavir NN B-noun.location	or CC 0	the DT 0	coadministered VBN B-noun.artifact	drug NN I-noun.artifact	. . 0	. . 0
DDI-MedLine.d110.s4	Both DT 0	ibogaine NN B-noun.person	and CC 0	18-MC JJ 0	ameliorate NN B-noun.artifact	opioid JJ B-adj.all	withdrawal NN B-noun.person	signs NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d29.s7	Esomeprazole NNP B-noun.person	may MD 0	potentially RB 0	interfere VB 0	with IN 0	CYP2C19 NNP B-noun.person	, , 0	the DT 0	major JJ B-adj.all	esomeprazole NN B-noun.communication	metabolizing VBG B-verb.cognition	enzyme NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d502.s1	Close JJ B-adj.all	observation NN B-noun.act	of IN 0	the DT 0	patient NN B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	a DT 0	beta NN B-noun.person	- : 0	blocker NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	catecholamine NN B-noun.person	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.state	such JJ 0	as IN 0	reserpine NN B-noun.person	, , 0	because IN 0	of IN 0	possible JJ B-adj.all	additive JJ B-adj.all	effects NNS B-noun.phenomenon	and CC 0	the DT 0	production NN B-noun.artifact	of IN 0	hypotension NN B-noun.act	and/or CC 0	marked VBD B-verb.communication	bradycardia NNS B-noun.person	, , 0	which WDT 0	may MD 0	produce VB B-verb.cognition	vertigo RB B-adv.all	, , 0	syncope NN B-noun.person	, , 0	or CC 0	postural JJ B-adj.all	hypotension NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d516.s23	Terfenadine NN B-noun.person	, , 0	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	changes NNS B-noun.relation	occurred VBD B-verb.stative	in IN 0	heart NN 0	rate NN B-noun.time	or CC 0	corrected VBN B-verb.change	QT NNP 0	intervals NNS 0	, , 0	or CC 0	in IN 0	terfenadine NN 0	metabolite NN B-noun.attribute	or CC 0	lomefloxacin NN B-adj.all	pharmacokinetics NNS B-noun.person	, , 0	during IN 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	lomefloxacin NN B-noun.food	and CC 0	terfenadine NN B-noun.person	at IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	in IN 0	28 CD B-adj.all	healthy JJ B-adj.all	males NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s78	Dose DT 0	reduction NN B-noun.act	of IN 0	CRIXIVAN NNP B-noun.group	to TO 0	600 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.person	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	administering VBG B-verb.perception	itraconazole NN I-verb.perception	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d434.s37	Effects NNS B-noun.phenomenon	of IN 0	Felbatol NNP B-noun.person	_ ( 0	on IN 0	Low JJ 0	- : 0	Dose NN B-noun.person	Combination_Oral_Contraceptives VBZ B-verb.stative	A DT 0	group NN 0	of IN 0	24 CD B-adj.all	nonsmoking NN B-noun.quantity	, , 0	healthy JJ B-adj.all	white JJ B-noun.attribute	female JJ B-adj.all	volunteers NNS B-noun.person	established VBN B-verb.social	on IN 0	an DT 0	oral JJ B-adj.all	contraceptive JJ B-adj.all	regimen NNS B-noun.person	containing VBG B-verb.stative	30 CD 0	mg PRP$ 0	ethinyl_estradiol NN 0	and CC 0	75 CD 0	mg IN 0	gestodene NN B-noun.person	for IN 0	at IN 0	least JJS B-noun.communication	3 CD B-adj.all	months NNS B-noun.person	received VBD B-verb.possession	2400 CD 0	mg RB 0	/ JJ 0	day NN 0	of IN 0	felbamate NN B-noun.person	from IN 0	midcycle NN B-noun.person	( ( 0	day NN 0	15 CD 0	) ) 0	to TO 0	midcycle NN B-noun.person	( ( 0	day NN 0	14 CD 0	) ) 0	of IN 0	two CD 0	consecutive JJ B-adj.all	oral JJ B-adj.all	contraceptive JJ B-adj.all	cycles NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d289.s15	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	tacrolimus NN B-noun.food	and CC 0	bosentan NN B-noun.person	resulted VBD B-verb.communication	in IN 0	markedly RB B-adv.all	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	bosentan NN B-noun.food	in IN 0	animals NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d331.s6	Thus RB 0	, , 0	probenecid NN B-noun.person	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	bumetanide NN 0	. . 0	. . 0
DDI-DrugBank.d529.s8	Flurbiprofen JJ B-adj.all	pretreatment NN B-noun.person	attenuated VBD B-verb.contact	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	propranolol NN B-noun.person	but CC 0	not RB 0	atenolol VB B-verb.stative	. . 0	. . 0
DDI-MedLine.d16.s6	It PRP 0	is VBZ 0	concluded VBN B-verb.cognition	that IN 0	ketamine NN B-noun.person	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	short JJ B-noun.body	- : 0	acting VBG B-verb.body	drug NN I-verb.body	and CC 0	that IN 0	concomitant JJ B-adj.all	use NN 0	with IN 0	halothane NN B-noun.person	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	prolong VB B-verb.communication	further RB B-verb.possession	the DT 0	duration NN 0	of IN 0	its PRP$ 0	action NN B-noun.process	on IN 0	the DT 0	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d438.s41	Gabapentin NNP B-adj.all	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.person	without IN 0	and CC 0	with IN 0	probenecid NN B-noun.person	were VBD B-verb.stative	comparable JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d267.s0	Prior JJ B-adj.all	administration NN B-noun.time	of IN 0	succinylcholine NN B-noun.person	has VBZ B-verb.possession	no DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	NUROMAX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d43.s2	Allopurinol NNP B-noun.person	, , 0	The DT 0	AUC NNP B-noun.group	of IN 0	didanosine NN B-noun.person	was VBD 0	increased VBN B-verb.change	about RB 0	4-fold JJ 0	when WRB 0	allopurinol NN B-noun.person	at IN 0	300 CD 0	mg RB 0	/ JJ 0	day NN B-noun.person	was VBD 0	coadministered VBN B-verb.contact	with IN 0	a DT 0	single JJ B-adj.all	200-mg JJ 0	dose NN B-noun.quantity	of IN 0	VIDEX NNP B-noun.group	to TO 0	two CD 0	patients NNS B-noun.person	with IN 0	renal JJ B-adj.all	impairment NN B-noun.attribute	( ( 0	CLcr=15 JJ 0	and CC 0	18 CD B-adj.all	mL CD B-noun.quantity	/ JJ 0	min NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d571.s4	Patients NNS B-noun.person	on IN 0	oral JJ B-adj.all	antidiabetic_agents NNS B-noun.artifact	receiving VBG B-verb.change	VELCADE NNP B-noun.group	treatment NN B-noun.group	may MD 0	require VB B-verb.stative	close JJ B-adj.all	monitoring NN B-noun.person	of IN 0	their PRP$ 0	blood NN B-noun.location	glucose NN B-noun.state	levels NNS B-noun.state	and CC 0	adjustment NN B-noun.person	of IN 0	the DT 0	dose NN B-noun.quantity	of IN 0	their PRP$ 0	antidiabetic_medication NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d340.s28	Little JJ 0	or CC 0	no DT 0	change NN B-noun.act	in IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	drug NN B-noun.person	was VBD 0	observed VBN B-verb.perception	when WRB 0	VIRACEPT NNP B-noun.person	was VBD 0	coadministered VBN B-verb.contact	with IN 0	lamivudine NN B-noun.act	or CC 0	stavudine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d289.s27	Bosentan NNP B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	expected VBN B-verb.cognition	to TO 0	reduce VB B-verb.change	plasma NN B-noun.food	concentrations NNS B-noun.attribute	of IN 0	other JJ 0	statins NNS B-noun.communication	that WDT 0	have VBP B-verb.stative	significant JJ B-adj.all	metabolism NN B-noun.attribute	by IN 0	CYP3A4 NNP B-noun.person	, , 0	such JJ 0	as IN 0	lovastatin NN B-noun.person	and CC 0	atorvastatin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d565.s35	These DT 0	pharmacokinetic JJ B-adj.all	effects NNS B-noun.phenomenon	seen VBN B-verb.perception	during IN 0	diltiazem NN B-noun.person	coadministration NN B-noun.person	can MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	clinical JJ B-adj.all	effects NNS B-noun.phenomenon	( ( 0	e.g. UH 0	, , 0	prolonged VBD B-verb.communication	sodation)of RP 0	both DT 0	midazolam NN B-noun.person	and CC 0	triazolam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d166.s2	In IN 0	particular JJ B-adj.all	, , 0	convulsions NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	ethionamide NN 0	is VBZ 0	administered VBN B-verb.possession	with IN 0	cycloserine NN B-noun.person	and CC 0	special JJ B-adj.all	care NN B-noun.group	should MD 0	be VB 0	taken VBN B-verb.cognition	when WRB 0	the DT 0	treatment NN B-noun.plant	regimen NN B-noun.person	includes VBZ B-verb.stative	both DT 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d175.s6	therefore RB B-adv.all	, , 0	nitroglycerin NN B-noun.person	or CC 0	other JJ B-adj.all	nitrates NNS B-noun.person	( ( 0	as IN 0	used VBN B-verb.consumption	for IN 0	management NN B-noun.act	of IN 0	angina NN 0	) ) 0	or CC 0	other JJ B-adj.all	drugs NNS B-noun.person	having VBG B-verb.social	vasodilator NN B-noun.phenomenon	activity NN B-noun.process	should MD 0	, , 0	if IN 0	possible JJ B-adj.all	, , 0	be VB 0	discontinued VBN B-verb.stative	before IN 0	starting VBG B-verb.change	captopril NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d179.s2	- : 0	Amiodarone NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Cordarone NNP 0	) ) 0	or CC 0	. . 0
DDI-DrugBank.d29.s6	Patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	proton_pump_inhibitors NNS B-noun.person	and CC 0	warfarin NN 0	concomitantly RB 0	may MD 0	need VB 0	to TO 0	be VB 0	monitored VBN B-verb.perception	for IN 0	increases NNS B-noun.event	in IN 0	INR NNP 0	and CC 0	prothrombin NN B-noun.person	time NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d415.s6	This DT 0	may MD 0	indicate VB B-verb.cognition	that DT 0	ibuprofen NN B-noun.person	could MD 0	enhance VB B-verb.social	the DT 0	toxicity NN B-noun.attribute	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d365.s1	H1 NN 0	and CC 0	H2_Blockers NNS B-noun.person	; : 0	Although IN 0	not RB 0	reported VBN B-verb.communication	, , 0	L NNP 0	- : 0	histidine NN B-noun.person	, , 0	via IN 0	its PRP$ 0	metabolism NN B-noun.attribute	to TO 0	histamine VB B-verb.social	, , 0	might MD 0	decrease VB B-verb.change	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	H1 : 0	and CC 0	H2_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s7	Antifungals NNS B-noun.person	, , 0	In IN 0	vitro NN B-noun.artifact	and/or CC 0	in IN 0	vivo JJ B-adj.all	data NNS B-noun.cognition	indicate VBP B-verb.communication	that IN 0	fluconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	and CC 0	oral JJ B-adj.all	ketoconazole NN B-noun.person	markedly RB B-adv.all	inhibit VBP B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.location	, , 0	which WDT 0	can MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	cisapride NN 0	levels NNS B-noun.state	and CC 0	prolongation NN B-noun.act	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d99.s14	It PRP 0	is VBZ B-verb.stative	desirable JJ B-adj.all	to TO 0	monitor VB B-verb.creation	TCA NNP B-noun.group	plasma NN B-noun.plant	levels NNS B-noun.body	whenever WRB 0	a DT 0	TCA NNP B-noun.group	is VBZ 0	going VBG 0	to TO 0	be VB 0	coadministered VBN B-verb.contact	with IN 0	another DT 0	drug NN B-noun.person	known VBN B-verb.cognition	to TO 0	be VB B-verb.stative	an DT 0	inhibitor NN B-noun.person	of IN 0	P450 JJ B-noun.artifact	2D6 NN I-noun.artifact	. . 0	. . 0
DDI-MedLine.d109.s11	The DT 0	mean NN B-noun.attribute	( ( 0	SD NNP 0	) ) 0	cumulative JJ B-adj.all	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	immunoreactive JJ B-adj.all	digoxin NN B-noun.person	after IN 0	concurrent JJ B-adj.all	treatment NN B-noun.communication	with IN 0	rofecoxib NN B-noun.artifact	or CC 0	placebo NN B-noun.substance	was VBD B-verb.stative	228.2 CD 0	( ( 0	+ UH 0	/- $ 0	30.8 CD 0	) ) 0	and CC 0	235.1 CD 0	( ( 0	+ UH 0	/- $ 0	39.1 CD 0	) ) 0	micrograms/120 NN 0	hours NNS B-noun.artifact	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d110.s5	Therefore RB 0	, , 0	chloroprocaine NN 0	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	in IN 0	any DT 0	condition NN B-noun.possession	in IN 0	which WDT 0	a DT 0	sulfonamide_drug NN B-noun.person	is VBZ 0	being VBG 0	employed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d238.s23	It PRP 0	is VBZ B-verb.stative	desirable JJ B-adj.all	to TO 0	monitor VB B-verb.change	TCAplasma NNP B-noun.group	levels NNS B-noun.attribute	whenever WRB 0	an DT 0	agent NN B-noun.person	of IN 0	the DT 0	tricyclic_antidepressant_class NN B-noun.plant	including VBG B-verb.change	Anafranil NNP B-noun.person	is VBZ 0	going VBG 0	to TO 0	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	another DT 0	drug NN B-noun.person	known VBN B-verb.cognition	to TO 0	be VB B-verb.stative	an DT 0	inhibitor NN B-noun.person	of IN 0	P450 JJ 0	2D6 NN 0	( ( 0	and/or CC 0	P450 JJ B-noun.group	1A2 NN I-noun.group	) ) 0	. . 0	. . 0
DDI-MedLine.d73.s0	Neurochemical JJ B-noun.person	and CC 0	functional JJ B-adj.all	consequences NNS B-noun.possession	following VBG B-verb.stative	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine JJ 0	( ( 0	MPTP NNP B-noun.group	) ) 0	and CC 0	methamphetamine NN B-noun.attribute	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d326.s1	Pyrantel NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Antiminth NNP B-noun.location	) ) 0	; : 0	Taking VBG 0	piperazine NN B-noun.person	and CC 0	pyrantel NN B-noun.artifact	together RB 0	may MD 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	piperazine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d18.s6	Survanta NNP B-noun.person	increased VBD B-verb.change	the DT 0	extent NN B-noun.attribute	of IN 0	dissolution NN B-noun.act	of IN 0	budesonide NN B-noun.food	in IN 0	proportion NN 0	to TO 0	the DT 0	added VBN B-verb.change	concentration NN 0	, , 0	which WDT 0	was VBD B-verb.stative	also RB B-adv.all	verified VBN B-verb.social	by IN 0	equilibrium NN B-noun.person	solubilization NN B-noun.phenomenon	studies NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d548.s10	Plasma NNP B-noun.person	TCA NNP I-noun.person	concentrations NNS B-noun.animal	may MD 0	need VB 0	to TO 0	be VB 0	monitored VBN B-verb.perception	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	the DT 0	TCA NNP B-noun.group	may MD 0	need VB 0	to TO 0	be VB 0	reduced VBN B-verb.change	if IN 0	a DT 0	TCA NNP B-noun.group	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	Duloxetine NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d53.s9	These DT 0	data NNS B-noun.cognition	emphasize VBP B-verb.change	that IN 0	apoptosis NN B-noun.person	can MD 0	be VB 0	induced VBN B-verb.creation	in IN 0	MCF-7 NNP B-noun.other	cells NNS B-noun.body	either CC 0	by IN 0	activation NN B-noun.act	of IN 0	vitamin NN B-noun.person	- : 0	D SYM 0	- : 0	mediated VBD B-verb.communication	signalling NN B-noun.communication	or CC 0	disruption NN B-noun.act	of IN 0	estrogen NN B-noun.act	- : 0	dependent JJ B-adj.all	signalling NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d141.s8	Cerivastatin NNP B-noun.person	plasma NN I-noun.person	concentrations NNS I-noun.person	were VBD B-verb.stative	also RB B-adv.all	not RB B-adv.all	affected VBN B-verb.change	by IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d128.s13	Loperamide NNP B-noun.person	and CC 0	morphine NN B-noun.person	( ( 0	0.1 CD 0	and CC 0	1.0 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	, , 0	s.c NNP B-noun.person	. . 0	) ) 0	inhibited VBD B-verb.change	the DT 0	dmPGE2 NNP B-noun.other	( ( 0	0.3 CD 0	mg FW 0	/ FW 0	kg FW 0	, , 0	p.o.)-induced JJ B-adj.all	diarrhea NN B-noun.person	in IN 0	cecectomized VBN B-verb.consumption	rats NNS I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d363.s2	Like IN 0	isoflurane NN B-noun.person	, , 0	desflurane NN B-noun.person	does VBZ 0	not RB B-adv.all	predispose VB B-verb.creation	to TO 0	premature VB B-verb.change	ventricular JJ B-adj.all	arrhythmias NN B-noun.food	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	exogenously RB B-adv.all	infused VBN B-verb.communication	epinephrine NN B-noun.person	in IN 0	swine NN 0	. . 0	. . 0
DDI-DrugBank.d316.s0	CYP3A4 NNP B-noun.group	Inhibitors NNP I-noun.group	Felodipine NNP B-noun.person	is VBZ 0	metabolized VBN B-verb.change	by IN 0	CYP3A4 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d78.s6	Theophylline PRP 0	, , 0	Grepafloxacin NNP B-noun.person	is VBZ B-verb.stative	a DT 0	competitive JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	theophylline NN 0	. . 0	. . 0
DDI-DrugBank.d353.s7	It PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	whether IN 0	other JJ B-adj.all	progestational_contraceptives NNPS B-noun.person	, , 0	such JJ 0	as IN 0	implants NNS B-noun.person	and CC 0	injectables NNS B-noun.artifact	, , 0	are VBP B-verb.stative	adequate JJ B-adj.all	methods NNS B-noun.attribute	of IN 0	contraception NN B-noun.act	during IN 0	acitretin NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d485.s26	Morphine NN B-noun.person	, , 0	Combination NNP B-noun.group	hormonal_contraceptives NNPS I-noun.group	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d198.s32	In IN 0	a DT 0	similar JJ B-adj.all	study NN B-noun.artifact	with IN 0	tamsulosin NN B-noun.food	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	1 CD 0	of IN 0	24 CD B-adj.all	subjects NNS B-noun.person	dosed VBN B-verb.social	with IN 0	Vardenafil NNP B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	and CC 0	tamsulosin VB B-verb.consumption	0.4 CD 0	mg NNS B-noun.quantity	separated VBN B-verb.social	by IN 0	6 CD B-adj.all	hours NNS B-noun.person	experienced VBD B-verb.perception	a DT 0	standing VBG B-verb.stative	systolic JJ B-adj.all	blood NN B-noun.group	pressure NN B-noun.person	below IN 0	85 CD 0	mm NN B-noun.quantity	Hg NNP 0	. . 0	. . 0
DDI-DrugBank.d32.s12	The DT 0	results NNS B-noun.communication	of IN 0	assays NNS B-noun.person	using VBG B-verb.consumption	red JJ B-noun.body	cells NNS I-noun.body	from IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	to TO 0	determine VB B-verb.communication	whether IN 0	ceftibuten NN B-noun.person	would MD 0	cause VB B-verb.change	direct JJ 0	Coombs NNP 0	reactions NNS 0	in IN 0	vitro NN B-noun.person	showed VBD B-verb.communication	no DT 0	positive JJ B-adj.all	reaction NN B-noun.process	at IN 0	ceftibuten JJ B-noun.body	concentrations NNS I-noun.body	as RB 0	high JJ 0	as IN 0	40 CD B-adj.all	_ CD 0	g FW 0	/ FW 0	mL. FW 0	. . 0
DDI-DrugBank.d131.s10	Data NNS B-noun.cognition	from IN 0	in IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	of IN 0	benzodiazepines NNS 0	other JJ 0	than IN 0	alprazolam NN B-noun.person	suggest VBP B-verb.communication	a DT 0	possible JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	for IN 0	the DT 0	following NN 0	, , 0	ergotamine NN B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	amiodarone NN 0	, , 0	nicardipine NN B-noun.person	, , 0	and CC 0	nifedipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d114.s11	Delayed NNP B-noun.group	Adverse NNP I-noun.group	Reactions NNPS I-noun.group	to TO 0	Iodinated_Contrast_Media NNS B-noun.location	, , 0	A DT 0	review NN B-noun.act	of IN 0	the DT 0	literature NN B-noun.person	revealed VBD B-verb.communication	that IN 0	12.6 CD 0	% NN 0	( ( 0	range NN B-noun.communication	11 CD B-noun.quantity	- : 0	28 CD B-adj.all	% NN 0	) ) 0	of IN 0	501 CD 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	various JJ B-adj.all	interleukin-2 NN B-noun.location	containing VBG B-verb.stative	regimens NNS B-noun.person	who WP 0	were VBD 0	subsequently RB B-adv.all	administered VBN B-verb.possession	radiographic_iodinated_contrast_media NNP B-noun.person	experienced VBD B-verb.emotion	acute NN I-verb.emotion	, , 0	atypical JJ B-adj.all	adverse JJ B-noun.act	reactions NNS I-noun.act	. . 0	. . 0
DDI-DrugBank.d558.s12	Hydrochlorothiazide NNP B-noun.person	( ( 0	HCTZ NNP B-noun.group	) ) 0	Alone RB 0	or CC 0	in IN 0	Combination NNP B-noun.person	with IN 0	Triamterene NNP B-noun.person	, , 0	Concomitant JJ 0	use NN 0	of IN 0	HCTZ NNP B-noun.group	alone RB 0	or CC 0	in IN 0	combination NN 0	with IN 0	triamterene NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d106.s9	The DT 0	immediate JJ B-adj.all	release NN B-noun.communication	, , 0	but CC 0	not RB 0	the DT 0	coat NN B-noun.person	- : 0	core NN B-noun.group	formulation NN B-noun.act	of IN 0	nisoldipine NN B-noun.person	increased VBN B-verb.change	plasma NN B-noun.substance	quinidine JJ B-adj.all	concentrations NNS B-noun.artifact	by IN 0	about IN 0	20 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d299.s6	Selective_Serotonin_Reuptake_Inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	SSRIs NNP 0	( ( 0	e.g. UH 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	have VBP 0	been VBN 0	rarely RB B-adv.all	reported VBN B-verb.communication	to TO 0	cause VB B-verb.emotion	weakness NN I-verb.emotion	, , 0	hyperreflexia NN B-noun.person	, , 0	and CC 0	incoordination NN B-noun.time	when WRB 0	coadministered VBN B-verb.communication	with IN 0	5-HT1_agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d250.s2	Curariform_muscle_relaxants NNS B-noun.artifact	( ( 0	eg UH 0	, , 0	tubocurarine NN 0	) ) 0	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.stative	ether NN B-noun.person	, , 0	succinylcholine NN B-noun.person	, , 0	gallamine NN B-noun.person	, , 0	decamethonium NN B-noun.person	and CC 0	sodium_citrate NNP B-noun.person	, , 0	potentiate VBP B-verb.communication	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	effect NN B-noun.cognition	and CC 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	extreme JJ B-adj.all	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.artifact	being VBG 0	treated VBN B-verb.change	with IN 0	Coly NNP B-noun.person	- : 0	Mycin_M NNP B-noun.person	Parenteral NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d420.s0	Antacids NNP B-noun.person	( ( 0	aluminum- RB B-adv.all	or CC 0	magnesium NN B-noun.person	- : 0	containing VBG B-verb.cognition	) ) 0	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	300-mg JJ 0	cefdinir NN B-noun.body	capsules NNS I-noun.body	with IN 0	30 CD B-adj.all	mL CD B-noun.quantity	Maalox_TC JJ B-adj.all	suspension NN B-noun.substance	reduces VBZ B-verb.change	the DT 0	rate NN B-noun.time	( ( 0	Cmax NNP B-noun.person	) ) 0	and CC 0	extent NN B-noun.person	( ( 0	AUC NNP 0	) ) 0	of IN 0	absorption NN B-noun.act	by IN 0	approximately RB B-noun.communication	40 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d382.s7	5-HT3_antagonists NNS B-noun.person	, , 0	In IN 0	clinical JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	, , 0	aprepitant NN B-noun.person	did VBD 0	not RB B-adv.all	have VB 0	clinically RB B-adv.all	important JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	ondansetron NN B-noun.act	or CC 0	granisetron NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d198.s33	Two CD 0	of IN 0	16 CD B-adj.all	subjects NNS B-noun.person	dosed VBD 0	simultaneously RB B-adv.all	with IN 0	Vardenafil NNP B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	tamsulosin VB B-verb.consumption	0.4 CD 0	mg NNS B-noun.quantity	experienced VBD B-verb.perception	a DT 0	standing VBG B-verb.stative	systolic JJ B-adj.all	blood NN B-noun.group	pressure NN B-noun.person	below IN 0	85 CD 0	mm NN B-noun.quantity	Hg NNP 0	. . 0	. . 0
DDI-DrugBank.d32.s7	however RB 0	, , 0	150 CD 0	mg NN B-noun.quantity	of IN 0	ranitidine JJ B-adj.all	q12h NN B-noun.person	for IN 0	3 CD B-adj.all	days NNS B-noun.person	increased VBD B-verb.change	the DT 0	ceftibuten JJ B-adj.all	C NNP 0	max NN 0	by IN 0	23 CD B-adj.all	% NN 0	and CC 0	ceftibuten VB B-verb.consumption	AUC NNP 0	by IN 0	16 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d5.s5	The DT 0	effects NNS B-noun.phenomenon	of IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.person	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	bupropion NN B-noun.act	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolites NNS B-noun.food	were VBD 0	studied VBN B-verb.cognition	in IN 0	24 CD B-adj.all	healthy JJ B-adj.all	young JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d277.s23	Because IN 0	of IN 0	the DT 0	possible JJ B-adj.all	additive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	drugs NNS B-noun.artifact	that WDT 0	may MD 0	depress VB B-verb.cognition	the DT 0	nervous JJ B-adj.all	system NN B-noun.cognition	, , 0	ethanol NN B-noun.person	or CC 0	triazolam NN B-noun.plant	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	combination NN 0	with IN 0	tiagabine NN 0	. . 0	. . 0
DDI-DrugBank.d466.s27	Therefore RB 0	, , 0	to TO 0	maximize VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	fexofenadine NN B-noun.location	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	ALLEGRA NNP B-noun.group	should MD 0	be VB 0	taken VBN B-verb.cognition	with IN 0	water NN 0	. . 0
DDI-DrugBank.d388.s1	Patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	acebutolol NN B-noun.person	plus IN 0	catecholamine_depletors NNS B-noun.location	should MD 0	, , 0	therefore RB B-adv.all	, , 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	evidence NN B-noun.time	of IN 0	marked VBN B-verb.contact	bradycardia NNS B-noun.shape	or CC 0	hypotension NN B-noun.act	which WDT 0	may MD 0	present VB B-verb.stative	as IN 0	vertigo RB B-adv.all	, , 0	syncope NN B-noun.cognition	/ : 0	presyncope VB B-verb.communication	, , 0	or CC 0	orthostatic JJ B-adj.all	changes NNS B-noun.relation	in IN 0	blood NN B-adj.all	pressure NN B-noun.act	without IN 0	compensatory JJ B-adj.all	tachycardia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s5	After IN 0	stopping VBG B-verb.motion	Fluvoxamine NNP B-noun.person	Tablets NNPS I-noun.person	, , 0	at IN 0	least JJS 0	2 CD B-adj.all	weeks NNS B-noun.time	should MD 0	be VB 0	allowed VBN B-verb.possession	before IN 0	starting VBG B-verb.change	a DT 0	MAOI NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d60.s12	Other JJ 0	drugs NNS B-noun.artifact	which WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	nondepolarizing_agents NNS 0	such JJ 0	as IN 0	NIMBEX NNP B-noun.group	include VBP B-verb.change	certain JJ B-adj.all	antibiotics NNS B-noun.attribute	( ( 0	e. FW 0	g. FW 0	, , 0	aminoglycosides NNS B-noun.person	, , 0	tetracyclines NNS B-noun.artifact	, , 0	bacitracin NN B-noun.person	, , 0	polymyxins NNS B-noun.person	, , 0	lincomycin NN B-noun.communication	, , 0	clindamycin NN B-noun.person	, , 0	colistin NN B-noun.person	, , 0	and CC 0	sodium_colistemethate NNP B-noun.location	) ) 0	, , 0	magnesium NN B-noun.person	salts NNS B-noun.substance	, , 0	lithium NN B-noun.person	, , 0	local JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	procainamide NN B-noun.person	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d322.s0	Amantadine NNP B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	and CC 0	MAOIs NNP B-noun.person	may MD 0	increase VB B-verb.change	anticholinergic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	clidinium NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d114.s10	Although IN 0	glucocorticoids NNS B-noun.person	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	reduce VB B-verb.change	PROLEUKIN NNP B-noun.group	- : 0	induced JJ B-verb.creation	side NN 0	effects NNS 0	including VBG B-verb.stative	fever NN I-verb.stative	, , 0	renal JJ B-adj.all	insufficiency NN B-noun.attribute	, , 0	hyperbilirubinemia NN B-noun.person	, , 0	confusion NN B-noun.cognition	, , 0	and CC 0	dyspnea NN B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	these DT 0	agents NNS B-noun.person	with IN 0	PROLEUKIN NNP B-noun.group	may MD 0	reduce VB B-verb.change	the DT 0	antitumor NN B-noun.attribute	effectiveness NN B-noun.cognition	of IN 0	PROLEUKIN NNP B-noun.group	and CC 0	thus RB 0	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	12 CD B-adj.all	Beta JJ B-noun.other	- : 0	blockers NNS B-noun.person	and CC 0	other JJ B-adj.all	antihypertensives NNS B-noun.object	may MD 0	potentiate VB B-verb.communication	the DT 0	hypotension NN 0	seen VBN B-verb.perception	with IN 0	PROLEUKIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d210.s30	Therefore RB 0	, , 0	there EX 0	is VBZ B-verb.stative	a DT 0	potential NN B-noun.person	for IN 0	an DT 0	interaction NN B-noun.act	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	CYP NNP B-noun.person	1A2 NNP I-noun.person	( ( 0	e.g. UH 0	, , 0	amitriptyline NN B-noun.person	, , 0	tacrine NN B-noun.person	, , 0	and CC 0	zileuton NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d93.s0	Clinical JJ B-adj.all	trials NNS B-noun.communication	have VBP 0	indicated VBN B-verb.cognition	that IN 0	Pulmozyme NNP B-noun.person	can MD 0	be VB 0	effectively RB B-adv.all	and CC 0	safely RB B-adv.all	used VBN B-verb.consumption	in IN 0	conjunction NN 0	with IN 0	standard JJ B-adj.all	cystic JJ B-adj.all	fibrosis NN B-noun.body	therapies NNS 0	including VBG B-verb.stative	oral JJ B-adj.all	, , 0	inhaled VBN B-verb.communication	and/or CC 0	parenteral JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	bronchodilators NNS B-noun.person	, , 0	enzyme NN B-noun.person	supplements NNS B-noun.person	, , 0	vitamins NNS B-noun.person	, , 0	oral JJ B-adj.all	or CC 0	inhaled VBN B-verb.emotion	corticosteroids NNS I-verb.emotion	, , 0	and CC 0	analgesics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d38.s8	However RB 0	, , 0	hydrocortisone NN 0	pretreatment NN B-noun.artifact	did VBD 0	not RB B-adv.all	affect VB B-verb.change	any DT 0	of IN 0	the DT 0	physiological NN B-noun.person	, , 0	behavioral JJ B-adj.all	, , 0	or CC 0	subjective JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	d SYM 0	- : 0	amphetamine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d132.s1	The DT 0	availability NN B-noun.attribute	of IN 0	potent JJ B-adj.all	non NN B-noun.person	- : 0	nucleoside_reverse_transcriptase_inhibitor NN B-noun.other	( ( 0	NNRTI)-based JJ 0	regimens NNS B-noun.person	for IN 0	antiretroviral JJ B-adj.all	therapy NN B-noun.act	and CC 0	concerns NNS B-noun.possession	regarding VBG B-verb.stative	protease_inhibitor NN 0	( ( 0	PI)-related VBN B-verb.contact	metabolic JJ B-adj.all	disturbances NNS B-noun.artifact	have VBP 0	led VBN B-verb.social	to TO 0	significant JJ B-adj.all	shifts NNS B-noun.state	in IN 0	treatment NN B-noun.animal	practices NNS I-noun.animal	in IN 0	HIV NNP 0	infection NN 0	. . 0	. . 0
DDI-DrugBank.d458.s20	In IN 0	simultaneous JJ B-adj.all	treatment NN B-noun.plant	with IN 0	imidazole_drugs NNS B-noun.artifact	and CC 0	coumarin_drugs NNS B-noun.location	, , 0	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.phenomenon	should MD 0	be VB 0	carefully RB B-adv.all	titrated VBN B-verb.communication	and CC 0	monitored VBD B-verb.perception	. . 0	. . 0
DDI-DrugBank.d143.s30	Amiodarone NN 0	taken VBN 0	concomitantly RB B-adv.all	with IN 0	quinidine NN B-noun.attribute	increases VBZ B-verb.change	quinidine JJ B-adj.all	serum NN B-noun.body	concentration NN B-noun.event	by IN 0	33 CD 0	% NN 0	after IN 0	two CD 0	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d521.s6	- : 0	a DT 0	diuretic JJ B-noun.person	( ( 0	water NN 0	pill NN 0	) ) 0	such JJ 0	as IN 0	hydrochlorothiazide NN 0	( ( 0	HCTZ NNP B-noun.group	, , 0	Hydrodiuril NNP B-noun.location	) ) 0	, , 0	chlorothiazide NN 0	( ( 0	Diuril NNP B-noun.person	) ) 0	, , 0	and CC 0	others NNS 0	, , 0	. . 0
DDI-DrugBank.d328.s24	Valdecoxib NNP B-noun.person	caused VBD B-verb.communication	a DT 0	statistically RB B-adv.all	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	plasma NN B-noun.substance	exposures NNS B-noun.event	of IN 0	R SYM 0	- : 0	warfarin NN B-noun.act	and CC 0	S NNP 0	- : 0	warfarin NN B-noun.substance	( ( 0	12 CD B-adj.all	% NN 0	and CC 0	15 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	) ) 0	, , 0	and CC 0	in IN 0	the DT 0	pharmacodynamic JJ B-adj.pert	effects NNS B-noun.phenomenon	( ( 0	prothrombin NN B-noun.person	time NN B-noun.person	, , 0	measured VBN B-verb.cognition	as IN 0	INR NNP 0	) ) 0	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d63.s0	Monoamine_oxidase_(MAO)_inhibitors NNS 0	such JJ 0	as IN 0	isocarboxazid NN 0	( ( 0	e.g. UH 0	, , 0	Marplan NNP B-noun.person	) ) 0	, , 0	phenelzine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Nardil NNP B-noun.location	) ) 0	, , 0	procarbazine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Matulane NNP B-noun.person	) ) 0	, , 0	selegiline NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Eldepryl NNP B-noun.location	) ) 0	, , 0	and CC 0	tranylcypromine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Parnate NNP B-noun.location	) ) 0	, , 0	Using VBG B-verb.consumption	these DT 0	medicines NNS B-noun.artifact	with IN 0	L SYM 0	- : 0	tryptophan NN B-noun.animal	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d316.s7	Erythromycin NNP B-noun.person	Co NNP I-noun.person	- : 0	administration NN B-noun.time	of IN 0	felodipine NN B-noun.person	( ( 0	PLENDIL NNP 0	) ) 0	with IN 0	erythromycin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	approximately RB B-adv.all	2.5- JJ B-adj.all	fold NN B-noun.artifact	increase NN I-noun.artifact	in IN 0	the DT 0	AUC NNP B-noun.group	and CC 0	Cmax NNP B-noun.person	, , 0	and CC 0	about IN 0	2- : 0	fold JJ B-adj.all	prolongation NN B-noun.person	in IN 0	the DT 0	half- JJ B-adj.all	life NN B-noun.time	of IN 0	felodipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d380.s7	Patients NNS B-noun.person	should MD 0	be VB 0	warned VBN B-verb.communication	of IN 0	the DT 0	potential JJ B-adj.all	danger NN B-noun.person	of IN 0	the DT 0	intravenous JJ B-adj.all	self NN B-noun.person	- : 0	administration NN B-noun.time	of IN 0	benzodiazepines NNS B-noun.attribute	while IN 0	under IN 0	treatment NN B-noun.plant	with IN 0	SUBOXONE NNP B-noun.group	or CC 0	SUBUTEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d398.s2	The DT 0	use NN 0	of IN 0	dextromethorphan_hydrobromide NN B-noun.location	may MD 0	result VB B-verb.stative	in IN 0	additive JJ B-adj.all	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	when WRB 0	coadministered VBN B-verb.communication	with IN 0	alcohol NN B-noun.food	, , 0	antihistamines NNS B-noun.attribute	, , 0	psychotropics NNS B-noun.person	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	produce VBP B-verb.stative	CNS NNP 0	depression NN 0	. . 0	. . 0
DDI-DrugBank.d393.s4	Drug NN B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	been VBN 0	found VBN B-verb.possession	with IN 0	theophylline PRP 0	at IN 0	a DT 0	low JJ B-adj.all	dose NN B-noun.person	, , 0	azithromycin NN B-noun.person	, , 0	pseudoephedrine NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	or CC 0	erythromycin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d74.s3	For IN 0	this DT 0	reason NN B-noun.communication	the DT 0	dose NN B-noun.quantity	of IN 0	adrenaline NN B-noun.location	should MD 0	be VB 0	restricted VBN B-verb.change	and CC 0	an DT 0	antiarrhythmic_agent JJ B-adj.all	administered VBN I-adj.all	as IN 0	appropriate JJ B-noun.person	. . 0	. . 0
DDI-DrugBank.d257.s3	Although IN 0	no DT 0	interaction NN B-noun.act	between IN 0	MAO_inhibitors NNS B-noun.person	and CC 0	Levo NNP B-noun.person	- : 0	Dromoran NN B-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	for IN 0	use NN 0	with IN 0	MAO_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d548.s11	Because IN 0	of IN 0	the DT 0	risk NN 0	of IN 0	serious JJ B-adj.all	ventricular JJ B-adj.all	arrhythmias NN B-noun.communication	and CC 0	sudden JJ B-adj.all	death NN 0	potentially RB B-adv.all	associated VBN B-verb.cognition	with IN 0	elevated JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	thioridazine NN 0	, , 0	Duloxetine NNP B-noun.location	and CC 0	thioridazine NN 0	should MD 0	not RB B-adv.all	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d531.s90	Other JJ 0	Drugs NNP B-noun.person	, , 0	Based VBN B-verb.cognition	on IN 0	the DT 0	results NNS B-noun.communication	of IN 0	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	, , 0	no DT 0	dosage NN B-noun.relation	adjustment NN I-noun.relation	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	SUSTIVA NNP 0	( ( 0	efavirenz NN 0	) ) 0	is VBZ 0	given VBN B-verb.possession	with IN 0	the DT 0	following NN 0	, , 0	aluminum NN 0	/ . 0	magnesium_hydroxide_antacids NNS B-noun.quantity	, , 0	azithromycin NN B-noun.person	, , 0	cetirizine NN B-noun.location	, , 0	famotidine NN 0	, , 0	fluconazole NN B-noun.person	, , 0	lamivudine NN 0	, , 0	lorazepam NN B-noun.person	, , 0	nelfinavir NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	and CC 0	zidovudine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s21	May MD 0	lead VB B-verb.cognition	to TO 0	loss NN B-noun.process	of IN 0	virologic JJ B-adj.pert	response NN B-noun.communication	and CC 0	possible JJ B-adj.all	resistance NN B-noun.phenomenon	to TO 0	CRIXIVAN NNP B-noun.group	or CC 0	to TO 0	the DT 0	class NN B-noun.attribute	of IN 0	protease_inhibitors NNS B-noun.person	or CC 0	other JJ 0	coadministered JJ B-adj.all	antiretroviral_agents NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d81.s11	Warfarin NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	no DT 0	clinically RB B-adv.all	relevant JJ B-adj.all	pharmacokinetic JJ B-noun.relation	or CC 0	pharmacodynamic JJ B-adj.all	interaction NN B-noun.act	between IN 0	isradipine NN B-noun.person	and CC 0	racemic JJ B-adj.all	warfarin NN B-noun.act	was VBD 0	seen VBN B-verb.perception	when WRB 0	two CD 0	single JJ B-adj.all	oral JJ B-noun.body	doses NNS I-noun.body	of IN 0	warfarin NN B-noun.substance	( ( 0	0.7 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.attribute	) ) 0	were VBD 0	administered VBN B-verb.possession	during IN 0	11 CD B-adj.all	days NNS B-noun.act	of IN 0	multipledose JJ B-adj.all	treatment NN B-noun.plant	with IN 0	5 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	isradipine VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d506.s9	Until IN 0	data NNS B-noun.cognition	on IN 0	possible JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	verapamil NN B-noun.person	and CC 0	disopyramide_phosphate NN B-noun.person	are VBP 0	obtained VBN B-verb.possession	, , 0	disopyramide NN 0	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	within IN 0	48 CD 0	hours NNS 0	before IN 0	or CC 0	24 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	verapamil JJ B-noun.body	administration NN I-noun.body	. . 0	. . 0
DDI-DrugBank.d434.s19	The DT 0	carbamazepine NN B-noun.cognition	steady JJ I-noun.cognition	- : 0	state NN B-adj.all	Cmin NNP B-noun.person	decreased VBD B-verb.competition	31 CD 0	% NN 0	to TO 0	5 CD B-adj.all	1 CD B-adj.all	micrograms NNS B-noun.quantity	/ : 0	mL PRP 0	when WRB 0	felbamate NN B-noun.person	( ( 0	3000 CD 0	mg RB 0	/ JJ 0	day NN 0	, , 0	divided VBN B-verb.social	into IN 0	three CD 0	doses NNS B-noun.quantity	) ) 0	was VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d198.s28	Alpha NNP B-noun.person	- : 0	blockers NNS B-noun.person	, , 0	When WRB 0	Vardenafil NNP B-noun.communication	10 CD B-adj.all	or CC 0	20 CD B-adj.all	mg DT B-noun.quantity	was VBD 0	given VBN B-verb.possession	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	either CC 0	simultaneously RB B-adv.all	or CC 0	6 CD B-adj.all	hours NNS B-noun.time	after IN 0	a DT 0	10 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	terazosin NN B-noun.communication	, , 0	significant JJ B-adj.all	hypotension NN 0	developed VBN B-verb.creation	in IN 0	a DT 0	substantial JJ B-adj.all	number NN B-noun.attribute	of IN 0	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d347.s4	However RB 0	, , 0	because IN 0	some DT 0	quinolones NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	enhance VB B-verb.change	the DT 0	anticoagulant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	warfarin NN B-noun.act	or CC 0	its PRP$ 0	derivatives NNS B-noun.event	in IN 0	patients NNS B-noun.person	, , 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	other JJ 0	suitable JJ B-adj.all	coagulation NN 0	test NN 0	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	if IN 0	a DT 0	quinolone_antimicrobial JJ B-noun.other	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	warfarin NN B-noun.act	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d277.s13	Valproate NNP B-noun.person	, , 0	The DT 0	addition NN 0	of IN 0	tiagabine NN 0	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	valproate NN B-noun.attribute	chronically RB B-noun.communication	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	tiagabine NN 0	pharmacokinetics NNS B-noun.person	, , 0	but CC 0	valproate VBP B-verb.change	significantly RB B-adv.all	decreased VBD B-verb.change	tiagabine NN B-noun.artifact	binding NN B-verb.contact	in IN 0	vitro NN B-noun.animal	from IN 0	96.3 CD 0	to TO 0	94.8 CD 0	% NN 0	, , 0	which WDT 0	resulted VBD B-verb.stative	in IN 0	an DT 0	increase NN B-noun.event	of IN 0	approximately RB B-adv.all	40 CD B-adj.all	% NN 0	in IN 0	the DT 0	free JJ B-adj.all	tiagabine NN B-noun.body	concentration NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d324.s35	Warfarin NNP B-noun.person	, , 0	Multiple JJ B-adj.all	oral JJ B-adj.all	doses NNS B-noun.event	of IN 0	Sonata NNP B-noun.person	( ( 0	20 CD 0	mg DT 0	q24h NNP B-noun.person	for IN 0	13 CD B-adj.all	days NNS B-noun.act	) ) 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	warfarin NN B-noun.substance	( ( 0	R+)- JJ 0	or CC 0	( ( 0	S-)-enantiomers NNS B-noun.person	or CC 0	the DT 0	pharmacodynamics NNS B-noun.person	( ( 0	prothrombin NN B-noun.person	time NN 0	) ) 0	following VBG B-verb.stative	a DT 0	single JJ B-adj.all	25-mg JJ 0	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d97.s40	The DT 0	optimal JJ B-adj.all	dose NN B-noun.quantity	of IN 0	indinavir NN B-noun.person	, , 0	when WRB 0	given VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	efavirenz NN B-noun.person	, , 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d210.s20	At IN 0	higher JJR B-adj.all	than IN 0	recommended VBN B-verb.communication	doses NNS B-noun.person	, , 0	VIOXX NNP B-noun.group	75 CD 0	mg NN B-noun.quantity	administered VBN B-verb.possession	once RB B-adv.all	daily RB B-adv.all	for IN 0	10 CD B-adj.all	days NNS B-noun.time	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.phenomenon	by IN 0	23 CD B-adj.all	% NN 0	as IN 0	measured VBN B-verb.cognition	by IN 0	AUC0 SYM 0	- : 0	24hr JJ 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	methotrexate NN B-noun.attribute	7.5 CD 0	to TO 0	15 CD 0	mg IN 0	/ DT 0	week NN B-noun.time	for IN 0	rheumatoid JJ B-adj.all	arthritis NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d289.s32	Digoxin NNP B-noun.person	, , 0	Nimodipine NNP B-noun.person	and CC 0	Losartan NNP B-noun.location	, , 0	Bosentan NNP B-noun.person	has VBZ B-verb.possession	no DT 0	significant JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	with IN 0	digoxin NN B-noun.person	and CC 0	nimodipine NN B-noun.person	, , 0	and CC 0	losartan NN B-noun.group	has VBZ B-verb.possession	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	bosentan NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d508.s3	Because IN 0	heparin NN 0	, , 0	aspirin NN B-noun.person	, , 0	or CC 0	Activase NNP B-noun.person	may MD 0	cause VB 0	bleeding VBG B-verb.body	complications NNS B-noun.person	, , 0	careful JJ B-adj.all	monitoring NN B-verb.perception	for IN 0	bleeding NN B-noun.act	is VBZ 0	advised VBN B-verb.communication	, , 0	especially RB B-adv.all	at IN 0	arterial JJ B-adj.all	puncture NN B-noun.phenomenon	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d143.s21	HMG SYM 0	- : 0	CoA_Reductase_Inhibitors NNS B-noun.person	, , 0	Simvastatin NNP B-noun.person	( ( 0	CYP3A4 JJ B-adv.all	substrate NN I-adv.all	) ) 0	in IN 0	combination NN 0	with IN 0	amiodarone NN 0	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	reports NNS B-noun.artifact	of IN 0	myopathy JJ B-adj.all	/ CD 0	rhabdomyolysis NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d512.s4	Effect NN 0	of IN 0	other JJ 0	drugs NNS B-noun.artifact	on IN 0	Sensipar NNP B-noun.person	, , 0	Sensipar NNP B-noun.person	_ ( 0	is VBZ 0	metabolized VBN B-verb.change	by IN 0	multiple JJ B-adj.all	cytochrome NN B-noun.person	P450 NN I-noun.person	enzymes NNS B-noun.person	, , 0	primarily RB B-adv.all	CYP3A4 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	and CC 0	CYP1A2 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d350.s11	Patients NNS B-noun.person	on IN 0	rifampin NN 0	should MD 0	receive VB B-verb.possession	70 CD B-adj.all	mg NN B-noun.quantity	of IN 0	CANCIDAS NNP B-noun.group	daily RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d411.s7	Anticoagulants NNS B-noun.person	( ( 0	Oral NNP B-noun.location	) ) 0	, , 0	The DT 0	hypoprothrombinemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	anticoagulants NNS B-noun.animal	may MD 0	be VB 0	potentiated VBN B-verb.communication	, , 0	apparently RB B-adv.all	by IN 0	increased JJ B-adj.all	catabloism NN B-noun.artifact	of IN 0	vitamin NN B-noun.group	K SYM 0	- : 0	dependent JJ B-adj.all	clotting NN B-verb.contact	factors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d544.s0	No DT 0	dose NN B-noun.relation	adjustment NN I-noun.relation	is VBZ B-verb.stative	necessary JJ B-adj.all	when WRB 0	Simulect NNP B-noun.person	is VBZ 0	added VBN B-verb.change	to TO 0	triple VB B-verb.social	- : 0	immunosuppression NN B-noun.act	regimens VBZ 0	including VBG B-verb.stative	cyclosporine NN 0	, , 0	corticosteroids NNS B-noun.person	, , 0	and CC 0	either RB 0	azathioprine JJ 0	or CC 0	mycophenolate_mofetil NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d53.s0	Induction NN 0	of IN 0	apoptosis NN B-noun.food	in IN 0	breast NN 0	cancer NN B-noun.body	cells NNS B-noun.body	in IN 0	response NN B-noun.communication	to TO 0	vitamin_D NNP B-noun.person	and CC 0	antiestrogens NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d437.s7	Saquinavir NNP B-noun.person	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	Cmax NNP B-noun.person	, , 0	A.C. NNP B-noun.person	and CC 0	Cmin NNP B-noun.person	were VBD 0	increased VBN B-verb.change	21 CD B-adj.all	% NN 0	, , 0	decreased VBD B-verb.change	19 CD B-adj.all	% NN 0	, , 0	and CC 0	decreased VBD B-verb.change	48 CD 0	% NN 0	, , 0	respectively RB B-adv.all	, , 0	by IN 0	concomitant JJ B-adj.all	amprenavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d137.s9	In IN 0	general JJ B-adj.all	, , 0	these DT 0	are VBP B-verb.stative	drugs NNS B-noun.artifact	that WDT 0	have VBP 0	one CD 0	or CC 0	more RBR B-adv.all	pharmacologic JJ B-adj.all	activities NNS B-noun.person	similar JJ B-adj.all	to TO 0	bepridil_hydrochloride VB B-verb.stative	, , 0	including VBG B-verb.change	anti NNS B-noun.attribute	- : 0	arrhythmic_agents NNS B-noun.person	such JJ 0	as IN 0	quinidine JJ B-adj.all	and CC 0	procainamide NN B-noun.person	, , 0	cardiac_glycosides NNS B-noun.group	and CC 0	tricyclic_anti NNS B-noun.person	- : 0	depressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d379.s1	It PRP 0	is VBZ B-verb.stative	, , 0	however RB 0	, , 0	possible JJ B-adj.all	that IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ B-adj.all	known JJ I-adj.all	photosensitizing_agents NNS B-noun.group	such JJ 0	as IN 0	griseofulvin NN 0	, , 0	thiazide_diuretics NNS B-noun.person	, , 0	sulfonylureas NNS B-noun.location	, , 0	phenothiazines NNS B-noun.body	, , 0	sulfonamides NNS B-noun.person	and CC 0	tetracyclines NNS B-noun.artifact	might MD 0	increase VB B-verb.change	the DT 0	photosensitivity NN B-noun.phenomenon	reaction NN B-noun.process	of IN 0	actinic JJ B-adj.all	keratoses NNS B-noun.person	treated VBN B-verb.social	with IN 0	the DT 0	LEVULAN_KERASTICK NN B-noun.attribute	for IN 0	Topical NNP B-noun.location	Solution NNP I-noun.location	. . 0	. . 0
DDI-DrugBank.d249.s5	Patients NNS B-noun.person	who WP 0	begin VBP B-verb.change	taking VBG B-verb.social	diclofenac NN I-verb.social	or CC 0	who WP 0	increase VBP B-verb.cognition	their PRP$ 0	diclofenac NN B-noun.artifact	dose NN I-noun.artifact	or CC 0	any DT 0	other JJ 0	NSAID NNP B-noun.group	while IN 0	taking VBG 0	digoxin NN B-noun.person	, , 0	methotrexate NN B-noun.person	, , 0	or CC 0	cyclosporine NN B-noun.act	may MD 0	develop VB B-verb.communication	toxicity NN B-noun.person	characteristics NNS B-noun.person	for IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d364.s8	Ketoconazole NNP B-noun.person	increased VBD B-verb.change	mean JJ B-adj.all	alosetron JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	AUC NNP 0	) ) 0	by IN 0	29 CD B-noun.quantity	% NN 0	. . 0	. . 0
DDI-DrugBank.d395.s1	Thus RB 0	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	enoxacin NN B-noun.person	and CC 0	bismuth_subsalicylate NNP B-noun.other	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d312.s5	Due JJ 0	to TO 0	high JJ B-adj.all	inter NN B-noun.attribute	- : 0	patient JJ B-noun.person	variability NN I-noun.person	and CC 0	limited JJ B-adj.all	sampling NN B-noun.act	, , 0	the DT 0	extent NN B-noun.attribute	of IN 0	the DT 0	increase NN B-noun.event	in IN 0	SN38 JJ B-adj.all	levels NNS B-noun.attribute	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concurrent JJ B-adj.all	irinotecan JJ B-noun.person	and CC 0	AVASTIN NNP B-noun.group	is VBZ B-verb.stative	uncertain JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d400.s9	Lithium NNP B-noun.person	, , 0	NSAIDs NNP B-noun.person	have VBP 0	produced VBN B-verb.creation	an DT 0	elevation NN B-noun.act	of IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	a DT 0	reduction NN B-noun.act	in IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d87.s1	ADL-8 SYM 0	- : 0	2698 CD 0	is VBZ B-verb.stative	a DT 0	novel JJ B-adj.all	peripherally_restricted_opioid_antagonist NN B-noun.person	that WDT 0	may MD 0	selectively RB B-verb.cognition	prevent VB B-verb.creation	opioid JJ B-adj.all	- : 0	induced VBN B-verb.communication	gastrointestinal JJ B-adj.pert	effects NNS B-noun.phenomenon	without IN 0	reversing VBG B-verb.perception	analgesia NN I-verb.perception	. . 0	. . 0
DDI-DrugBank.d460.s15	Certain JJ B-adj.all	drugs NNS B-noun.artifact	including VBG B-verb.change	thiazides NNS B-noun.artifact	, , 0	corticosteroids NNS B-noun.person	, , 0	thyroid_products NNS B-noun.body	, , 0	and CC 0	sympathomimetics NNS B-noun.person	may MD 0	reduce VB B-verb.change	the DT 0	hypoglycemic JJ B-adj.all	action NN B-noun.state	of IN 0	Starlix NNP B-noun.person	and CC 0	other JJ 0	oral JJ B-adj.all	antidiabetic_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d198.s12	Ritonavir NNP B-noun.person	( ( 0	600 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	) ) 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	Vardenafil NNP B-noun.communication	5 CD B-adj.all	mg NN B-noun.quantity	resulted VBD B-verb.stative	in IN 0	a DT 0	49-fold JJ B-noun.artifact	increase NN I-noun.artifact	in IN 0	vardenafil NN 0	AUC NNP 0	and CC 0	a DT 0	13-fold JJ B-noun.artifact	increase NN I-noun.artifact	in IN 0	vardenafil NNP B-noun.person	Cmax NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d499.s22	Methotrexate NNP B-noun.person	, , 0	Ketoprofen NNP B-noun.person	, , 0	like IN 0	other JJ 0	NSAIDs NNP B-noun.person	, , 0	may MD 0	cause VB B-verb.communication	changes NNS B-noun.phenomenon	in IN 0	the DT 0	elimination NN B-noun.act	of IN 0	methotrexate NN B-noun.person	leading VBG B-verb.motion	to TO 0	elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	the DT 0	drug NN B-noun.artifact	and CC 0	increased VBD B-verb.change	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d238.s15	cimetidine NN B-noun.act	) ) 0	and CC 0	many JJ 0	that WDT 0	are VBP B-verb.stative	substrates NNS B-noun.person	for IN 0	P450 JJ 0	2D6 NN 0	( ( 0	many JJ 0	other JJ 0	antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	and CC 0	the DT 0	Type_1C_antiarrhythmics NNS B-noun.group	propafenone NN B-noun.person	and CC 0	flecainide NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d90.s9	At IN 0	75 CD 0	% NN 0	recovery NN B-noun.act	of IN 0	fade NN B-noun.attribute	, , 0	hoof JJ B-adj.all	twitch NN B-noun.person	was VBD B-verb.stative	87 CD 0	+ SYM 0	/- $ 0	3 CD B-adj.all	% NN 0	for IN 0	atracurium NN 0	alone RB 0	and CC 0	82 CD 0	+ SYM 0	/- $ 0	4 CD B-adj.all	% NN 0	for IN 0	atracurium NN B-noun.person	plus CC 0	gentamycin NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d71.s6	Therefore RB 0	, , 0	use NN 0	of IN 0	lamivudine NN B-noun.act	in IN 0	combination NN 0	with IN 0	zalcitabine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0
DDI-DrugBank.d364.s7	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	, , 0	38 CD 0	healthy JJ B-adj.all	female JJ B-noun.person	subjects NNS B-noun.person	received VBD B-verb.possession	ketoconazole NN B-noun.communication	200 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	, , 0	with IN 0	coadministration NN B-noun.person	of IN 0	alosetron RB B-noun.communication	1 CD B-adj.all	mg NN B-noun.quantity	on IN 0	the DT 0	last JJ B-adj.all	day NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d163.s17	No DT 0	formal JJ B-adj.all	clinical JJ B-adj.all	studies NNS B-noun.group	have VBP 0	been VBN 0	conducted VBN B-verb.social	to TO 0	assess VB B-verb.communication	if IN 0	there EX 0	is VBZ B-verb.stative	an DT 0	interactive JJ B-adj.all	effect NN B-noun.cognition	on IN 0	bone NN 0	loss NN B-noun.process	between IN 0	systemic_corticosteroids NNS B-noun.body	and CC 0	Accutane NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d54.s14	Therefore RB 0	, , 0	patients NNS B-noun.person	without IN 0	a DT 0	functioning VBG B-verb.body	thyroid JJ B-noun.body	gland NN I-noun.body	who WP 0	are VBP B-verb.stative	on IN 0	thyroid JJ B-adj.all	replacement NN B-noun.person	therapy NN 0	may MD 0	need VB 0	to TO 0	increase VB B-verb.change	their PRP$ 0	thyroid JJ B-noun.body	dose NN I-noun.body	if IN 0	estrogens NNS B-noun.artifact	or CC 0	estrogen NN B-noun.substance	- : 0	containing VBG B-verb.stative	oral JJ B-adj.all	contraceptives NNS B-noun.feeling	are VBP 0	given VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d217.s7	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	quinolones NNS B-noun.communication	including VBG B-verb.stative	norfloxacin NN B-noun.person	with IN 0	glyburide NN 0	( ( 0	a DT 0	sulfonylurea_agent NN B-noun.artifact	) ) 0	has VBZ 0	, , 0	on IN 0	rare JJ B-adj.all	occasions NNS B-noun.event	, , 0	resulted VBD B-verb.stative	in IN 0	severe JJ B-adj.all	hypoglycemia NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d30.s9	As IN 0	with IN 0	other JJ B-adj.all	antihypertensive_agents NNS B-noun.location	, , 0	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	losartan NN B-noun.animal	may MD 0	be VB 0	blunted VBN B-verb.cognition	by IN 0	the DT 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_drug NN 0	indomethacin NN 0	. . 0
DDI-DrugBank.d299.s4	Other JJ 0	5-HT1B/1D_Agonists NNS 0	Concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ B-adj.all	5-HT1B/1D_agonists NNS B-noun.person	within IN 0	24 CD B-adj.all	hours NNS B-noun.time	of IN 0	treatment NN B-noun.plant	with IN 0	AXERT NNP B-noun.group	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d284.s13	Beta SYM 0	- : 0	blockers NNS B-noun.person	not RB B-adv.all	only RB B-adv.all	block VB B-verb.change	the DT 0	therapeutic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	beta JJ B-adj.pert	- : 0	agonists NNS B-noun.person	, , 0	but CC 0	may MD 0	produce VB B-verb.cognition	severe JJ B-adj.all	bronchospasm NN B-noun.feeling	in IN 0	COPD NNP B-noun.group	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d485.s44	Grapefruit NNP B-noun.person	juice NN I-noun.person	increases VBZ B-verb.change	ethinyl_estradiol JJ B-noun.body	concentrations NNS I-noun.body	and CC 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	increase VB B-verb.change	progesterone NN 0	serum NN B-noun.body	levels NNS B-noun.attribute	as RB 0	well RB 0	, , 0	. . 0
DDI-DrugBank.d132.s22	Therefore RB 0	, , 0	indomethacin NN B-noun.person	and CC 0	diflunisal NN B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d562.s5	Although IN 0	this DT 0	interaction NN B-noun.act	has VBZ 0	not RB 0	been VBN 0	reported VBN B-verb.communication	with IN 0	cinoxacin NN B-noun.food	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	cinoxacin NN B-noun.person	is VBZ 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	caffeine NN B-noun.person	- : 0	containing VBG B-verb.communication	products NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d314.s27	Phenytoin NN B-noun.person	, , 0	In IN 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	both DT 0	increases NNS B-noun.event	and CC 0	decreases VBZ B-verb.change	in IN 0	phenytoin NN B-noun.animal	levels NNS B-noun.state	with IN 0	dexamethasone NN B-noun.person	co SYM 0	- : 0	administration NN B-noun.time	, , 0	leading VBG B-verb.motion	to TO 0	alterations NNS B-noun.act	in IN 0	seizure NN B-noun.act	control NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d231.s17	Patients NNS B-noun.person	receiving VBG B-verb.communication	both DT 0	indomethacin NN B-noun.communication	and CC 0	furosemide NN B-noun.attribute	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	diuretic JJ B-adj.all	and/or CC 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.attribute	is VBZ 0	achieved VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d422.s3	BREVIBLOC NNP B-noun.person	concentrations NNS I-noun.person	were VBD B-verb.stative	equivocally RB B-adv.all	higher JJR B-adj.all	when WRB 0	given VBN B-verb.possession	with IN 0	warfarin NN B-noun.act	, , 0	but CC 0	this DT 0	is VBZ B-verb.stative	not RB B-adv.all	likely JJ B-adj.all	to TO 0	be VB B-verb.stative	clinically RB B-adv.all	important JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d82.s0	In IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	receiving VBG B-verb.perception	indomethacin NN I-verb.perception	, , 0	the DT 0	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.person	decreased VBD B-verb.communication	the DT 0	renal JJ B-adj.all	clearance NN B-noun.act	and CC 0	significantly RB B-adv.all	increased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	indomethacin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d150.s1	FLEXERIL NNP B-noun.group	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.food	, , 0	barbiturates NNS B-noun.person	, , 0	and CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d106.s5	Pharmacokinetic JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	nisoldipine NN B-noun.person	and CC 0	beta JJ B-noun.body	- : 0	blockers NNS B-noun.person	( ( 0	atenolol NN 0	, , 0	propranolol NN 0	) ) 0	were VBD B-verb.stative	variable JJ B-adj.all	and CC 0	not RB B-adv.all	significant JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d395.s12	Sucralfate NNP B-noun.person	and CC 0	antacids NNS B-noun.person	, , 0	Quinolones NNPS 0	form VBP B-verb.creation	chelates NNS I-verb.creation	with IN 0	metal NN B-noun.artifact	cations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d395.s6	Cyclosporine NNP B-noun.person	, , 0	Elevated NNP B-noun.person	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	cyclosporine NN B-noun.person	with IN 0	other JJ B-adj.all	members NNS B-noun.person	of IN 0	the DT 0	quinolone_class NNP B-noun.other	. . 0	. . 0
DDI-DrugBank.d502.s0	Ocupress NNP B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.communication	a DT 0	beta NN B-noun.person	- : 0	adrenergic_blocking_agent JJ B-adv.all	orally RB I-adv.all	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	additive JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	systemic JJ B-adj.all	beta NNS B-noun.body	- : 0	blockade NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d158.s24	Veratrum_alkaloids NNS B-noun.artifact	, , 0	Amphetamines NNS B-noun.person	inhibit VBP B-verb.possession	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	veratrum_alkaloids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d46.s17	Refer VB B-verb.cognition	to TO 0	the DT 0	package NN B-noun.artifact	insert NN B-noun.person	for IN 0	lithium NN B-noun.substance	preparations NNS B-noun.artifact	before IN 0	use NN 0	of IN 0	such JJ B-adj.all	preparations NNS B-noun.person	with IN 0	chlorothiazide NN 0	. . 0
DDI-MedLine.d103.s1	Two CD 0	different JJ B-adj.all	types NNS B-noun.cognition	of IN 0	therapy NN 0	with IN 0	magnesium NN B-noun.person	are VBP 0	used VBN B-verb.consumption	, , 0	physiological JJ B-adj.all	oral JJ B-adj.all	magnesium NN B-noun.artifact	supplementation NN B-noun.artifact	which WDT 0	is VBZ B-verb.stative	totally RB B-adv.all	atoxic JJ B-adj.all	since IN 0	it PRP 0	palliates VBZ B-verb.body	magnesium NN B-noun.animal	deficiencies NNS I-noun.animal	by IN 0	simply RB 0	normalizing VBG B-verb.communication	the DT 0	magnesium NN B-noun.artifact	intake NN I-noun.artifact	and CC 0	pharmacological JJ B-adj.all	magnesium NN B-noun.person	therapy NN 0	which WDT 0	may MD 0	induce VB B-verb.cognition	toxicity NN B-noun.attribute	since IN 0	it PRP 0	creates VBZ B-verb.creation	iatrogenic JJ B-adj.all	magnesium NN B-noun.person	overload NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d120.s3	Both DT 0	the DT 0	toxicity NN B-noun.attribute	of IN 0	filipin NN B-noun.communication	and CC 0	the DT 0	therapeutic JJ B-adj.all	value NN B-noun.attribute	of IN 0	amphotericin_B NNP B-noun.person	can MD 0	be VB 0	rationalized VBN B-verb.cognition	at IN 0	the DT 0	cellular JJ B-noun.body	and CC 0	molecular JJ B-adj.all	level NN B-noun.state	by IN 0	the DT 0	following JJ B-adj.all	observations NNS B-noun.act	, , 0	( ( 0	i NN 0	) ) 0	these DT 0	polyene_antibiotics NNS B-noun.person	showed VBD B-verb.communication	differential JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	cells NNS B-noun.body	, , 0	. . 0
DDI-DrugBank.d289.s13	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan NN B-noun.substance	decreased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	cyclosporine_A NNP B-noun.person	( ( 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN I-adj.all	) ) 0	by IN 0	approximately RB B-adv.all	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d565.s20	Since IN 0	there EX 0	have VBP 0	been VBN 0	conflicting VBG B-verb.communication	results NNS B-noun.communication	regarding VBG B-verb.stative	the DT 0	effect NN B-noun.cognition	of IN 0	digoxin NN B-noun.food	levels NNS B-noun.attribute	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	digoxin NN B-noun.state	levels NNS B-noun.state	be VB 0	monitored VBN B-verb.perception	when WRB 0	initiating VBG B-verb.communication	, , 0	adjusting NN B-verb.change	, , 0	and CC 0	discontinuing VBG B-verb.change	diltiazem_hydrochloride JJ 0	therapy NN 0	to TO 0	avoid VB B-verb.social	possible JJ B-adj.all	over- JJ B-noun.other	or CC 0	under IN 0	- : 0	digitalization NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d263.s2	In IN 0	the DT 0	same JJ B-adj.all	study NN B-noun.artifact	it PRP 0	was VBD 0	shown VBN B-verb.cognition	that IN 0	didanosine NN B-noun.person	and CC 0	stavudine NN B-noun.person	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	intracellular JJ B-adj.all	phosphorylation NN B-noun.artifact	of IN 0	zalcitabine NN B-noun.person	in IN 0	peripheral JJ B-adj.pert	blood NN B-noun.body	mononuclear NN B-noun.body	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d53.s14	Ergotamine NN B-noun.person	or CC 0	dihydroergotamine VB B-verb.social	acute JJ B-adj.all	ergot NN B-noun.person	toxicity NN B-noun.person	characterized VBN B-verb.communication	by IN 0	severe JJ B-adj.all	peripheral JJ B-adj.pert	vasospasm NN B-noun.cognition	and CC 0	dysesthesia NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d488.s2	Platelet_inhibitors NNS B-noun.person	, , 0	Drugs NNS B-noun.person	such JJ 0	as IN 0	acetylsalicylic_acid JJ 0	, , 0	dextran NN B-noun.person	, , 0	phenylbutazone NN B-noun.person	, , 0	ibuprofen NN B-noun.person	, , 0	indomethacin NN B-noun.person	, , 0	dipyridamole NN B-noun.person	, , 0	hydroxychloroquine NN B-noun.person	and CC 0	others NNS 0	that WDT 0	interfere VBP B-verb.stative	with IN 0	platelet NN B-noun.person	- : 0	aggregation NN B-noun.act	reactions NNS B-noun.cognition	( ( 0	the DT 0	main JJ B-adj.all	hemostatic JJ B-adj.all	defense NN B-noun.communication	of IN 0	heparinized VBN B-verb.cognition	patients NNS B-noun.person	) ) 0	may MD 0	induce VB B-verb.cognition	bleeding NN B-noun.act	and CC 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	heparin_sodium NN I-verb.communication	. . 0	. . 0
DDI-DrugBank.d499.s24	Lithium NNP B-noun.person	, , 0	Nonsteroidal_anti JJ 0	- : 0	inflammatory_agents NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	steadystate JJ B-adj.all	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d531.s78	Drug NN 0	interaction NN 0	studies NNS B-noun.artifact	with IN 0	SUSTIVA NNP B-noun.group	and CC 0	these DT 0	imidazole NN B-noun.attribute	and CC 0	triazole_antifungals NNS B-noun.communication	have VBP 0	not RB 0	been VBN 0	conducted VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d523.s16	The DT 0	adverse JJ B-adj.all	experience NN B-noun.person	profile RB B-adv.all	seen VBN B-verb.perception	with IN 0	KEMSTROTM NNP B-noun.group	was VBD B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	seen VBN B-verb.perception	with IN 0	baclofen JJ B-adj.all	tablets NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d165.s29	Edema NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	receiving VBG B-verb.communication	Itraconazole NNP B-noun.person	and CC 0	dihydropyridine_calcium_channel_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d363.s0	No DT 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.person	with IN 0	commonly RB B-adv.all	used VBN B-verb.consumption	preanesthetic JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	or CC 0	drugs NNS B-noun.artifact	used VBN B-verb.consumption	during IN 0	anesthesia NN 0	( ( 0	muscle_relaxants NNS B-noun.person	, , 0	intravenous JJ B-adj.all	agents NNS B-noun.person	, , 0	and CC 0	local JJ B-adj.all	anesthetic_agents NNS B-noun.group	) ) 0	were VBD 0	reported VBN B-verb.communication	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d471.s0	Mineral_oil NN B-noun.substance	interferes VBZ B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	fat SYM 0	- : 0	soluble_vitamins NNS B-noun.person	, , 0	including VBG B-verb.stative	vitamin_D_preparations NNS I-verb.stative	. . 0	. . 0
DDI-DrugBank.d538.s0	Known VBN B-verb.cognition	drug NN B-noun.act	interactions NNS I-noun.act	include VBP B-verb.stative	barbiturates NNS I-verb.stative	, , 0	tranquilizers NNS B-noun.person	, , 0	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d352.s3	conversely RB B-adv.all	, , 0	diethylpropion NN B-noun.act	may MD 0	interfere VB B-verb.stative	with IN 0	antihypertensive_drugs NNS B-noun.substance	( ( 0	i.e. FW B-adv.all	, , 0	guanethidine NN B-noun.person	, , 0	a SYM 0	- : 0	methyldopa NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d3.s11	Lithium NNP B-noun.person	, , 0	Inhibition NNP B-noun.person	of IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.attribute	, , 0	leading VBG B-verb.motion	to TO 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	lithium NN B-noun.substance	concentration NN I-noun.substance	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	some DT 0	prostaglandin NN B-adj.all	synthesis NN B-noun.cognition	- : 0	inhibiting VBG B-verb.contact	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d525.s0	Eprosartan NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	have VB B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	and CC 0	the DT 0	pharmacodynamics NNS B-noun.person	of IN 0	warfarin NN B-noun.act	and CC 0	glyburide NN 0	. . 0	. . 0
DDI-DrugBank.d384.s2	Phenytoin NN 0	/ '' 0	Phenobarbital NNP B-noun.other	, , 0	The DT 0	coadministration NN B-noun.person	of IN 0	phenytoin NN B-noun.substance	or CC 0	phenobarbital NN B-noun.artifact	will MD 0	not RB B-adv.all	affect VB B-verb.change	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	vitamin_D NNP B-noun.location	, , 0	but CC 0	may MD 0	reduce VB B-verb.change	endogenous JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	calcitriol NN B-noun.communication	/ : 0	ergocalcitriol NN B-noun.act	by IN 0	accelerating VBG B-verb.change	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d69.s1	The DT 0	homodimeric JJ B-adj.all	disintegrin NN B-noun.substance	contortrostatin NN B-noun.food	was VBD 0	compared VBN B-verb.change	directly RB B-adv.all	to TO 0	the DT 0	monomeric JJ B-adj.all	disintegrins NNS B-noun.phenomenon	echistatin NN 0	and CC 0	flavoridin NN B-noun.person	for IN 0	the DT 0	ability NN B-noun.cognition	to TO 0	affect VB B-verb.change	protein JJ B-adj.all	tyrosine JJ B-adj.all	phosphorylation NN B-noun.artifact	in IN 0	tumor NN B-noun.body	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d455.s6	Treatment NN B-noun.person	with IN 0	entacapone NN B-noun.person	coadministered VBD B-verb.communication	with IN 0	levodopa NN B-noun.attribute	/ : 0	dopa_decarboxylase_inhibitor NN 0	does VBZ 0	not RB B-adv.all	change VB B-verb.change	these DT 0	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d245.s4	These DT 0	drugs NNS B-noun.artifact	include VBP B-verb.change	the DT 0	thiazides NNS B-noun.artifact	and CC 0	other JJ 0	diuretics NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	thyroid JJ B-noun.body	products NNS I-noun.body	, , 0	estrogens VBZ B-verb.cognition	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	nicotinic_acid JJ 0	, , 0	sympathomimetics NNS B-noun.person	, , 0	calcium_channel_blocking_drugs NNS B-noun.communication	, , 0	and CC 0	isoniazid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s26	Oral JJ B-adj.all	contraceptives NNS B-noun.event	and CC 0	other JJ 0	hormonalmethods NNS B-noun.person	of IN 0	birth NN 0	control NN B-noun.act	should MD 0	not RB 0	be VB 0	usedas VBN B-verb.consumption	the DT 0	sole JJ B-adj.all	method NN B-noun.attribute	of IN 0	contraception NN B-noun.act	inwomen NNS B-noun.person	taking VBG B-verb.social	nevirapine JJ I-verb.social	, , 0	since IN 0	nevirapinemay RB 0	lower JJR B-adj.all	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	thesemedications NNS B-noun.communication	. . 0	. . 0
DDI-MedLine.d105.s1	Two CD 0	studies NNS B-noun.group	were VBD 0	conducted VBN B-verb.communication	in IN 0	HIV NNP 0	- : 0	infected JJ B-adj.all	subjects NNS B-noun.person	to TO 0	assess VB B-verb.cognition	the DT 0	potential NN B-noun.person	for IN 0	azithromycin NN 0	to TO 0	interact VB B-verb.contact	with IN 0	zidovudine NN B-noun.person	and CC 0	dideoxyinosine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d25.s10	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	macrolide_antibiotics NNS B-noun.person	and CC 0	other JJ 0	hydroxymethylglutaryl_coenzyme_A_(HMG JJ 0	- : 0	CoA)_reductase_inhibitors NNS B-noun.person	have VBP 0	resulted VBN B-verb.social	in IN 0	previous JJ B-adj.all	reports NNS B-noun.artifact	of IN 0	rhabdomyolysis NN B-noun.food	. . 0	. . 0
DDI-MedLine.d133.s5	Verapamil NNP B-noun.person	also RB B-adv.all	significantly RB B-adv.all	decreased VBD B-verb.change	the DT 0	incidence NN B-noun.event	of IN 0	lymphatic JJ B-adj.all	invasion NN B-noun.event	of IN 0	adenocarcinomas NNS B-noun.communication	, , 0	which WDT 0	was VBD 0	enhanced VBN B-verb.change	by IN 0	bombesin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d75.s15	There EX 0	is VBZ B-verb.stative	a DT 0	single JJ B-noun.artifact	case NN I-noun.artifact	report NN B-noun.person	, , 0	which WDT 0	suggests VBZ B-verb.communication	that IN 0	sucralfate NN B-noun.person	may MD 0	interfere VB B-verb.stative	with IN 0	anagrelide JJ 0	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d410.s3	Beta_Blockers NNS B-noun.person	, , 0	Although IN 0	the DT 0	results NNS B-noun.communication	of IN 0	a DT 0	clinical JJ B-adj.all	study NN B-noun.artifact	did VBD 0	not RB B-adv.all	indicate VB B-verb.communication	a DT 0	safe JJ B-adj.all	problem NN B-noun.communication	associated VBN B-verb.cognition	with IN 0	the DT 0	administration NN B-noun.time	of IN 0	D.H.E._45 NNP B-noun.person	_ . 0	( ( 0	dihydroergotamine_mesylate JJ 0	) ) 0	Injection NN B-noun.location	, , 0	USP NNP 0	to TO 0	subjects NNS B-noun.person	already RB 0	receiving VBG B-verb.communication	propranolol NN B-noun.person	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	that IN 0	propranolol NN B-noun.person	may MD 0	potentiate VB B-verb.communication	the DT 0	vasoconstrictive JJ B-adj.all	action NN B-noun.process	of IN 0	ergotamine NN B-noun.phenomenon	by IN 0	blocking VBG B-verb.change	the DT 0	vasodilating VBG B-verb.change	property NN B-noun.possession	of IN 0	epinephrine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d57.s2	Those DT 0	for IN 0	which WDT 0	effectiveness NN 0	is VBZ 0	reported VBN B-verb.communication	includes VBZ B-verb.stative	diphenhydramine NN 0	, , 0	hydroxyzine NN B-noun.person	, , 0	orphenadrine NN 0	, , 0	pyrilamine NN B-noun.person	, , 0	phenyltoloxamine NN B-noun.person	, , 0	promethazine NN B-noun.person	, , 0	methdilazine NN B-noun.person	, , 0	and CC 0	tripelennamine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d143.s50	Since IN 0	amiodarone NN 0	is VBZ B-verb.stative	a DT 0	substrate NN B-noun.person	for IN 0	CYP3A4 NNP B-noun.person	, , 0	there EX 0	is VBZ B-verb.stative	the DT 0	potential NN B-noun.cognition	that IN 0	the DT 0	use NN 0	of IN 0	St. NNP B-noun.group	John NNP I-noun.group	s VBZ B-verb.stative	Wort NNP B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	amiodarone NN B-noun.person	could MD 0	result VB B-verb.perception	in IN 0	reduced VBN B-verb.change	amiodarone NN 0	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d485.s39	Selegiline NN B-noun.person	, , 0	Combination_hormonal_contraceptives NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	serum NN B-noun.body	concentration NN B-noun.event	of IN 0	selegiline NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d124.s9	Additional JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	for IN 0	coadministration NN B-noun.person	with IN 0	INVIRASE NNP B-noun.group	and CC 0	ritonavir NN B-noun.person	are VBP 0	included VBN B-verb.stative	below IN 0	. . 0	. . 0
DDI-DrugBank.d195.s7	Based VBN B-verb.cognition	on IN 0	clinical JJ B-adj.all	and CC 0	pharmacokinetic JJ B-adj.all	results NNS B-noun.event	from IN 0	the DT 0	ATAC NNP B-noun.group	trial NN B-noun.act	, , 0	tamoxifen NNS B-noun.person	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	with IN 0	anastrozole NN B-noun.attribute	( ( 0	see VB 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	__ NNP I-noun.group	Drug NNP I-noun.group	Interactions NNP I-noun.group	and CC 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	; : 0	Clinical NNP B-noun.other	Studies NNPS I-noun.other	; : 0	Adjuvant NNP B-noun.other	Treatment NNP I-noun.other	of IN I-noun.other	Breast NNP I-noun.other	Cancer NNP I-noun.other	in IN 0	Postmenopausal NNP B-noun.other	Women NNP I-noun.other	subsections NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d69.s0	Use NNP B-noun.person	of IN 0	Cerubidine NNP B-noun.location	in IN 0	a DT 0	patient NN B-noun.person	who WP 0	has VBZ 0	previously RB B-adv.all	received VBD B-verb.possession	doxorubicin NN B-noun.communication	increases VBZ B-verb.change	the DT 0	risk NN 0	of IN 0	cardiotoxicity NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d140.s7	Digoxin NNP B-noun.person	, , 0	When WRB 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	atorvastatin NN B-noun.food	and CC 0	digoxin NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	, , 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	plasma NN 0	digoxin NN 0	concentrations NNS 0	increased VBN B-verb.change	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d334.s12	No DT 0	clinically RB B-adv.all	important JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	occurred VBD B-verb.cognition	when WRB 0	PRINIVIL NNP B-noun.person	was VBD 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	propranolol NN B-noun.person	or CC 0	hydrochlorothiazide NN 0	. . 0	. . 0
DDI-DrugBank.d3.s14	The DT 0	effect NN B-noun.cognition	of IN 0	TORADOL NNP B-noun.person	on IN 0	methotrexate JJ B-adj.all	clearance NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d460.s3	Glyburide NNP B-noun.person	, , 0	In IN 0	a DT 0	randomized VBN B-verb.cognition	, , 0	multiple JJ B-noun.person	- : 0	dose NN 0	crossover NN 0	study NN B-noun.artifact	, , 0	patients NNS B-noun.person	with IN 0	Type NNP B-noun.person	2 CD B-adj.all	diabetes NNS B-noun.person	were VBD 0	administered VBN B-verb.possession	120 CD 0	mg IN 0	Starlix NNP B-noun.person	three CD I-noun.person	times NNS B-noun.event	a DT 0	day NN 0	before IN 0	meals NNS B-noun.food	for IN 0	1 CD B-adj.all	day NN 0	in IN 0	combination NN 0	with IN 0	glyburide NN B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d197.s5	Neuromuscular_Blockers NNS B-noun.person	, , 0	In IN 0	one CD 0	study NN B-verb.cognition	of IN 0	10 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	administration NN B-noun.person	of IN 0	PRECEDEX NNP B-noun.group	for IN 0	45 CD 0	minutes NNS B-noun.time	at IN 0	a DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	1 CD B-adj.all	( ( 0	one CD 0	) ) 0	ng UH 0	/ : 0	mL PRP 0	resulted VBD B-verb.communication	in IN 0	no DT 0	clinically RB B-adv.all	meaningful JJ B-adj.all	increases NNS B-noun.event	in IN 0	the DT 0	magnitude NN B-noun.person	or CC 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	associated VBN B-verb.cognition	with IN 0	rocuronium NN B-noun.artifact	administration NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d78.s8	When WRB 0	initiating VBG B-verb.creation	a DT 0	multi NNS B-noun.person	- : 0	day NN B-noun.person	course NN B-noun.group	of IN 0	grepafloxacin NN B-noun.food	in IN 0	a DT 0	patient NN B-noun.person	maintained VBN B-verb.consumption	on IN 0	theophylline PRP 0	, , 0	the DT 0	theophylline JJ 0	maintenance NN 0	dose NN 0	should MD 0	be VB 0	halved VBN B-verb.social	for IN 0	the DT 0	period NN B-noun.time	of IN 0	concurrent JJ B-adj.all	use NN 0	of IN 0	grepafloxacin NN B-noun.food	and CC 0	monitoring NN B-verb.perception	of IN 0	serum NN 0	theophylline NN 0	concentrations NNS B-noun.attribute	should MD 0	be VB 0	initiated VBN B-verb.creation	as IN 0	a DT 0	guide NN B-noun.cognition	to TO 0	further JJ B-adj.all	dosage NN B-noun.artifact	adjustments NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d67.s2	Although IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	C NNP 0	max NN 0	and CC 0	AUC NNP B-noun.group	0 CD B-noun.quantity	- : 0	24 CD B-adj.all	hrs NNS B-noun.artifact	) ) 0	of IN 0	desloratadine NN B-noun.location	and CC 0	3-hydroxydesloratadine JJ 0	were VBD 0	observed VBN B-verb.perception	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	the DT 0	safety NN B-noun.person	profile NN B-noun.quantity	of IN 0	desloratadine NN B-noun.location	, , 0	as IN 0	assessed VBN B-verb.communication	by IN 0	electrocardiographic JJ B-adj.pert	parameters NNS B-noun.person	( ( 0	including VBG B-verb.change	the DT 0	corrected VBN B-verb.change	QT NNP 0	interval NN 0	) ) 0	, , 0	clinical JJ B-adj.all	laboratory NN B-noun.artifact	tests NNS I-noun.artifact	, , 0	vital JJ B-adj.all	signs NNS B-noun.communication	, , 0	and CC 0	adverse JJ B-adj.all	events NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d516.s0	Theophylline PRP 0	, , 0	In IN 0	three CD 0	pharmacokinetic JJ B-adj.all	studies NNS B-noun.artifact	including VBG B-verb.stative	46 CD 0	normal JJ B-adj.all	, , 0	healthy JJ B-adj.all	subjects NNS B-noun.person	, , 0	theophylline JJ 0	clearance NN B-noun.attribute	and CC 0	concentration NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	by IN 0	the DT 0	addition NN B-noun.act	of IN 0	lomefloxacin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d531.s80	Anti NNP B-noun.person	- : 0	HIV_protease_inhibitors NNS B-noun.person	, , 0	Saquinavir NNP B-noun.person	/ POS 0	ritonavir NN B-noun.person	combination NN B-noun.event	. . 0
DDI-DrugBank.d478.s2	The DT 0	administration NN B-noun.time	of IN 0	naratriptan NN B-noun.communication	with IN 0	other JJ B-adj.all	5-HT1_agonists NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	in IN 0	migraine NN 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d297.s1	Population NNP B-noun.person	pharmacokinetic JJ B-adj.all	analyses NNS B-noun.person	revealed VBD B-verb.communication	that IN 0	MTX NNP 0	, , 0	NSAIDs NNP B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	and CC 0	TNF_blocking_agents NNS B-noun.person	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	abatacept JJ B-adj.all	clearance NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d367.s15	Cardiovascular JJ B-adj.all	agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	atenolol NN B-noun.person	, , 0	hydrochlorothiazide NN 0	, , 0	propranolol NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d46.s9	and CC 0	phase NN B-noun.communication	3 CD B-adj.all	( ( 0	days NNS B-noun.time	45 CD 0	- : 0	52 LS 0	) ) 0	, , 0	cisapride RB 0	10 CD 0	mg RB 0	4 CD B-adj.all	times NNS B-noun.event	/ JJ 0	day NN 0	( ( 0	days NNS B-noun.time	45 CD 0	- : 0	51 LS 0	) ) 0	plus CC 0	fluoxetine VBP B-verb.change	20 CD B-adj.all	mg RB B-noun.quantity	/ JJ 0	day NN 0	( ( 0	days NNS B-noun.time	45 CD 0	- : 0	52 LS 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d246.s0	Concurrent JJ B-adj.all	use NN 0	of IN 0	butorphanol NN 0	with IN 0	central_nervous_system_depressants NNS B-noun.location	( ( 0	e.g. UH 0	, , 0	alcohol NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	and CC 0	antihistamines NNS B-noun.attribute	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	central_nervous_system_depressant JJ 0	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d449.s2	Fluoxetine NNP B-noun.person	, , 0	OCs NNP B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	macrolide_antibiotics NNS B-noun.person	( ( 0	exercise NN B-noun.act	caution NN B-noun.cognition	) ) 0	. . 0	. . 0
DDI-DrugBank.d309.s1	Patients NNS B-noun.person	receiving VBG B-verb.communication	antihistamines NNS B-noun.attribute	should MD 0	be VB 0	advised VBN B-verb.communication	against IN 0	the DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	other JJ B-adj.all	CNS_depressant_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d438.s32	The DT 0	effect NN B-noun.cognition	of IN 0	gabapentin NN B-noun.animal	on IN 0	cimetidine NN B-noun.location	was VBD B-verb.stative	not RB B-adv.all	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d299.s7	If IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	AXERT NNP B-noun.group	and CC 0	an DT 0	SSRI NNP B-noun.group	is VBZ B-verb.stative	clinically RB B-adv.all	warranted VBN B-verb.communication	, , 0	appropriate JJ B-adj.all	observation NN B-noun.act	of IN 0	the DT 0	patient NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d51.s2	Anticholinergic_agents NNS B-noun.artifact	, , 0	Although IN 0	ipratropium_bromide NN 0	is VBZ B-verb.stative	minimally RB B-adv.all	absorbed VBN B-verb.contact	into IN 0	the DT 0	systemic JJ B-adj.all	circulation NN B-noun.act	, , 0	there EX 0	is VBZ B-verb.stative	some DT 0	potential NN B-noun.person	for IN 0	an DT 0	additive JJ B-adj.all	interaction NN B-noun.act	with IN 0	concomitantly RB B-adv.all	used VBN B-verb.consumption	anticholinergic_medications NNS I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d263.s21	Patients NNS B-noun.person	receiving VBG B-verb.communication	these DT 0	drugs NNS B-noun.artifact	in IN 0	combination NN 0	with IN 0	zalcitabine NN B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.perception	for IN 0	signs NNS B-noun.communication	of IN 0	toxicity NN B-noun.attribute	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	zalcitabine NN 0	reduced VBN B-verb.change	if IN 0	warranted VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d547.s3	An DT 0	increase NN B-noun.event	in IN 0	serum NN 0	lithium NN 0	concentration NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	during IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lithium NN B-noun.substance	with IN 0	ATACAND NNP B-noun.group	, , 0	so RB B-adv.all	careful JJ B-adj.all	monitoring NN B-noun.person	of IN 0	serum NN B-noun.body	lithium NN B-noun.body	levels NNS B-noun.attribute	is VBZ 0	recommended VBN B-verb.communication	during IN 0	concomitant JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s65	Carbamazepine NNP B-noun.person	, , 0	clonazepam NN B-noun.person	, , 0	ethosuximide NN 0	. . 0
DDI-DrugBank.d171.s0	Tagamet NNP B-noun.person	, , 0	apparently RB B-adv.all	through IN 0	an DT 0	effect NN B-noun.cognition	on IN 0	certain JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.plant	systems NNS B-noun.body	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	the DT 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	warfarin NN B-noun.act	- : 0	type_anticoagulants NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	propranolol NN B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	chlordiazepoxide NN 0	, , 0	diazepam NN B-noun.person	, , 0	certain JJ B-adj.all	tricyclic_antidepressants NNS B-noun.person	, , 0	lidocaine NN B-noun.person	, , 0	theophylline PRP 0	and CC 0	metronidazole NN B-noun.attribute	, , 0	thereby RB 0	delaying VBG B-verb.stative	elimination NN B-noun.act	and CC 0	increasing VBG B-verb.change	blood NN B-noun.body	levels NNS B-noun.attribute	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d246.s1	When WRB 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	the DT 0	dose NN B-noun.quantity	of IN 0	butorphanol NN 0	should MD 0	be VB B-verb.stative	the DT 0	smallest JJS B-adj.all	effective JJ B-noun.phenomenon	dose NN I-noun.phenomenon	and CC 0	the DT 0	frequency NN B-noun.person	of IN 0	dosing VBG 0	reduced VBN B-verb.change	as RB 0	much JJ 0	as IN 0	possible JJ B-adj.all	when WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	that WDT 0	potentiate VBP B-verb.stative	the DT 0	action NN B-noun.process	of IN 0	opioids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d522.s14	However RB 0	, , 0	theophylline JJ 0	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	with IN 0	dosage NN B-noun.food	adjustment NN I-noun.food	as IN 0	appropriate JJ B-adj.all	, , 0	in IN 0	patients NNS B-noun.person	whose WP$ 0	pulmonary JJ B-adj.all	disease NN B-noun.communication	requires VBZ I-noun.communication	maintaining VBG B-verb.possession	a DT 0	given VBN B-verb.possession	theophylline JJ 0	plasma NN 0	concentration NN 0	for IN 0	optimal JJ B-adj.all	pulmonary JJ B-adj.all	function NN B-noun.act	or CC 0	in IN 0	patients NNS B-noun.person	with IN 0	theophylline JJ B-noun.body	concentrations NNS I-noun.body	at IN 0	the DT 0	higher JJR B-adj.all	end NN B-noun.person	of IN 0	the DT 0	therapeutic JJ B-adj.pert	range NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d85.s9	Naproxen NNP B-noun.person	and CC 0	other JJ B-adj.all	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	propranolol NN B-noun.person	and CC 0	other JJ 0	beta JJ 0	- : 0	blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d522.s19	Triazolam NNP B-noun.person	, , 0	Erythromycin NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.communication	the DT 0	clearance NN B-noun.act	of IN 0	triazolam NN B-noun.act	and CC 0	, , 0	thus RB 0	, , 0	may MD 0	increase VB B-verb.change	the DT 0	pharmacologic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	triazolam NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d420.s7	The DT 0	effect NN B-noun.cognition	of IN 0	foods NNS B-noun.food	highly RB B-adv.all	fortified VBN B-verb.stative	with IN 0	elemental JJ B-adj.all	iron NN B-noun.person	( ( 0	primarily RB B-adv.all	iron NN B-noun.person	- : 0	fortified VBN B-verb.cognition	breakfast NN 0	cereals NNS 0	) ) 0	on IN 0	cefdinir NN B-noun.location	absorption NN B-noun.act	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d143.s48	Administration NN B-noun.person	of IN 0	rifampin NN 0	concomitantly RB 0	with IN 0	oral JJ B-adj.all	amiodarone NN 0	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	result VB B-verb.stative	in IN 0	decreases NNS B-noun.food	in IN 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	amiodarone NN B-noun.person	and CC 0	desethylamiodarone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d94.s15	Given VBN B-verb.possession	the DT 0	anticonvulsant JJ B-adj.all	properties NNS B-noun.attribute	of IN 0	carbamazepine NN B-noun.communication	, , 0	EQUETROTM NNP B-noun.group	may MD 0	reduce VB B-verb.change	the DT 0	thyroid JJ B-noun.body	function NN I-noun.body	as IN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	other JJ 0	anticonvulsants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d212.s5	Potential JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	were VBD 0	assessed VBN B-verb.communication	in IN 0	clinical JJ B-adj.all	pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	( ( 0	phenytoin NN B-noun.person	, , 0	valproate NN B-noun.attribute	, , 0	oral JJ B-adj.all	contraceptive NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	probenecid NN 0	) ) 0	and CC 0	through IN 0	pharmacokinetic JJ B-adj.all	screening NN B-noun.event	in IN 0	the DT 0	placebo NN B-noun.person	- : 0	controlled VBN B-verb.social	clinical JJ B-adj.all	studies NNS B-noun.communication	in IN 0	epilepsy NN B-noun.location	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s17	Cimetidine NNP B-noun.person	, , 0	caffeine NN B-noun.person	, , 0	and CC 0	erythromycin NN B-noun.person	may MD 0	increase VB B-verb.change	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	Clozapine NNP B-noun.other	, , 0	potentially RB B-adv.all	resulting VBG B-verb.stative	in IN 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d85.s6	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	naproxen NN B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	because IN 0	naproxen NN B-noun.person	is VBZ 0	displaced VBN B-verb.creation	from IN 0	its PRP$ 0	binding JJ B-adj.pert	sites NNS B-noun.location	during IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.food	, , 0	resulting VBG B-verb.stative	in IN 0	lower JJR B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	and CC 0	peak JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d313.s10	Because IN 0	there EX 0	are VBP B-verb.stative	no DT 0	data NNS B-noun.cognition	on IN 0	the DT 0	compatibility NN B-noun.attribute	of IN 0	NovoLog NNP B-noun.person	and CC 0	crystalline JJ B-adj.all	zinc_insulin JJ B-noun.body	preparations NNS I-noun.body	, , 0	NovoLog NNP B-noun.person	should MD 0	not RB 0	be VB 0	mixed VBN B-verb.change	with IN 0	these DT 0	preparations NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d83.s19	The DT 0	reduced JJ B-adj.all	risk NN 0	of IN 0	adverse JJ B-adj.all	events NNS B-noun.person	and CC 0	therapeutic JJ B-adj.pert	superiority NN B-noun.feeling	compared VBN B-verb.change	with IN 0	haloperidol NN B-noun.person	and CC 0	risperidone NN 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	negative JJ B-adj.all	and CC 0	depressive JJ B-adj.all	symptoms NNS B-noun.animal	support VBP B-verb.contact	the DT 0	choice NN B-noun.act	of IN 0	olanzapine JJ 0	as IN 0	a DT 0	first JJ B-noun.person	- : 0	line NN B-noun.phenomenon	option NN B-noun.process	in IN 0	the DT 0	management NN B-noun.group	of IN 0	schizophrenia NN B-noun.person	in IN 0	the DT 0	acute JJ B-noun.artifact	phase NN I-noun.artifact	and CC 0	for IN 0	the DT 0	maintenance NN B-noun.act	of IN 0	treatment NN B-noun.plant	response NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d84.s0	Antimicrobial JJ B-adj.all	activity NN B-noun.process	of IN 0	Ganoderma_lucidum_extract NN B-noun.phenomenon	alone RB B-adv.all	and CC 0	in IN 0	combination NN 0	with IN 0	some DT 0	antibiotics NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d234.s1	however RB 0	, , 0	no DT 0	deleterious JJ B-noun.person	interactions NNS I-noun.person	were VBD 0	seen VBN B-verb.perception	when WRB 0	ROMAZICON NNP B-noun.group	was VBD 0	administered VBN B-verb.possession	after IN 0	narcotics NNS B-noun.person	, , 0	inhalational JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	muscle_relaxants NNS B-noun.person	and CC 0	muscle NN B-noun.body	relaxant JJ B-adj.all	antagonists NNS B-noun.person	administered VBN B-verb.possession	in IN 0	conjunction NN 0	with IN 0	sedation NN B-noun.feeling	or CC 0	anesthesia NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d373.s1	Long NNP B-noun.person	Acting NNP I-noun.person	Nitrates NNP I-noun.person	, , 0	Nifedipine NNP B-noun.person	may MD 0	be VB 0	safely RB B-adv.all	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	nitrates NNS B-noun.time	, , 0	but CC 0	there EX 0	have VBP 0	been VBN B-verb.stative	no DT 0	controlled JJ B-adj.all	studies NNS B-noun.artifact	to TO 0	evaluate VB B-verb.communication	the DT 0	antianginal JJ B-adj.all	effectiveness NN B-noun.cognition	of IN 0	this DT 0	combination NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d314.s8	Antidiabetics NNS B-noun.person	, , 0	Because IN 0	corticosteroids NNS B-noun.communication	may MD 0	increase VB B-verb.change	blood NN B-noun.act	glucose NN B-noun.act	concentrations NNS B-noun.artifact	, , 0	dosage NN B-noun.artifact	adjustments NNS B-noun.person	of IN 0	antidiabetic_agents NNS B-noun.object	may MD 0	be VB 0	required VBN B-verb.stative	. . 0	. . 0
DDI-MedLine.d110.s5	Both DT 0	ibogaine NN B-noun.person	and CC 0	18-MC JJ 0	decrease NN B-verb.change	extracellular JJ B-adj.all	levels NNS B-noun.state	of IN 0	dopamine NN B-noun.act	in IN 0	the DT 0	nucleus NN B-noun.group	accumbens VBZ B-verb.social	, , 0	but CC 0	only RB B-adv.all	ibogaine JJ B-adj.all	increases NNS B-noun.event	extracellular JJ B-adj.all	levels NNS B-noun.state	of IN 0	serotonin NN B-noun.person	in IN 0	the DT 0	nucleus JJ B-noun.group	accumbens NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d289.s30	Warfarin NNP B-noun.person	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan NN B-noun.communication	500 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	for IN 0	6 CD B-adj.all	days NNS B-noun.person	decreased VBD B-verb.communication	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	both DT 0	S NNP B-noun.group	- : 0	warfarin NN B-noun.substance	( ( 0	a DT 0	CYP2C9 JJ B-adj.all	substrate NN I-adj.all	) ) 0	and CC 0	R NNP 0	- : 0	warfarin NN B-noun.substance	( ( 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN I-adj.all	) ) 0	by IN 0	29 CD B-noun.quantity	and CC 0	38 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d401.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	The DT 0	central JJ B-adj.all	anticholinergic JJ B-adj.pert	syndrome NN B-noun.person	can MD 0	occur VB B-verb.cognition	when WRB 0	anticholinergic JJ B-adj.all	agents NNS B-noun.person	such JJ 0	as IN 0	AKINETON NNP B-noun.group	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	that WDT 0	have VBP B-verb.stative	secondary JJ B-adj.all	anticholinergic JJ B-adj.pert	actions NNS B-noun.person	, , 0	e.g. NNP B-noun.person	, , 0	certain JJ B-adj.all	narcotic_analgesics NNS B-noun.state	such JJ 0	as IN 0	meperidine NN B-noun.person	, , 0	the DT 0	phenothiazines NNS B-noun.artifact	and CC 0	other JJ 0	antipsychotics NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	certain JJ B-adj.all	antiarrhythmics NNS B-noun.attribute	such JJ 0	as IN 0	the DT 0	quinidine JJ B-adj.all	salts NNS B-noun.substance	, , 0	and CC 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d219.s14	Glyburide NNP B-noun.person	, , 0	Etodolac NNP B-noun.person	has VBZ B-verb.possession	no DT 0	apparent JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.event	when WRB 0	administered VBN B-verb.possession	with IN 0	glyburide NN 0	. . 0	. . 0
DDI-DrugBank.d60.s4	The DT 0	use NN 0	of IN 0	NIMBEX NNP B-noun.group	before IN 0	succinylcholine NN 0	to TO 0	attenuate VB B-verb.social	some DT 0	of IN 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	succinylcholine NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d325.s4	Cardiac NNP B-noun.person	effects NNS B-noun.phenomenon	of IN 0	dopamine NN 0	are VBP 0	antagonized VBN B-verb.cognition	by IN 0	beta NNS B-noun.person	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	such JJ 0	as IN 0	propranolol NN B-noun.person	and CC 0	metoprolol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d70.s11	The DT 0	potential JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	fulvestrant JJ B-adj.all	on IN 0	the DT 0	fertility NN B-noun.state	of IN 0	male NN B-noun.plant	animals NNS B-noun.food	were VBD 0	not RB B-adv.all	studied VBN B-verb.cognition	but CC 0	in IN 0	a DT 0	6-month JJ B-adj.all	toxicology NN B-noun.artifact	study NN B-noun.artifact	, , 0	male NN B-noun.person	rats NNS B-noun.person	treated VBN B-verb.social	with IN 0	intramuscular JJ B-adj.all	doses NNS B-noun.event	of IN 0	15 CD 0	mg IN 0	/ $ 0	kg/30 CD 0	days NNS B-noun.person	, , 0	10 CD B-adj.all	mg RB B-noun.quantity	/ RB 0	rat/30 JJ 0	days NNS B-noun.person	, , 0	or CC 0	10 CD B-adj.all	mg PRP 0	/ $ 0	rat/15 JJ B-adj.all	days NNS B-noun.phenomenon	fulvestrant JJ 0	showed VBD B-verb.communication	a DT 0	loss NN B-noun.process	of IN 0	spermatozoa NN B-noun.possession	from IN 0	the DT 0	seminiferous JJ B-adj.all	tubules NNS B-noun.artifact	, , 0	seminiferous JJ B-adj.all	tubular JJ B-adj.all	atrophy NN B-noun.artifact	, , 0	and CC 0	degenerative JJ B-adj.all	changes NNS B-noun.food	in IN 0	the DT 0	epididymides NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d220.s16	Nevertheless RB B-adv.all	, , 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	Mefloquine NNP B-noun.person	on IN 0	travelers NNS B-noun.person	receiving VBG B-verb.communication	comedication NN B-noun.person	, , 0	particularly RB B-adj.all	diabetics NNS B-noun.person	or CC 0	patients NNS B-noun.person	using VBG B-verb.consumption	anticoagulants NNS I-verb.consumption	, , 0	should MD 0	be VB 0	checked VBN B-verb.cognition	before IN 0	departure NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d97.s70	HMG SYM 0	- : 0	CoA_Reductase_Inhibitor NN B-noun.person	, , 0	atorvastatin NN 0	. . 0
DDI-DrugBank.d474.s1	These DT 0	agents NNS B-noun.person	include VBP B-verb.stative	medications NNS I-verb.stative	such JJ 0	as IN 0	, , 0	anticoagulants NNS B-noun.person	, , 0	platelet_inhibitors NNS B-noun.person	including VBG B-verb.social	acetylsalicylic_acid JJ I-verb.social	, , 0	sali NNS B-noun.person	- : 0	cylates NNS B-noun.time	, , 0	NSAIDs NNP B-noun.person	( ( 0	including VBG B-verb.stative	ketorolac_tromethamine NN 0	) ) 0	, , 0	dipyridamole NN B-noun.person	, , 0	or CC 0	sulfinpyrazone NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d179.s3	- : 0	Anabolic_steroids NNS B-noun.group	( ( 0	nandrolone NN B-noun.person	[ '' 0	e.g. NNP B-noun.person	, , 0	Anabolin NNP B-noun.person	] NNP I-noun.person	, , 0	oxandrolone NN 0	[ '' 0	e.g. NNP B-noun.person	, , 0	Anavar NNP B-noun.person	] . 0	, , 0	oxymetholone NN 0	[ '' 0	e.g. NNP B-noun.person	, , 0	Anadrol NNP B-noun.person	] NNP I-noun.person	, , 0	stanozolol NN B-noun.cognition	[ : 0	e.g. NN B-noun.person	, , 0	Winstrol NNP B-noun.person	] NNP I-noun.person	) ) 0	or CC 0	. . 0
DDI-DrugBank.d263.s6	however RB 0	, , 0	it PRP 0	is VBZ 0	considered VBN B-verb.cognition	to TO 0	be VB B-verb.stative	unlikely JJ B-adj.all	that IN 0	this DT 0	decrease NN B-noun.event	of IN 0	phosphorylated JJ B-adj.all	lamivudine NN B-noun.body	concentration NN B-noun.event	is VBZ B-verb.stative	of IN 0	clinical JJ B-adj.all	significance NN B-noun.communication	, , 0	as IN 0	lamivudine NN 0	is VBZ B-verb.stative	a DT 0	more RBR B-adv.all	efficient JJ B-adj.all	substrate NN B-noun.person	for IN 0	deoxycytidine NN 0	kinase NN 0	than IN 0	zalcitabine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d160.s0	The DT 0	results NNS B-noun.communication	of IN 0	a DT 0	study NN B-noun.artifact	of IN 0	coadministration NN B-noun.person	of IN 0	ethambutol NN 0	( ( 0	50 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	with IN 0	an DT 0	aluminum_hydroxide JJ 0	containing VBG B-verb.communication	antacid NN I-verb.communication	to TO 0	13 CD B-adj.all	patients NNS B-noun.person	with IN 0	tuberculosis NN B-noun.person	showed VBD B-verb.communication	a DT 0	reduction NN B-noun.act	of IN 0	mean JJ B-adj.all	serum NN B-noun.artifact	concentrations NNS B-noun.artifact	and CC 0	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	ethambutol NN 0	of IN 0	approximately RB B-adv.all	20 CD B-adj.all	% NN 0	and CC 0	13 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	suggesting VBG B-verb.communication	that IN 0	the DT 0	oral JJ B-adj.all	absorption NN B-noun.process	of IN 0	ethambutol NN B-noun.animal	may MD 0	be VB 0	reduced VBN B-verb.change	by IN 0	these DT 0	antacid_products NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d353.s1	Glibenclamide NN 0	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	7 CD B-adj.all	healthy JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	, , 0	acitretin NN B-noun.person	treatment NN B-noun.person	potentiated VBD B-verb.communication	the DT 0	blood NN B-noun.location	glucose NN B-noun.person	lowering VBG B-verb.motion	effect NN 0	of IN 0	glibenclamide NN 0	( ( 0	a DT 0	sulfonylurea NN B-noun.plant	similar JJ B-adj.all	to TO 0	chlorpropamide VB B-verb.social	) ) 0	in IN 0	3 CD 0	of IN 0	the DT 0	7 CD B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d410.s0	Vasoconstrictors NNS B-noun.person	, , 0	D.H.E._45 NNP B-noun.person	_ . 0	( ( 0	dihydroergotamine_mesylate JJ 0	) ) 0	Injection NN B-noun.location	, , 0	USP NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	with IN 0	peripheral_vasoconstrictors NNS B-noun.person	because IN 0	the DT 0	combination NN B-noun.group	may MD 0	cause VB B-verb.creation	synergistic JJ B-adj.all	elevation NN B-noun.act	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d189.s0	No DT 0	Important NNP B-noun.person	Interactions NNP I-noun.person	To NNP I-noun.person	Date NNP I-noun.person	Levosimendan NNP I-noun.person	does VBZ 0	not RB B-adv.all	have VB 0	clinically RB B-adv.all	important JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	with IN 0	captopril NN B-noun.artifact	, , 0	beta JJ 0	- : 0	blockers NNS B-noun.person	, , 0	felodipine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	isosorbide_mononitrate JJ B-adj.all	, , 0	carvedilol NN B-noun.person	, , 0	ethanol NN B-noun.person	or CC 0	itraconazole NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d229.s0	Drug NNP B-noun.person	Interaction NNP I-noun.person	During NNP I-noun.person	Pregnancy NNP I-noun.person	, , 0	Cromolyn_sodium NN B-noun.person	and CC 0	isoproterenol NN B-noun.person	were VBD 0	studied VBN B-verb.cognition	following VBG B-verb.stative	subcutaneous JJ B-adj.all	injections NNS B-noun.communication	in IN 0	pregnant JJ B-adj.all	mice NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d256.s2	Antagonism NNP B-noun.attribute	has VBZ 0	been VBN 0	demonstrated VBN B-verb.perception	between IN 0	clindamycin NN B-noun.person	and CC 0	erythromycin NN B-noun.person	in IN 0	vitro NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d4.s2	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	dyphylline NN B-noun.act	and CC 0	probenecid NN B-noun.person	, , 0	which WDT 0	competes VBZ B-verb.change	for IN 0	tubular JJ B-adj.all	secretion NN B-noun.act	, , 0	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.plant	half NN B-noun.quantity	- : 0	life NN B-noun.time	of IN 0	dyphylline NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d508.s1	In IN 0	addition NN 0	to TO 0	bleeding VBG B-verb.body	associated VBN B-verb.cognition	with IN 0	heparin NN B-noun.person	and CC 0	vitamin_K_antagonists NNS B-noun.person	, , 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	platelet NN B-verb.creation	function NN B-noun.attribute	( ( 0	such JJ 0	as IN 0	acetylsalicylic_acid JJ 0	, , 0	dipyridamole NN B-noun.person	and CC 0	Abciximab NNP B-noun.location	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	bleeding VBG B-verb.communication	if IN 0	administered VBN B-verb.possession	prior RB 0	to TO 0	, , 0	during IN 0	, , 0	or CC 0	after IN 0	Activase NNP B-noun.person	therapy NN 0	. . 0	. . 0
DDI-MedLine.d15.s0	[ SYM 0	Stimulation NN B-noun.cognition	by IN 0	cerulein NN B-noun.communication	-- : 0	an DT 0	analog NN B-noun.group	of IN 0	the DT 0	octapeptide NN 0	cholecystokinin NN B-noun.group	-- : 0	of IN 0	3H SYM 0	- : 0	spiroperidol NN B-noun.substance	binding NN B-verb.contact	after IN 0	the DT 0	long JJ B-noun.body	- : 0	term NN B-noun.time	administration NN B-noun.time	of IN 0	neuroleptics NNS B-noun.person	] : 0	_ : 0	It PRP 0	has VBZ 0	been VBN 0	established VBN B-verb.creation	in IN 0	experiments NNS B-noun.animal	on IN 0	white JJ B-adj.all	male NN B-noun.artifact	rats NNS I-noun.artifact	that WDT 0	prolonged VBD B-verb.communication	administration NN B-noun.person	( ( 0	twice RB B-adv.all	a DT 0	day NN B-noun.person	for IN 0	14 CD B-adj.all	days NNS B-noun.act	) ) 0	of IN 0	haloperidol NN B-noun.person	( ( 0	0.25 CD 0	mg PRP B-noun.quantity	/ : 0	kg LS 0	) ) 0	and CC 0	pyreneperone NN 0	( ( 0	0.25 CD 0	mg PRP B-noun.quantity	/ : 0	kg LS 0	) ) 0	resulted VBD B-verb.stative	in IN 0	the DT 0	reduced JJ B-adj.all	interaction NN B-noun.act	between IN 0	3H SYM 0	- : 0	spiroperidol NN B-noun.person	and CC 0	low JJ B-adj.all	affinity NN B-noun.phenomenon	binding NN B-noun.process	sites NNS B-noun.location	for IN 0	apomorphine NN B-noun.person	in IN 0	subcortical JJ B-adj.all	structures NNS B-noun.body	, , 0	whereas IN 0	3H SYM 0	- : 0	spiroperidol NN B-noun.substance	binding NN B-verb.contact	with IN 0	high JJ B-adj.all	affinity NN B-noun.phenomenon	binding NN B-noun.process	sites NNS B-noun.location	for IN 0	apomorphine NN B-noun.person	increased VBD B-verb.change	both DT 0	in IN 0	the DT 0	frontal JJ B-adj.all	cortex NN B-noun.person	and CC 0	subcortical JJ B-adj.all	structures NNS B-noun.cognition	of IN 0	the DT 0	forebrain NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d108.s5	The DT 0	monoamine NN 0	oxidase NN 0	inhibitory JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	Isocarboxazid NNP B-noun.other	may MD 0	persist VB B-verb.social	for IN 0	a DT 0	substantial JJ B-adj.all	period NN B-noun.time	after IN 0	discontinuation NN B-noun.act	of IN 0	the DT 0	drug NN B-noun.artifact	, , 0	and CC 0	this DT 0	should MD 0	be VB 0	borne VBN B-verb.contact	in IN 0	mind NN 0	when WRB 0	another DT 0	drug NN B-noun.person	is VBZ 0	prescribed VBN B-verb.contact	following VBG 0	Isocarboxazid NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d248.s0	May MD 0	interact VB B-verb.emotion	anticoagulants NNS I-verb.emotion	( ( 0	altered JJ B-adj.all	hypo NN B-noun.person	- : 0	prothrombinemic JJ B-adj.all	effect NN B-noun.cognition	) ) 0	, , 0	barbiturates NNS B-noun.person	, , 0	rifampin NN B-noun.person	and CC 0	other JJ 0	inducers NNS B-noun.person	of IN 0	hepatic JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.person	oxidation NN 0	system NN 0	( ( 0	decreased VBN B-verb.change	effect NN 0	of IN 0	diethylstilbestrol NN B-noun.act	) ) 0	, , 0	corticosteroids NNS B-noun.person	( ( 0	increased VBN B-verb.change	effect NN 0	of IN 0	corticosteroids NNS B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d389.s0	Antihistamines NNS B-noun.animal	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	tricyclic_antidepressants NNS B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	alcohol NN B-noun.person	, , 0	and CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d83.s0	Patients NNS B-noun.person	on IN 0	warfarin NN B-noun.act	- : 0	type_anticoagulant JJ B-adj.all	therapy NN B-noun.act	may MD 0	require VB B-verb.consumption	dosage NN B-noun.food	adjustment NN B-noun.act	of IN 0	the DT 0	anticoagulant NN B-noun.location	during IN 0	and CC 0	after IN 0	griseofulvin NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d238.s7	Administration NN B-noun.person	of IN 0	CMI NNP B-noun.group	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	phenobarbital NN B-noun.artifact	, , 0	if IN 0	given VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d422.s15	Additionally RB B-adv.all	, , 0	BREVIBLOC NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	to TO 0	control VB B-verb.change	supraventricular JJ B-adj.all	tachycardia NN B-noun.location	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	agents NNS B-noun.person	which WDT 0	are VBP B-verb.stative	vasoconstrictive JJ B-adj.all	and CC 0	inotropic NN 0	such JJ 0	as IN 0	dopamine NN 0	, , 0	epinephrine NN B-noun.person	, , 0	and CC 0	norepinephrine NN B-noun.act	because IN 0	of IN 0	the DT 0	danger NN B-noun.person	of IN 0	blocking VBG B-verb.change	cardiac JJ B-adj.all	contractility NN B-noun.attribute	when WRB 0	systemic JJ B-adj.all	vascular JJ B-adj.all	resistance NN B-noun.phenomenon	is VBZ B-verb.stative	high JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d328.s35	Because IN 0	changes NNS B-noun.phenomenon	in IN 0	glucose NN 0	concentrations NNS 0	with IN 0	valdecoxib NN B-noun.artifact	coadministration NN B-noun.person	were VBD B-verb.stative	within IN 0	the DT 0	normal JJ B-adj.all	variability NN B-noun.attribute	and CC 0	individual JJ B-adj.all	glucose NN B-noun.event	concentrations NNS B-noun.person	were VBD B-verb.stative	above IN 0	or CC 0	near IN 0	70 CD B-adj.all	mg NN B-noun.quantity	/ : 0	dL PRP 0	, , 0	dose JJ B-adj.all	adjustment NN B-noun.communication	for IN 0	glyburide NN 0	( ( 0	5 CD 0	mg IN 0	QD NNP 0	and CC 0	10 CD B-adj.all	mg IN 0	BID NNP 0	) ) 0	with IN 0	valdecoxib NN B-noun.attribute	coadministration NN I-noun.attribute	( ( 0	up IN 0	to TO 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	) ) 0	is VBZ B-verb.stative	not RB B-adv.all	indicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d263.s1	Zalcitabine NNP B-noun.person	also RB B-adv.all	has VBZ B-verb.possession	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	intracellular JJ B-adj.all	phosphorylation NN B-noun.artifact	of IN 0	ZDV NNP B-noun.group	, , 0	as IN 0	shown VBN B-verb.perception	in IN 0	vitro NN B-noun.food	in IN 0	peripheral JJ B-adj.pert	blood NN B-noun.body	mononuclear NN B-noun.body	cells NNS B-noun.body	or CC 0	in IN 0	two CD 0	other JJ B-adj.all	cell NN B-noun.body	lines NNS B-noun.communication	( ( 0	U937 NN B-noun.person	and CC 0	Molt-4 NN B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d97.s84	Dose DT 0	reduction NN B-noun.act	of IN 0	rifabutin NN 0	to TO 0	half PDT B-verb.motion	the DT 0	standard JJ B-adj.all	dose NN B-noun.act	and CC 0	a DT 0	dose NN B-noun.act	increase NN B-noun.event	of IN 0	CRIXIVAN NNP B-noun.group	to TO 0	1000 CD 0	mg NN B-noun.quantity	( ( 0	three CD 0	333-mg JJ B-adj.all	capsules NNS B-noun.artifact	) ) 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.person	are VBP 0	recommended VBN B-verb.communication	when WRB 0	rifabutin NN B-noun.person	and CC 0	CRIXIVAN NNP B-noun.group	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d324.s20	Coadministration NN B-noun.person	of IN 0	single JJ B-adj.all	, , 0	oral JJ B-adj.all	doses NNS B-noun.event	of IN 0	zaleplon NN B-noun.person	with IN 0	erythromycin NN B-noun.substance	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	800 CD 0	mg NN B-noun.quantity	, , 0	respectively RB B-adv.all	) ) 0	, , 0	a DT 0	strong JJ B-adj.all	, , 0	selective JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	produced VBD B-verb.creation	a DT 0	34 CD 0	% NN 0	increase NN B-noun.event	in IN 0	zaleplons NNS B-noun.animal	maximal JJ B-adj.all	plasma NN B-noun.act	concentrations NNS I-noun.act	and CC 0	a DT 0	20 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	area NN B-noun.body	under IN 0	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	- : 0	time NN B-noun.time	curve NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d167.s2	In IN 0	addition NN 0	, , 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	is VBZ 0	enhanced VBN B-verb.change	by IN 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	local JJ B-adj.all	anesthetics NNS B-noun.person	like IN 0	lidocaine NN B-noun.person	, , 0	procaine NN B-noun.person	, , 0	beta JJ 0	- : 0	blockers NNS B-noun.person	, , 0	metaclopramide NN B-noun.attribute	, , 0	lithium_carbonate JJ B-noun.location	, , 0	and CC 0	terbutaline NN B-noun.person	. . 0	. . 0
DDI-MedLine.d137.s1	AIMS NNS B-noun.cognition	/ IN 0	HYPOTHESIS NNP B-noun.group	, , 0	There EX 0	is VBZ B-verb.stative	evidence NN B-noun.attribute	that IN 0	insulin NN B-noun.person	and CC 0	glucose VB 0	cause VB B-verb.communication	renal JJ B-adj.all	and CC 0	ocular JJ B-adj.all	vasodilation NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d288.s1	Pharmacokinetic JJ B-adj.all	data NNS B-noun.cognition	from IN 0	these DT 0	patients NNS B-noun.person	demonstrated VBD B-verb.perception	a DT 0	decrease NN B-noun.event	in IN 0	paclitaxel JJ B-adj.all	clearance NN B-noun.act	of IN 0	approximately RB B-adv.all	33 CD 0	% NN 0	when WRB 0	TAXOL NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	following VBG 0	cisplatin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d219.s0	ACE NNP B-noun.person	- : 0	inhibitors NNS B-noun.person	Reports NNS I-noun.person	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	ACE NNP B-noun.group	- : 0	inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d140.s6	Cimetidine NNP B-noun.person	, , 0	Atorvastatin NNP B-noun.person	plasma NN I-noun.person	concentrations NNS I-noun.person	and CC 0	LDL NNP B-noun.group	- : 0	C SYM 0	reduction NN B-noun.act	were VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	cimetidine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d288.s14	However RB 0	, , 0	severe JJ B-adj.all	reactions NNS B-noun.person	, , 0	such JJ 0	as IN 0	hypotension NN 0	requiring VBG B-verb.stative	treatment NN I-verb.stative	, , 0	dyspnea NN 0	requiring VBG B-verb.stative	bronchodilators NNS B-noun.person	, , 0	angioedema NN B-noun.person	, , 0	or CC 0	generalized VBN B-verb.communication	urticaria NNS B-noun.person	require VBP B-verb.consumption	immediate JJ B-adj.all	discontinuation NN B-noun.communication	of IN 0	TAXOL NNP B-noun.group	and CC 0	aggressive JJ B-adj.all	symptomatic JJ B-adj.all	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d172.s18	CELEBREX NNP B-noun.group	should MD 0	be VB 0	introduced VBN B-verb.contact	at IN 0	the DT 0	lowest JJS 0	recommended VBN B-verb.communication	dose NN B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	fluconazole NN I-verb.communication	. . 0	. . 0
DDI-DrugBank.d190.s2	Approximately RB B-adv.all	2/3 CD 0	of IN 0	the DT 0	patients NNS B-noun.person	in IN 0	the DT 0	Phase NN B-noun.time	3 CD B-adj.all	study NN B-noun.artifact	received VBD B-verb.communication	either RB 0	prophylactic JJ B-adj.all	low JJ B-adj.all	dose NN 0	heparin NN 0	( ( 0	unfractionated_heparin JJ 0	up IN 0	to TO 0	15,000 CD 0	units NNS B-noun.quantity	/ : 0	day NN 0	) ) 0	or CC 0	prophylactic JJ B-adj.all	doses NNS B-noun.event	of IN 0	low_molecular_weight_heparins NNS B-noun.object	as IN 0	indicated VBN B-verb.communication	in IN 0	the DT 0	prescribing VBG B-adj.all	information NN B-noun.cognition	for IN 0	the DT 0	specific JJ B-adj.all	products NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d202.s14	In IN 0	addition NN 0	, , 0	certain JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isoenzyme NN B-noun.attribute	, , 0	including VBG B-verb.change	many JJ 0	antidepressants NNS B-noun.person	( ( 0	tricyclic_antidepressants NNS B-noun.person	, , 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	, , 0	and CC 0	others NNS 0	) ) 0	, , 0	may MD 0	inhibit VB B-verb.change	the DT 0	activity NN B-noun.process	of IN 0	this DT 0	isoenzyme NN B-noun.attribute	, , 0	and CC 0	thus RB 0	may MD 0	make VB B-verb.change	normal JJ B-adj.all	metab NN B-noun.attribute	- : 0	olizers NNS B-noun.person	resemble VBP B-verb.social	poor JJ B-adj.all	metabolizers NNS B-noun.person	with IN 0	regard NN B-noun.act	to TO 0	concomitant VB B-verb.communication	therapy NN I-verb.communication	with IN 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	this DT 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	leading VBG B-verb.motion	to TO 0	drug NN B-noun.act	interactions NNS I-noun.act	. . 0	. . 0
DDI-DrugBank.d565.s23	When WRB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	anesthetics NNS B-noun.person	and CC 0	calcium_channel_blockers NNS B-noun.person	should MD 0	be VB 0	titrated VBN B-verb.change	carefully RB B-adv.all	. . 0	. . 0
DDI-MedLine.d115.s14	However RB 0	, , 0	careful JJ B-adj.all	attention NN B-noun.act	must MD 0	be VB 0	directed VBN B-verb.communication	to TO 0	cross VB B-verb.motion	toxicity NN B-noun.feeling	and CC 0	possible JJ B-adj.all	pharmacokinetic JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	antiretroviral JJ B-adj.all	and CC 0	antineoplastic_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d536.s7	Acarbose NNP B-noun.person	did VBD 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	or CC 0	disposition NN B-noun.act	of IN 0	the DT 0	sulfonylurea NN 0	glyburide NN 0	in IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d413.s7	The DT 0	clinical JJ B-adj.all	basis NN B-noun.cognition	of IN 0	this DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.cognition	but CC 0	should MD 0	be VB 0	noted VBN B-verb.perception	when WRB 0	allopurinol NN B-noun.person	is VBZ 0	given VBN B-verb.possession	to TO 0	patients NNS B-noun.person	already RB B-adv.all	on IN 0	dicumarol NN B-noun.act	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d223.s19	MAO_Inhibitors NNS B-noun.person	, , 0	Serious JJ B-adj.all	side NN B-noun.attribute	effects NNS B-noun.phenomenon	and CC 0	even RB B-adv.all	death NN 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	certain JJ B-adj.all	drugs NNS B-noun.artifact	with IN 0	MAO_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d108.s0	Isocarboxazid NNP B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	Antabuse NNP B-noun.person	( ( 0	disulfiram NN B-noun.person	, , 0	Wyeth NNP B-noun.person	- : 0	Ayerst NNP B-noun.group	Laboratories NNPS I-noun.group	) ) 0	. . 0	. . 0
DDI-MedLine.d12.s2	Although IN 0	neither DT 0	dexamethasone NN B-noun.person	nor CC 0	retinyl_acetate NNP B-noun.person	affected VBD B-verb.change	the DT 0	proliferation NN B-noun.act	of IN 0	prostatic JJ B-adj.all	epithelium NN B-noun.person	in IN 0	RPMI1640 NN 0	containing VBG B-verb.stative	transferrin NN 0	alone RB 0	, , 0	they PRP 0	modify VBP B-verb.change	the DT 0	mitogenic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	EGF NNP B-noun.group	and CC 0	insulin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d463.s7	The DT 0	patient NN B-noun.person	was VBD 0	also RB B-adv.all	chronically RB B-adv.all	receiving VBG B-verb.perception	phenytoin NN I-verb.perception	, , 0	phenobarbital JJ B-adj.all	, , 0	digoxin NN B-noun.person	, , 0	and CC 0	levothyroxine_sodium NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d431.s9	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	antacids NNS B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	with IN 0	lansoprazole NN B-noun.communication	delayed VBN B-verb.stative	- : 0	release NN B-noun.act	capsules NNS B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d141.s3	CHOLESTYRAMINE NN B-noun.act	, , 0	The DT 0	influence NN B-noun.cognition	of IN 0	the DT 0	bile NN B-noun.group	- : 0	acidsequestering VBG B-verb.cognition	agent NN B-noun.person	cholestyramine NN B-noun.person	on IN 0	the DT 0	pharmacokinetits NNS B-noun.person	of IN 0	cerivastatin_sodium NN B-noun.location	was VBD 0	evaluated VBN B-verb.change	in IN 0	12 CD B-adj.all	healthy JJ B-adj.all	males NNS B-noun.person	in IN 0	2 CD B-adj.all	separate JJ B-adj.all	randomized JJ B-adj.all	crossover NN B-noun.animal	studies NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d333.s6	Although IN 0	clinical JJ B-adj.all	studies NNS B-noun.group	have VBP 0	not RB 0	been VBN 0	performed VBN B-verb.social	, , 0	based VBN B-verb.cognition	on IN 0	the DT 0	involvement NN B-noun.person	of IN 0	the DT 0	cytochrome NN 0	P-450 NN 0	3A PRP$ 0	family NN B-noun.group	in IN 0	clonazepam NN B-noun.phenomenon	metabolism NN B-noun.attribute	, , 0	inhibitors NNS B-noun.person	of IN 0	this DT 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	notably RB B-adv.all	oral JJ B-adj.all	antifungal_agents NNS B-noun.location	, , 0	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	clonazepam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s26	Ritonavir NNP B-noun.person	; : 0	Combined VBN B-verb.cognition	administration NN B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	ritonavir NN B-noun.person	( ( 0	600 CD 0	mg NN B-noun.quantity	) ) 0	, , 0	both DT 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN B-noun.person	and CC 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	and CC 0	escitalopram NN B-noun.person	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	) ) 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	ritonavir NN B-noun.location	or CC 0	escitalopram NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d497.s0	AZOPT NNP 0	( ( 0	brinzolamide VB 0	ophthalmic JJ 0	suspension NN 0	) ) 0	1 CD B-adj.all	% NN 0	contains VBZ B-verb.communication	a DT 0	carbonic_anhydrase_inhibitor NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d443.s1	Alcohol NNP B-noun.person	, , 0	Has VBZ 0	a DT 0	synergistic JJ B-adj.all	effect NN B-noun.cognition	with IN 0	aspirin NN B-noun.food	in IN 0	causing VBG B-verb.communication	gastrointestinal JJ B-adj.all	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d516.s26	However RB 0	, , 0	no DT 0	clinically RB B-noun.communication	or CC 0	statistically RB B-adj.all	significant JJ B-adj.all	differences NNS B-noun.cognition	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	ratio NN B-noun.time	or CC 0	warfarin NN B-noun.location	enantiomer NN B-noun.person	pharmacokinetics NNS B-noun.person	were VBD 0	observed VBN B-verb.perception	in IN 0	a DT 0	small JJ B-adj.all	study NN B-noun.artifact	of IN 0	7 CD B-adj.all	healthy JJ B-adj.all	males NNS B-noun.person	who WP 0	received VBD B-verb.possession	both DT 0	warfarin NN B-noun.location	and CC 0	lomefloxacin NN B-noun.act	under IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	conditions NNS I-noun.state	. . 0	. . 0
DDI-DrugBank.d314.s29	Thalidomide IN 0	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	with IN 0	thalidomide DT 0	should MD 0	be VB 0	employed VBN B-verb.consumption	cautiously RB B-adv.all	, , 0	as IN 0	toxic JJ B-adj.all	epidermal JJ B-adj.all	necrolysis NN B-noun.motive	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	use NN B-noun.person	. . 0	. . 0
DDI-MedLine.d25.s12	CONCLUSIONS NNS B-noun.artifact	, , 0	Macrolide_antibiotics NNS B-noun.person	inhibit VBP B-verb.possession	the DT 0	metabolism NN B-noun.attribute	of IN 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	CYP3A4 NNP B-noun.person	( ( 0	i.e. FW B-adv.all	, , 0	atorvastatin NN B-noun.person	, , 0	cerivastatin NN B-noun.communication	, , 0	lovastatin NN B-noun.person	, , 0	simvastatin NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d388.s5	No DT 0	significant JJ B-adj.all	interactions NNS B-noun.person	with IN 0	digoxin NN B-noun.person	, , 0	hydrochlorothiazide NN 0	, , 0	hydralazine NN B-noun.person	, , 0	sulfinpyrazone NN 0	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	tolbutamide NN 0	, , 0	or CC 0	warfarin NN B-noun.communication	have VBP 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d390.s0	Antipsychotic_drugs NNS B-noun.object	such JJ 0	as IN 0	phenothiazines NNS B-noun.artifact	or CC 0	haloperidol NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d533.s1	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	lovastatin NN B-noun.feeling	, , 0	atenolol NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	furosemide RB 0	, , 0	digoxin NN B-noun.person	, , 0	celecoxib NN B-noun.body	, , 0	hydrochlorothiazide NN 0	, , 0	ramipril NN B-noun.person	, , 0	valsartan NN B-noun.attribute	, , 0	metformin NN B-noun.person	and CC 0	amlodipine NN B-noun.person	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	clinically RB B-adv.all	significant JJ B-adj.all	increases NNS B-noun.event	in IN 0	aliskiren JJ B-adj.all	exposure NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d178.s9	A DT 0	potential JJ B-adj.all	interaction NN B-noun.act	between IN 0	oral JJ B-adj.all	miconazole NN B-noun.person	and CC 0	oral JJ B-adj.all	hypoglycemic_agents NNS 0	leading VBG B-verb.stative	to TO 0	severe JJ B-adj.all	hypoglycemia NN B-noun.state	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d219.s10	Diuretics NNS B-noun.person	, , 0	Etodolac NNP B-noun.person	has VBZ B-verb.possession	no DT 0	apparent JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.event	when WRB 0	administered VBN B-verb.possession	with IN 0	furosemide NN B-noun.attribute	or CC 0	hydrochlorothiazide NN 0	. . 0	. . 0
DDI-DrugBank.d514.s1	In IN 0	combination NN 0	with IN 0	other JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	, , 0	heroin NN 0	may MD 0	still RB 0	kill VB B-verb.contact	even RB B-adv.all	experienced JJ B-adj.all	users NNS B-noun.person	, , 0	particularly RB B-adv.all	if IN 0	their PRP$ 0	tolerance NN 0	to TO 0	the DT 0	drug NN B-noun.group	has VBZ 0	reduced VBN B-verb.change	or CC 0	the DT 0	strength NN B-noun.attribute	of IN 0	their PRP$ 0	usual JJ B-adj.all	dose NN B-noun.act	has VBZ 0	increased VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d60.s2	The DT 0	serum NN B-noun.body	concentration NN B-noun.event	of IN 0	phenytoin NN B-noun.person	increased VBD B-verb.change	dramatically RB B-adv.all	from IN 0	16.6 CD 0	to TO 0	49.1 CD 0	microg NNS B-noun.quantity	/ : 0	mL PRP 0	when WRB 0	fluvoxamine NN B-noun.person	was VBD 0	coadministered VBN B-verb.communication	, , 0	although IN 0	the DT 0	daily JJ B-adj.pert	dosage NN B-noun.act	of IN 0	phenytoin NN B-noun.food	and CC 0	other JJ 0	drugs NNS B-noun.person	had VBD 0	not RB B-adv.all	changed VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d353.s5	However RB 0	, , 0	it PRP 0	has VBZ 0	been VBN 0	established VBN B-verb.cognition	that IN 0	acitretin NN B-noun.person	interferes VBZ B-verb.contact	with IN 0	the DT 0	contraceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	microdosed JJ B-adj.all	progestin NN B-adj.all	minipill NN B-noun.location	preparations NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d16.s3	However RB 0	, , 0	halothane NN 0	anesthetic JJ B-adj.all	requirement NN B-noun.object	( ( 0	i.e. FW B-adv.all	, , 0	MAC NNP 0	) ) 0	was VBD 0	depressed VBN B-verb.creation	in IN 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	fashion NN B-noun.cognition	as RB 0	much JJ 0	as IN 0	56 CD 0	% NN 0	1 CD B-adj.all	- : 0	2 CD B-adj.all	hours NNS B-noun.person	and CC 0	as RB 0	much JJ 0	as IN 0	14 CD B-adj.all	% NN 0	5 CD B-adj.all	- : 0	6 CD B-adj.all	hours NNS B-noun.time	after IN 0	injection NN B-noun.time	of IN 0	ketamine NN B-noun.person	, , 0	50 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	, , 0	i PRP 0	m VBP 0	. . 0	. . 0
DDI-DrugBank.d158.s15	Lithium_carbonate JJ B-adj.all	, , 0	The DT 0	anorectic JJ B-adj.all	and CC 0	stimulatory JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	amphetamines NNS B-noun.animal	may MD 0	be VB 0	inhibited VBN B-verb.change	by IN 0	lithium_carbonate JJ B-noun.time	. . 0	. . 0
DDI-DrugBank.d43.s1	Neuropathy NNP B-noun.person	has VBZ 0	occurred VBN B-verb.cognition	more RBR B-adv.all	frequently RB B-adv.all	in IN 0	patients NNS B-noun.person	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	neuropathy JJ B-adj.all	or CC 0	neurotoxic JJ B-adj.all	drug NN B-noun.person	therapy NN 0	, , 0	including VBG B-verb.change	stavudine NN B-noun.attribute	, , 0	and CC 0	these DT 0	patients NNS B-noun.person	may MD 0	be VB B-verb.stative	at IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	neuropathy JJ 0	during IN 0	VIDEX NNP B-noun.group	therapy NN 0	( ( 0	see VB B-verb.social	ADVERSE JJ B-noun.group	REACTIONS NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d511.s4	Because IN 0	of IN 0	foscarnets NNS B-noun.artifact	tendency NN 0	to TO 0	cause VB B-verb.communication	renal JJ B-noun.phenomenon	impairment NN I-noun.phenomenon	, , 0	the DT 0	use NN 0	of IN 0	FOSCAVIR NNP B-noun.group	should MD 0	be VB 0	avoided VBN B-verb.social	in IN 0	combination NN 0	with IN 0	potentially RB B-adj.all	nephrotoxic JJ B-adj.all	drugs NNS B-noun.state	such JJ 0	as IN 0	aminoglycosides NNS B-noun.person	, , 0	amphotericin_B JJ 0	and CC 0	intravenous JJ B-adj.all	pentamidine NN B-noun.communication	unless IN 0	the DT 0	potential JJ B-adj.all	benefits NNS B-noun.person	outweigh VBP B-verb.communication	the DT 0	risks NNS B-noun.body	to TO 0	the DT 0	patient NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d310.s1	In IN 0	Europe NNP B-noun.location	, , 0	Nimotop NNP B-noun.person	_ NNP I-noun.person	was VBD 0	observed VBN B-verb.perception	to TO 0	occasionally RB B-adv.all	intensify VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	antihypertensive_compounds NNS B-noun.attribute	taken VBN B-verb.cognition	concomitantly RB B-adv.all	by IN 0	patients NNS B-noun.person	suffering VBG B-verb.body	from IN 0	hypertension NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d346.s5	In IN 0	an DT 0	emergency NN B-noun.event	situation NN 0	when WRB 0	opioid JJ B-adj.all	analgesia NN B-noun.object	must MD 0	be VB 0	administered VBN B-verb.perception	to TO 0	a DT 0	patient NN B-noun.person	receiving VBG B-verb.body	REVIA NNP B-noun.group	, , 0	the DT 0	amount NN B-noun.possession	of IN 0	opioid NN B-noun.person	required VBN B-verb.stative	may MD 0	be VB B-verb.stative	greater JJR B-adj.all	than IN 0	usual JJ B-noun.person	, , 0	and CC 0	the DT 0	resulting VBG B-verb.possession	respiratory JJ B-adj.pert	depression NN B-noun.process	may MD 0	be VB B-verb.stative	deeper JJR B-adj.all	and CC 0	more RBR B-adv.all	prolonged VBN B-verb.competition	. . 0	. . 0
DDI-DrugBank.d359.s5	Although IN 0	there EX 0	is VBZ B-verb.stative	no DT 0	documentation NN 0	of IN 0	such JJ B-adj.all	, , 0	a DT 0	similar JJ B-adj.all	interaction NN B-noun.act	between IN 0	ethotoin NN B-noun.person	and CC 0	the DT 0	coumarin_anticoagulants NNS B-noun.group	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d162.s12	Non SYM 0	- : 0	steroidal_Anti SYM 0	- : 0	inflammatory_Drugs NNS B-noun.time	, , 0	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_agent NN B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	diuretic JJ B-adj.all	, , 0	natriuretic JJ B-adj.all	, , 0	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	loop NN B-noun.location	, , 0	potassium NN B-noun.person	- : 0	sparing NN B-verb.communication	and CC 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s0	Oral NNP B-noun.group	Anticoagulants NNPS I-noun.group	, , 0	In IN 0	some DT 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.state	and CC 0	warfarin NN B-noun.act	, , 0	acenocoumarol NN B-noun.person	, , 0	or CC 0	phenprocoumon NN B-noun.person	resulted VBD B-verb.stative	in IN 0	prolongation NN 0	of IN 0	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-MedLine.d110.s2	Like IN 0	ibogaine NN B-noun.person	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	18-MC JJ 0	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	decreases VBZ B-verb.change	the DT 0	intravenous JJ B-adj.all	self NN B-noun.person	- : 0	administration NN B-noun.time	of IN 0	morphine NN B-noun.person	and CC 0	cocaine NN B-noun.person	and CC 0	the DT 0	oral JJ B-adj.all	self NN B-noun.person	- : 0	administration NN B-noun.time	of IN 0	ethanol NN B-noun.food	and CC 0	nicotine NN B-noun.person	in IN 0	rats NNS B-noun.animal	, , 0	. . 0
DDI-DrugBank.d290.s5	Caverject NNP B-noun.person	, , 0	The DT 0	potential NN B-noun.person	for IN 0	pharmacokinetic JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	between IN 0	alprostadil NN B-noun.person	and CC 0	other JJ 0	agents NNS B-noun.person	has VBZ 0	not RB 0	been VBN 0	formally RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d450.s2	Quinidine NNP B-noun.location	, , 0	verapamil RB B-adv.all	, , 0	amiodarone NN 0	, , 0	propafenone NN B-noun.person	, , 0	indomethacin NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	alprazolam NN B-noun.person	, , 0	and CC 0	spironolactone NN 0	raise VB B-verb.creation	the DT 0	serum NN B-noun.body	digoxin NN 0	concentration NN 0	due JJ 0	to TO 0	a DT 0	reduction NN B-noun.act	in IN 0	clearance NN B-noun.act	and/or CC 0	in IN 0	volume NN B-noun.artifact	of IN 0	distribution NN B-noun.act	of IN 0	the DT 0	drug NN B-noun.artifact	, , 0	with IN 0	the DT 0	implication NN B-noun.communication	that IN 0	digitalis PRP$ 0	intoxication NN B-noun.act	may MD 0	result VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d434.s20	Carbamazepine_epoxide RB 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	Cmin NNP B-noun.person	concentrations NNS I-noun.person	increased VBD B-verb.change	57 CD 0	% NN 0	from IN 0	1.0 CD 0	0.3 CD 0	to TO 0	1.6 CD 0	0.4 CD 0	micrograms NNS B-noun.quantity	/ : 0	mL CC 0	with IN 0	the DT 0	addition NN B-noun.act	of IN 0	felbamate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d54.s7	Patients NNS B-noun.person	receiving VBG B-verb.communication	insulin NN B-noun.substance	or CC 0	oral JJ B-adj.all	hypoglycemics NNS B-noun.person	should MD 0	be VB B-verb.stative	closely RB B-adv.all	watched VBN B-verb.social	during IN 0	initiation NN B-noun.act	of IN 0	thyroid JJ B-adj.all	replacement NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d380.s1	Because IN 0	CYP NNP 0	3A4 CD 0	inhibitors NNS B-noun.person	may MD 0	increase VB B-verb.change	plasma NN 0	concentrations NNS 0	of IN 0	buprenorphine NN B-noun.location	, , 0	patients NNS B-noun.person	already RB B-adv.all	on IN 0	CYP NNP B-noun.group	3A4 CD 0	inhibitors NNS B-noun.attribute	such JJ 0	as IN 0	azole_antifungals NNS B-noun.person	( ( 0	e.g. FW B-adv.all	. . 0
DDI-DrugBank.d382.s36	Ketoconazole NNP B-noun.person	, , 0	When WRB 0	a DT 0	single JJ B-adj.all	125-mg JJ 0	dose NN B-noun.quantity	of IN 0	Aprepitant NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	on IN 0	Day5 NN 0	of IN 0	a DT 0	10-day JJ B-adj.all	regimen NNS B-noun.person	of IN 0	400 CD 0	mg RB 0	/ JJ 0	day NN 0	of IN 0	ketoconazole NN B-noun.shape	, , 0	a DT 0	strong JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitor NN I-noun.person	, , 0	the DT 0	AUC NNP B-noun.group	of IN 0	aprepitant JJ B-noun.person	increased VBD B-verb.change	approximately RB B-adv.all	5-fold JJ 0	and CC 0	the DT 0	mean JJ B-adj.all	terminal JJ B-noun.artifact	half NN I-noun.artifact	- : 0	life NN B-noun.time	of IN 0	aprepitant JJ B-noun.person	increased VBD B-verb.change	approximately RB B-adv.all	3-fold JJ 0	. . 0	. . 0
DDI-DrugBank.d98.s2	Phenytoin NN 0	/ '' 0	Phenobarbital NNP B-noun.other	, , 0	The DT 0	coadministration NN B-noun.person	of IN 0	phenytoin NN B-noun.substance	or CC 0	phenobarbital NN B-noun.artifact	will MD 0	not RB B-adv.all	affect VB B-verb.change	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	vitamin_D NNP B-noun.location	, , 0	but CC 0	may MD 0	reduce VB B-verb.change	endogenous JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	calcitriol NN B-noun.communication	/ : 0	ergocalcitriol NN B-noun.act	by IN 0	accelerating VBG B-verb.change	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d150.s2	Tricyclic_antidepressants NNS B-noun.act	may MD 0	block VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	action NN B-noun.process	of IN 0	guanethidine NN B-noun.location	and CC 0	similarly RB B-adv.all	acting VBG B-verb.body	compounds NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d93.s9	These DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	exposure NN B-noun.person	to TO 0	environmental JJ B-adj.all	lead NN B-noun.act	may MD 0	alter VB B-verb.change	the DT 0	biological JJ B-adj.all	and CC 0	behavioral JJ B-adj.all	responsiveness NN B-noun.cognition	of IN 0	an DT 0	animal NN B-noun.animal	to TO 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d84.s3	The DT 0	effect NN B-noun.cognition	of IN 0	digoxin NN B-noun.person	on IN 0	Exjade JJ 0	pharmacokinetics NNS B-noun.group	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d74.s11	Further RB B-adv.all	, , 0	these DT 0	results NNS B-noun.communication	confirm VBP B-verb.cognition	that IN 0	the DT 0	diabetic JJ B-adj.all	Chinese JJ B-adj.pert	hamster NN B-noun.person	's POS 0	alpha NN B-noun.artifact	and CC 0	beta JJ B-noun.body	cells NNS B-noun.body	respond VBP B-verb.contact	normally RB B-adv.all	to TO 0	theophylline PRP 0	, , 0	but CC 0	are VBP B-verb.stative	relatively RB B-adv.all	insensitive JJ B-adj.all	to TO 0	glucose VB B-verb.change	. . 0	. . 0
DDI-DrugBank.d234.s5	ROMAZICON NN B-noun.artifact	blocks VBZ B-verb.change	the DT 0	central JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	benzodiazepines NNS B-noun.food	by IN 0	competitive JJ B-adj.all	interaction NN B-noun.act	at IN 0	the DT 0	receptor NN B-noun.artifact	level NN B-noun.state	. . 0	. . 0
DDI-MedLine.d38.s3	OBJECTIVES NNS B-noun.artifact	, , 0	To TO 0	examine VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	acute JJ B-adj.all	hydrocortisone NN B-noun.person	pretreatment NN B-noun.person	on IN 0	the DT 0	subjective JJ B-adj.all	and CC 0	behavioral JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	d SYM 0	- : 0	amphetamine NN B-noun.person	. . 0	. . 0
